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 Healthy cells maintain a dynamic and responsive intracellular environment that is 
marked by the synthesis and degradation of proteins, complex macromolecules and 
organelles.  Autophagy, literally ‘self-eating,’ is a mechanism that delivers cellular cargo 
to the lytic compartment for digestion.  Defects in the regulation of autophagy have been 
implicated in pathologies such as cancer and neurodegenerative disease, making the study 
of its regulation compelling.  However, few studies have looked at the regulation of 
mammalian autophagy as a function of a specific cargo protein.  Previous studies had 
indicated that the metabolic enzyme betaine homocysteine methyltransferase (BHMT) is 
degraded through an autophagic mechanism.  One aim of this study has centered on the 
role of BHMT quaternary structure in determining the efficiency of autophagic 
sequestration and degradation.  In these studies, an oligomerization deficient form of 
BHMT was used to show that modulation of the Class III PI3 kinase signaling pathway is 
likely involved in discerning monomeric from multimeric BHMT and that this has a role 
in the subsequent degradation of BHMT by autophagy. 
 The second aim has been to study to role of the nutrient-regulated mTOR pathway 




inactivation of S6 kinase is required for induction of autophagy in mammals.  However in 
Drosophila melanogaster, S6 kinase activity has been shown to be essential for induction 
of autophagy.  The current study demonstrates that the inhibitory signal from mTOR to 
autophagy does not go through S6 kinase or subsequent phosphorylation of the ribosomal 
protein S6.  The significance of these observations in terms of misfolded proteins, 
neurodegenerative diseases and therapeutics is discussed. 
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I.  INTRODUCTION 
1.1. Introduction 
Healthy cells maintain a dynamic and responsive intracellular environment that is 
marked by both the synthesis and degradation of proteins, complex macromolecules and 
organelles.  Autophagy, literally ‘self-eating,’ is a mechanism that delivers cellular cargo 
to a lytic compartment for digestion.  In basal conditions, this process removes cellular 
‘garbage’ such as damaged or unwanted proteins, defective mitochondria, or excessive 
internal membranes[1].  Autophagy also responds to conditions of cellular stress.  When 
nutrients are scarce, autophagy is induced to replenish the cell with essential building 
blocks such as amino acids, lipids and nucleic acids that are needed to maintain cellular 
processes necessary for survival.  In metazoans, there are times in development when the 
need for new synthesis for cellular growth and proliferation is predominant, and the need 
for autophagy recedes[2].  Developmental periods of tissue remodeling tip the scales 
toward more autophagy and less synthesis in the autophagic death and removal of 
unwanted cells, as seen in Drosophila[3].  In the worm Caenorhabditis elegans, 
autophagy is important for normal dauer formation, allowing survival during long periods 
of limiting nutrients[4].  In mammals, the importance of autophagy to the whole 
organism is apparent in the neonate.  Shortly after birth, before suckling is able to 
effectively provide nutrients, the newborn relies on autophagy, primarily of liver 
glycogen, to maintain circulating glucose levels and for survival[5].  There is an 
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increasing awareness of the significance of autophagy in human disease as defects in its 
regulation have been shown to contribute to cancer, aging, cardiomyopathy, myopathy, 
and neurodegenerative diseases[6, 7]. 
1.2. Types of autophagy  
Autophagy is the lysosomal digestion of cytoplasmic cargo and occurs in all 
eukaryotic cells.  There are three main types of autophagy:  macroautophagy, chaperone-
mediated autophagy (CMA) and microautophagy (Fig. 1).  Macroautophagy is the most 
common type of autophagy and the terms autophagy and macroautophagy are often used 
synonymously.  Distinct types of macroautophagy include the Cvt pathway (in yeast 
only), pexophagy (degradation of peroxisomes), mitophagy (degradation of 
mitochondria), and crinophagy (degradation of secretory vesicles)[6]. 
Macroautophagy and the yeast-specific Cvt pathway both require the formation of 
an enclosed double-membrane vesicle to sequester cargo destined for the lytic 
compartment.  They share many of the same genes for the development of the 
sequestering vesicle, but differ in select genes that are pathway specific, in vesicle size, 
and in the nutrient conditions of activation.  Macroautophagy is a non-specific 
degradation pathway in all eukaryotic cells that is active when nutrients are limiting.  
While non-lysosomal mechanisms exist for the degradation of protein, macroautophagy 
is the only cellular pathway to remove organelles and macromolecular complexes such as 
mitochondria and ribosomes respectively.  The Cvt pathway is a biosynthetic pathway 
specific to yeast that delivers the hydrolytic enzymes aminopeptidase 1 (Ape1) and α-
mannosidase to the vacuole.  Ape1 is synthesized in the cytosol in an inactive form and 
assembles into a large, multimeric complex which is recognized by Atg19 (Fig. 2).  
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Figure 1.  Schematic overview of macroautophagy, microautophagy, and chaperone-
mediated autophagy.  Macroautophagy involves the formation of a double-membrane 
autophagosome.  Steps of macroautophagy include 1) induction at the pre-
autophagosomal structure (PAS), 2) growth and elongation, 3) sequestration of cargo 
within the autophagosome, 4) fusion with the lysosome/vacuole to create the 
autolysosome, and 5) degradation of cargo.  Microautophagy is the invagination of the 
lysosomal membrane for the direct import of cargo.  Chaperone-mediated autophagy 
requires a KFERQ-like sequence on the substrate protein, recognition by hsc73, assembly 
of the chaperone complex and binding to lysosome associated membrane protein 2a 
(LAMP2a) at the lysosome.  After the chaperone-mediated unfolding of the substrate 
protein, it is threaded through the lysosome membrane, binds the lysosomal hsc73 protein 
and is degraded. 
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Figure 2.  The Cvt pathway cargo recognition system.  The Cvt pathway is a type of 
specific autophagy.  Aminopeptidase 1, a substrate of the Cvt pathway, is a dodecamer 
which multimerizes into a larger Ape1 complex.  The Ape1 complex is recognized by 
Atg19, which in concert with Atg11 and perhaps Atg1, delivers it to the pre-
autophagosomal structure (PAS), where it directly interacts with Atg8.  After Ape1 is 
delivered to the vacuole, it is proteolytically cleaved and becomes an active resident 
hydrolase. 
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Atg19 is an adapter protein that links the Ape1 dodecamer with Atg8 at the pre-
autophagosomal membrane, in concert with Atg11 and other proteins that may include 
Atg1.  Once in the vacuole, cleavage of in inhibitory peptide converts Ape1 into an 
active, resident enzyme.  Phosphatidylinositol 3-phosphate (PI3P) is thought to be 
important for the Cvt pathway because some of the Cvt-specific proteins contain FYVE 
(first described in proteins Fab1, YOTB/ZK632.12, Vac1, and EEA1) or Phox homology 
(PX) PI3P binding domains[8]. 
Microautophagy involves invagination and fission of the lysosome membrane to 
create small intralysosomal vesicles.  Little is know about this process in mammals, but 
in yeast, membrane-associated complexes form and mediate this process.  The EGO 
complex, comprised of a Ras-related GTPase, Gtr2, Ego1 and Ego3, has been linked to 
the target of rapamycin (TOR) kinase.  Nutrient depletion or inhibition of TOR with the 
drug rapamycin increases macroautophagy and the influx of membrane to the yeast 
vacuole.  When rapamycin is removed, microautophagy is activated in a TOR-dependent 
manner to reduce the size of the vacuole[9].  It is not known if this type of TOR-mediated 
mechanism for microautophagy exists in higher organisms. 
Chaperone-mediated autophagy (CMA) is an autophagy pathway in mammalian 
cells that responds to prolonged starvation.  CMA is specific for proteins with a target 
recognition sequence similar to the KFERQ sequence identified in RNase A, the first 
known CMA substrate.  Upon recognition of this motif by the heat shock cognate protein 
hsc73, the substrate protein is surrounded by a chaperone complex, and delivered to the 
lysosome.  At the lysosome, the chaperone complex interacts specifically with lysosomal 
associated membrane protein 2a (LAMP2a) and facilitates the unfolding of the substrate 
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protein, allowing it to be threaded through the lysosome membrane to be degraded[10].  
In CMA, proteins are imported and degraded one protein at a time.  There are estimates 





 double knockout mouse shows no defect in total protein 
degradation[11].  It may be that other autophagy pathways compensate for this defect as 
the selective knockout of the LAMP2a isoform results in a compensatory increase in 
macroautophagy[12]. 
1.3. The process of macroautophagy 
Macroautophagy proceeds in a step-wise fashion that includes:  1) induction, 2) 
growth and elongation of a pre-autophagosomal structure (PAS), 3) sequestration of 
cargo within the double-membrane autophagosome, 4) fusion with the lytic compartment, 
and 5) degradation[13].  Genetic studies in S. cerevisiae have identified specific genes 
required for autophagy and for survival in nutrient-limiting conditions, leading to an 
increase in an understanding of some of the interactions and mechanisms involved in the 
autophagic process[14, 15].  A unified nomenclature system is now used that identifies 
these genes as autophagy-related genes (Atg) 1-27 (Table 1)[16].  Many of these genes, 
protein complexes and molecular mechanism are conserved in higher eukaryotes. 
1.4. Molecular complexes in macroautopahgy 
1.4.1. The ubiquitin-like conjugation systems 
The formation of autophagosomes requires the function of two, novel, interrelated 
ubiquitin-like conjugation systems (Fig. 3)[17].  Atg8 and Atg12 are ubiquitin-like 
(UBL) modifiers which share the same E1-like activating enzyme Atg7.  Atg8 and Atg12  
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Figure 3.  The Ubiquitin-like conjugation systems of macroautophagy.  Ubiquitin-
like proteins Atg8 and Atg12 are activated by the E1-like enzyme Atg7 and ATP, 
transferred to their respective E2-like enzymes Atg3 and Atg10, and then conjugated to 
their targets.  Atg8 is covalently attached to phosphatidylethanolamine and Atg12 is 
conjugated to Atg5.  The Atg12-Atg5 heterodimer then forms a larger complex with 
Atg16. 
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are then conjugated to their respective targets through the action of their specific E2-like 
enzymes, Atg3 and Atg10 respectively.  Atg8 is translated in a pro-form that requires 
cleavage by the protease Atg4 to reveal a carboxy-terminal glycine necessary for 
conjugation.  Atg8 is activated by Atg7 and ATP, transferred to Atg3, and then uniquely 
conjugated to phosphatidylethanolamine (PE).  Atg8-PE remains associated with both 
inner and outer membranes of the expanding autophagosome, although Atg4-dependent 
cleavage of some Atg8-PE from the outer membrane is required for fusion with the 
vacuole (Fig. 3)[18].  In yeast, ∆atg8 mutants form aberrantly small autophagosomes 
suggesting that Atg8 may be necessary for growth and elongation of the autophagosomes 
membrane[19]. 
The Atg8 conjugation system is well conserved in higher eukaryotes.  In 
mammals, microtubule associating protein light chain (MAP-LC3) is the best known 
ortholog of Atg8 and is often used as a specific marker of autophagosomes[20].  Three 
isoforms of LC3 have been identified and are known as LC3A, LC3B and LC3C, with 
some overlapping and some specific distribution among cell types[21].  In addition to the 
LC3s, multiple other mammalian orthologs of Atg8 are known, although they are less 
well characterized in terms of autophagy.  These include Golgi-associated ATPase 
enhancer of 16 kDa (GATE-16) and γ-aminobutyric acid receptor associated proteins 
(GABARAP-I and GABARAP-II) and Atg8L[22, 23].   
Atg12 is also activated by Atg7 and ATP, transferred to its own E2-like enzyme 
Atg10, and conjugated to its only known target, Atg5[24].  The Atg5-Atg12 heterodimer 
then assembles into a higher molecular weight complex through interaction with 
Atg16[25].  The Atg5-Atg12 complex is found only on the outer, concave surface of the 
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growing autophagosome and may have a structural role in the curvature of the membrane.  
In addition, the Atg5-Atg12 complex may play a role in the recruitment and assembly of 
the other Atg proteins at the PAS.  The Atg12-Atg5-Atg16 complex does not remain with 
the autophagosome but dissociates before fusion with the vacuole/lysosome.   
The Atg12-Atg5 conjugation system is conserved in mammals[26].  Mice with 
total disruption of either Atg5 or Atg7 develop normally but die within 24 hours of 
birth[27, 28].  Early death is likely through a nutritional and energy collapse due to 
defective glycogen autophagy.  Gene disruption of either Atg5 or Atg7 in the central 
nervous system results in a progressive, degenerative neurological phenotype causing 
death before 28 weeks.   Neurons in these targeted knock-out mice are characterized by 
aggregates of poly-ubiquitinated protein and inclusion bodies[29, 30].  Protein 
aggregates, inclusion bodies, and autophagosomes are often observed upon biopsy or 
necroscopy of patients with neurodegenerative disease; however it had not been clear 
whether they were a cause or effect of the neurodegenerative process.  The Atg5 and 
Atg7 targeted knock-out mice provide the first evidence that defects in autophagy can be 
a cause rather than a consequence of neurodegeneration. 
1.4.2. The Class III PI 3-Kinase and Atg6 complex 
In yeast, Atg6 associates with Vps34, a Class III PI3-kinase that phosphorylates 
the 3'-OH on the inositol ring of phosphatidylinositol to form phosphatidylinositol 3-
phosphate (PI3P)[31].  Vps34 associates with the serine kinase Vps15, which has a role 
in the membrane localization and activation of Vps34 (Fig. 4).  Vps34 activity or function 
may also be regulated by complexes of associating proteins:  Vsp34, Vsp15, Atg6 and  
 
 14  
Figure 4.  The Vps34/Atg6 and Atg1 complexes in yeast.  Class III PI 3-kinase Vps34 
activity is controlled by its binding partners, Vps15, Atg6 and Atg14.  Atg1 functions in 
complex with multiple Atg proteins.  Some of the Atg proteins in complex with Atg1 are 
specific for the Cvt pathway, which has led to the proposal that the Atg1 complex acts as 
a switch between the Cvt pathway and macroautophagy.  When TOR and Atg1 are active, 
the Cvt pathway is dominant, and when TOR is inactive, macroautophagy is preferred 
over the Cvt pathway. 
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Atg14 promote autophagy, and a modified complex with Vps38 in place of Atg14 favors 
the Cvt pathway[32].  Atg6 and Vps34 localize to the trans-Golgi.  The production of 
PI3P may play a role in the recruitment of other Atg proteins to the pre-autophagosome 
structure.  Vps34 activity is thought to promote autophagy, and the activity of Class I PI3 
kinases suppresses autophagy.  This is based on several pieces of evidence.   First, an 
increase of PI3P increases degradation of long-lived protein, while the increase in 
PI(3,4)P2 or PI(3,4,5)P3, products of the Class I PI3 kinases, inhibits degradation[33].  
Second, injection of Vps34 antisense oligonucleotides inhibits autophagosome formation 
in interphase cells[34].  And third, knockout mice for the myotubularin MTMR3, a 
member of a large family of lipid phosphatases that specifically remove the 3′ phosphate 
from PI3P, suffer from a large accumulation of autophagosomes in skeletal muscle, 
resulting in a severe, progressive myopathy[35].  Contrary to this data, two recent studies 
report that amino acids increase Vps34 activity which in turn activates the mTOR 
signaling pathway[36, 37].  It may be that hVps34 activity, like yeast Vps34, is also 
regulated by associating proteins.  Wortmannin and 3-methyladenine (3MA) are 
traditionally used as autophagy inhibitors, and their effectiveness is thought to be through 
inhibition of Vps34 kinase activity[33].   
Beclin1 is the mammalian ortholog of Atg6 and it has many of the same 
characteristics of yeast Atg6:  it forms a complex with hVps34 at the trans-Golgi and it 
can complement autophagy in ∆atg6 mutant yeast[38, 39].  Beclin1, originally described 
as a Bcl-2 binding protein[40], is the first autophagy protein whose disruption has been 
implicated in cancer[41, 42].  Beclin1 is mono-allelically deleted in 40-70% of human 
breast cancers, and its ectopic expression in MCF7 cells can induce autophagy and inhibit 
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tumorigenicity[38].  Total disruption of beclin1 in mice is embryonic lethal, but 
significantly, beclin1
+/-
 mice have a high propensity to develop spontaneous tumors, 
providing genetic evidence that Beclin1 may play a role in tumor suppression[19, 42].  
The association between Beclin1 and Bcl-2 suggests a potential molecular link between 
autophagy and apoptosis and a possible mechanism for the increased tumors in beclin1
+/-
 
mice.  In one model, there is a balance between free Beclin1, free Bcl-2, and the 
Beclin1/Bcl-2 complex; increased free Beclin1 induces autophagy and inhibits tumors; 
increased Bcl-2 inhibits autophagy and increases oncogenesis[43].  Although further 
studies are needed to determine the accuracy of this model, it demonstrates the potential 
relevance of Beclin1 and autophagy in human disease. 
1.4.3. The Atg1 Complex 
Atg1 was the first Atg gene identified in the genetic screens in S. cerevisiae and is 
the only Atg gene that codes for a serine-threonine kinase[44].  In yeast, Atg1 is thought 
to be downstream of the target of rapamycin TOR signaling pathway[45].  There are two 
models of how TOR regulates Atg1 in yeast, and both place Atg1 within the context of a 
complex of associating proteins (Fig. 4).  In the first model, Atg1 activity is regulated by 
its association with Atg13.  When nutrients are plentiful and TOR signaling is active, 
Atg13 is hyperphosphorylated and forms a loose complex with Atg1 that prevents its 
activation.  When nutrients are scarce and TOR signaling is off, the hypo-phosphorylated 
Atg13 forms a tight complex with Atg1 that results in increased Atg1 activity and 
autophagy[45].  In the second model, the Atg1 complex includes proteins that function in 
only one of the autophagy pathways, Cvt or macroautophagy.  This led to the hypothesis 
that Atg1 activity is a switch that directs which pathway will be active.  In the second  
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model, Atg1 activity is important for the Cvt pathway but is dispensable for 
autophagy[46].  The specific action or target of Atg1 activity is not known, however it 
may have a role in the trafficking of the only Atg integral trans-membrane protein, Atg9, 
between the PAS and autophagosome[47].  To date, no endogenous substrates of Atg1 
catalytic activity are known.   
Orthologs of Atg1 have been identified in many species from plants to humans 
and all have been implicated in the autophagy process.  Defects in autophagy have been 
noted in Atg1 mutants in Dictyostelium dicoideum, C. elegans, and Drosophila 
melanogaster[4, 48, 49].  Mammals have at least two orthologs of Atg1, unc-51 like 
kinase 1 (hULK1) and hULK2[50, 51].  Consistent with the role of Atg1 in yeast, hULK1 
is necessary for the localization of mAtg9 to LC3-marked membranes during autophagy 
induction[52].  Unlike yeast, in higher organisms, the Atg1 orthologs have not yet been 
shown to function downstream of TOR, nor has the connection between Atg1 and the 
TOR pathway been unambiguously established. 
1.5. Macroautophagy and the TOR pathway in higher eukaryotes 
In the field of autophagy, there is general agreement that autophagy must be 
tightly regulated because of the pathological consequences of deregulated autophagy.  
The protein kinase mTOR plays a central role in the ability of cells to sense growth 
signals, amino acid levels, and energy in order to make decisions that effect translation of 
new proteins, cell growth and proliferation (Fig. 5)[53].  It is generally accepted that 
mTOR also makes decisions that affect autophagy.  If nutrients are readily available from 
the extracellular milieu, mTOR signals for the cell to grow.  But when extracellular 
nutrients are scarce, mTOR signaling allows the cell to survive by increasing autophagy 
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Figure 5.  The mTOR pathway and autophagy in mammals.  mTOR senses mitogen 
signals through the PI3K/PKB pathway.  Amino acids increase Vps34 activity and 
increase the mTOR signaling pathway.  mTOR is a negative regulator of autophagy.  
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to degrade internal proteins for energy and raw materials necessary for survival. 
In higher eukaryotes, the connection between mammalian mTOR and hULK1 is 
not obvious.  In mammalian cells, it has been proposed that the regulation of autophagy 
involving mTOR may be through its downstream effector, p70S6 Kinase.  mTOR 
phosphorylates p70S6K on T389, which leads to p70S6K activation and the 
phosphorylation of its downstream substrate, S6.  Blommaart et al. (1995) demonstrated a 
strong negative correlation between phospho-S6 and autophagy in rat hepatocytes and 
proposed a model that the signal for autophagosome formation may be through 
dephosphorylation of S6[54].  For many years, this data supported a role for mTOR, 
p70S6K, and S6 in the regulation of autophagy.  Although a recent paper suggests that 
hAtg1 (hULK1) is a negative regulator of mTORs downstream effector, p70S6K, the 
strongest data is based on ectopic expression of hAtg1[55].  Recently in Drosophila, it 
was demonstrated that some p70S6K activity was required for maximum autophagic 
activity[49].  The dilemma of an inactive mTOR and an active p70S6K is difficult to 
resolve, but it is proposed to be a self-limiting mechanism for autophagy.   
mTOR responds to signals from growth receptors through the Class I PI 3-
kinase/PKB pathway.  Importantly, PTEN and TSC2 are two tumor suppressors on the 
PI3K/PKB/mTOR pathway that are involved in the regulation of mTOR[56].  In both 
mammals and Drosophila, positive signals through the PI3K/PKB pathway inhibit 
autophagy and negative signals induce autophagy[57, 58].  Amino acid stimulation of 
mTOR is independent of the PI3-kinase/PKB pathway[59].  It was recently shown by two 
laboratories that the amino acid input to the mTOR pathway is through the Class III PI 3-
kinase Vps34[36, 37].  This interesting link between mTOR and Vps34 in the response to 
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amino acids is unexpected, as Vps34 activity is also thought to regulate the induction of 
autophagy[33].  However, as in yeast, it may be that the regulation of Vps34 occurs 
through its association with different binding partners.  The link between Vps34/Beclin1 
and mTOR puts another tumor suppressor, Beclin1, upstream of mTOR in a potential 
regulatory role.  This brings one more layer of complexity and relevance to the pathways 
regulating autophagy. 
1.6. Significance of autophagy 
The significance of autophagy in maintaining the health of not just the cell, but 
the entire organism, is apparent in human disease.  In cancer, the importance of 
maintaining the balance in the mTOR pathway between synthesis and autophagy is 
striking when one considers the tumor suppressors that keep this pathway in check.  The 
down-regulation of autophagy may be one way that tumor cells use to gain an advantage 
in growth and proliferation.  It suggests that negative regulators of the mTOR pathway 
may be effective therapeutics for certain types of cancer, and indeed, rapamycin has 
success in the treatment of renal cancer[60].  However, in certain cases, increased 
autophagy may actually promote tumor survival in harsh, non-vascular, nutrient-limiting 
conditions.  It’s even thought that some tumors are resistant to cell-damaging agents 
because of autophagy, underscoring the importance of understanding the regulation of 
this process[61]. 
While decreased autophagy may tip the scales in favor of cancer in proliferating 
cells, in differentiated cells, decreased autophagy may instead lead to degeneration and 
cell death.  The selective loss of the autophagy-related genes Atg7 and Atg5 in the 
neurons of mice results in neurodegeneration with aging[29, 30].  Autophagy has long 
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been suspected of being involved in degenerative diseases of both the neural and 
muscular systems because of the appearance of autophagosomes in the post-mortem 
tissue or biopsies of patients with diseases such as Alzheimer’s, Parkinson’s, 
Huntington’s, Inclusion-body myositis, and X-linked myopathy with excessive 
autophagy.  These findings suggest that drugs which increase autophagy may be an 
effective treatment for patients with neurodegenerative disease, and in support of this, 
preliminary tests show that treatment with rapamycin can increase the autophagy-
mediated removal of huntingtin aggregates[62]. 
Significantly, many of these diseases are associated with aging, and a decrease of 
autophagic or lysosomal function is thought to be part of the aging process[63].  If true, 
then more efficient autophagy should retard aging.  This is supported by studies in 
C.elegans where loss of signaling to TOR increased longevity, presumably by increasing 
autophagy[4]. 
Autophagy can play a more acute role in human pathology by protecting cells 
from invading intracellular pathogens.  Autophagy has recently been described as 
participating in the innate immune response to some bacteria and viruses.  Autophagy can 
be either friend or foe to microorganisms.  Some, such as Coxiella burnetii use autophagy 
to replicate while others such as Streptococcus pyogenes are removed from the cytoplasm 
by autophagy and destroyed[64].  Understanding the difference is likely to be important 
for therapeutics. 
1.7. Thesis focus and significance 
This research has focused on understanding the regulation and molecular 
mechanisms of mammalian macroautophagy.  To aid in this study, new methods were 
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developed to unambiguously measure the induction and inhibition of autophagy.  The 
macroautophagy-specific degradation of BHMT was used to study the importance of 
higher order structure on the efficiency of autophagic degradation.  The data presented 
here support a hypothesis that modulation of the Class III PI3-kinase pathway may lead 
to the selective degradation of cargo based on quaternary structure.  This is significant in 
terms of understanding the mechanism that cells use to remove potentially damaging 
protein aggregates by macroautophagy. 
In addition, this study has sought to understand the relationship between mTOR, 
p70S6 Kinase and macroautophagy.  Using the methods developed in the course of this 
study, the data show that the mTOR-dependent signal to autophagy does not go through 
p70S6 Kinase or S6.  The signal to macroautophagy through other downstream effectors 
of mTOR is explored.  Together, the data here confirm the importance of mTOR in the 
induction of autophagy and offer new insights into how the modulation of the Class III 













II.  MATERIALS AND METHODS 
 
Cell lines and cell culture 
HEK-293, T98G and A10 cells were purchased from ATCC.  MCF7 cells were a 
kind gift of the Moscat-Diaz laboratory at UC/GRI, C2C12, A2780, NIH-3T3 cells from 
the Thomas-Kozma laboratory at UC/GRI, and H1299 cells from the Kadakia laboratory 
at WSU.  Cells were maintained in a custom-prepared DMEM media, supplemented with 
4-6mM final concentration L-glutamine and either 10% fetal calf serum or 10% Nu-
Serum I (BD), at 37°C in 5% CO2. 
DMEM custom media (minus glucose, essential amino acids, L-glutamine, and 
serum) was prepared as follows.  For five liters of basic media, combine 1g CaCl2, 2g 
KCl, 488.5mg MgSO4, 32g NaCl, 625mg NaH2PO4, 1ml of 0.5mg/ml Fe(NO3)3 stock, 
5ml of 15mg/ml phenol red stock, 18.5gm NaHCO3, 50ml Pen/Strep 5,000 I.U. 
Penicillin/5,000 µg/ml streptomycin (Cellgro/Mediatech: MT30-002-CI), 200ml MEM 
Vitamins 100x solution (Cellgro/Mediatech: MT25-020-CI), 200ml MEM non-essential 
amino acids (Cellgro/Mediatech: MT25-025-CI) in water, pH to 7.0, and sterile filter.   
100mls of a 100x stock of either individual or 10 essential amino acids was prepared in 
water with the following:  660mg L-phenylalanine, 840mg L-arginine, 952mg L-
threonine, 160mg L-tryptophan, 1462mg L-lysine, 300mg L-methionine, 420mg L-
histidine, 1050mg L-isoleucine, 940mg L-valine, 1050mg leucine.  50mls of a 200x stock 




cystine.  A 10x, 250mM glucose solution was prepared in water.  All solutions were 
sterile filtered. 
Antibodies and reagents 
The following antibodies were purchased from SantaCruz:  GST (Z5), HA-probe 
(Y-11) GFP (FL), p-p70 S6 Kinase (Thr389), Beclin1 (D-18).  Antibodies purchased 
from Cell Signaling include:  Myc-Tag (9B11)  LC3 (human) antibody (NB 100-2331) 
was purchased from Novus Biologicals.   Leupeptin (Bachem), E64d, chloroquine and 
3MA were purchased from Sigma.  PMSF (Acros) was purchased from Fisher Scientific. 
SDS-PAGE, immunoprecipitation, pull-downs, and western blot 
Cells to be extracted were washed with ice-cold PBS and scraped into extraction 
buffer (EB)(50mM TRIS-HCl pH 8, 120mM NaCl, 5mM NaPPi, 10mM NaF, 30mM 
paranitrophenylphosphate, 1mM benzamidine, 0.1% NP-40, 0.2mM PMSF).  In most 
cases, 1% Triton-X100 was added to the EB.  Extracted cells were homogenized 10 
strokes in a Dounce homogenizer and centrifuged to clear the supernatant of cellular 
debris.  Total protein of cell extracts was determined by Bradford method.  For whole cell 
extract (WCE) aliquots, SDS sample buffer was added and sample was boiled for 3 
minutes before loading on SDS-PAGE gels.  After SDS electrophoresis, protein was 
electrophoretically transferred to PVDF membrane, blocked with 1% BSA in TBS/Tween 
20, incubated with primary antibody diluted in 1% BSA in TBS/Tween 20 overnight at 
4°C.  Blots were then incubated with either a species-appropriate HRP-conjubated 
secondary antibody, or with a species-appropriate biotin-conjugated second antibody 
followed by a HRP-strepavidin conjugate. 
Cell fractionation and Sucrose Gradient 
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PBS-washed cells were scraped from a 10cm culture dish in 1ml of ice-cold PBS 
and centrifuged at 1000xg for 5 minutes.  All steps were carried out at 4°C.  The cell 
pellet was resuspended in 500ul homogenization buffer (HB) (10mM TRIS pH 7.5, 
300mM sucrose, 0.2mM EDTA) and disrupted in a Dounce homogenizer with 10 strokes, 
followed by centrifugation at 540xg to pellet the nucleus and large membrane pieces.  
The supernatant was reserved in a separate 1.5ml eppendorf tube.  The pellet was gently 
resuspended in an additional 500ul HB, centrifuged at 540xg for 5 minutes, and the 
supernatant combined with the reserved supernatant from the first spin.  The combined 
supernatant was centrifuged for 12,000xg for 20 minutes to pellet the light membrane 
fraction (LMF).  This pellet was then gently washed x3 with HB and centrifuged 5 
minutes each at 12,000xg.  The washed pellet was gently resuspended in 50 to 100ul HB 
for analysis.  In some cases, the protein of the LMF was determined by Bradford analysis 
to normalize loading of sucrose gradients. 
Percent sucrose solutions (60%, 45%, 35%, 27.5%, 20%, 15%) were prepared by 
dissolving sucrose in HB.  All preparation steps of gradients were performed with ice-
cold solutions and tubes.  Discontinuous sucrose gradients were prepared within an hour 
of use by sequentially layering 1.8ml of 45% sucrose, 2.4ml of 35%, 1.6ml of 27.5%, 
1.6ml of 20% and 2.4% of 15% in a 14 x 89mm polyallomer tube.  Sample LMF in 1ml 
of HB was gently layered on top of prepared gradient.  Gradients were centrifuged at 
200,000xg for 2 hours at 2°C in a Sorvall SV41 rotor.  1ml fractions were collected by 
displacement, using 60% sucrose as the chase solution.  Fractions were numbered with 1 
being the top, least dense fraction and 10 the bottom, most dense fraction. 
In-vitro Thrombin cleavage assay 
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Thrombin Protease (Amersham Biosciences 27-0846-01) was diluted in cold PBS 
to a concentration of 1 unit/ul.  For on-bead cleavage, overexpressed GST-fusion protein 
was pulled out of cell extracts with glutathione agarose beads.  Beads were washed with 
dilution buffer x1 and PBS x1, removing all excess PBS after final wash.  0.5ug of 
thrombin in 15-20ul of PBS was added to beads and incubated for 2 hours at room 
temperature.  Reaction was stopped with SDS-sample buffer, boiled for 3 minutes and 
run on SDS-PAGE. 
Trypsin Protection Assay 
In 10 mM TRIS-HCl pH 7.5, dilute Trypsin-TPCK (Worthington) to 1mg/ml, 
Soybean Trypsin Inhibitor (STI) (Sigma T-9128) to 2mg/ml, and prepare a separate 1% 
Triton X-100 solution.  To digest extra-vesicular protein, add dilute trypsin to sucrose 
fraction, incubate 5 minutes at 37°C, and stop with equal volume of STI and 0.1M PMSF.  
Amount of trypsin was determined experimentally.  For digestion of intra-vesicular 
protein, add 1% Triton X-100 to a final concentration of 0.2%.  Proceed as described 
above.  After reaction has been stopped, total protein can be TCA precipitated, or 
individual tagged proteins can be isolated by affinity chromatography or 
immunoprecipitation. 
Quick-change mutagenesis 
Method for mutagenesis was patterned from Stratagene’s QuikChange Site-
Directed Mutagenesis Kit.  Briefly, sense and antisense primers were designed to anneal 
to the same sequence with the mutated codon in the middle of the primer.  Primers were 
between 25 and 45 bases in length, with a Tm greater than or equal to 78° 
(Tm=81.5+0.41(%GC)-(675/N)-%mismatch).  PCR was performed with primer in excess 
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of plasmid template (125ng of each primer and 50ng of template) and with an annealing 
temperature of 55°C or less for 18-24 cycles.  DNA polymerases used successfully 
include rTth DNA Polymerase XL (Applied Biosystems), Platinum Pfx DNA polymerase 
(Invitrogen) and Deep Vent DNA polymerase (New England Biolabs (NEB)).  Dpn1 
restriction enzyme (NEB) was added to finished PCR reaction to digest template and the 
mix was ethanol precipitated and reconstituted with sterile water.  Successful production 
of product was checked on an agarose gel before being transformed into either XL1-Blue 
or DH5α competent cells. 
TCA precipitation 
Make a 100% solution of TCA (Fisher A322) in water.  Add 100% TCA to dilute 
protein to a final concentration of 15-20%.  Use higher percentage of TCA for smaller 
proteins.  Mix and incubate on ice for a minimum of 2 hours.  Centrifuge at 4°C at 12-
13,000 xg for 20 minutes to pellet protein.  Carefully remove and discard supernatant.  
Wash pellet x2 with ice-cold acetone.  Allow pellet to air dry on ice and resuspend pellet 
in 1x SDS sample buffer. 
Kinase assay 
Immunoprecipitated hULK1 was incubated with 5µg MBP, 10mM MgCl2, γ-
32
P 
ATP, and reaction buffer (50mM Tris pH 7.5, 10mM NaCl, 1mM DTT, 10% glycerol) at 
30º C for 30 min. 
qPCR 
Cells were detached by trypsin digestion and total RNA was extracted using the 
NucleoSpin RNAII extraction kit according to manufacturer’s instructions.  For RT-PCR 
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Strand Synthesis Kit using random hexamer primers according to manufacturer’s 
recommendation.  Conditions of RT-PCR:  70ºC for 5 min; put on ice; add Reverse-IT 
enzyme; 47ºC 60 min; 75ºC 10min. Final product was diluted 1:10 with nuclease-free 
water for qPCR.  Primer sets for qPCR were purchased from Qiagen.  Target genes were 








3.1. Autophagy Assay Development 
3.1.1. Autophagy Conjugation Systems 
3.1.1.1. Atg12-Atg5 conjugation 
Autophagosome formation requires the recruitment and assembly of autophagy-
specific proteins to a pre-existing, or de-novo membrane structure that elongates and 
eventually fuses to form an enclosed, double-membrane autophagosome.  hAtg12 and 
hAtg5 are covalently linked in an ubiquitin-like posttranslational modification, and then 
assembled with hAtg16 in a large multimeric complex that coats the convex side of 
developing autophagosomes.  Like the ubiquitin conjugation system, the Atg12-Atg5 
system requires the activity of E1- and E2-like enzymes, hAtg7 and hAtg10, which might 
be regulated by conditions known to induce autophagy[26].   
One of the goals of this research project was to develop novel ways to study 
autophagy, and the hAtg12-hAtg5 conjugate was an attractive target because it was both 
specific and required for autophagosome formation.  Conceptually, it was not unlike 
another specific marker of autophagosomes, LC3-II, whose levels were already being 
used to measure autophagy.  At the time of this study, there were no reports in the 
literature on how an increase in autophagy might affect levels or regulation of the 
hAtg12-hAtg5 conjugate, but it seemed likely that a demand for new autophagosomes 




Because commercial antibodies were not available for either endogenous hAtg12 
or hAtg5, both genes were cloned from a human B-cell cDNA library and subcloned into 
mammalian expression vectors downstream of the respective epitope tags HA and GST, 
for which antibodies were readily available.  In a subcloning strategy that will be used for 
multiple reporters in this study, heamagglutinin (HA) epitope-tagged hAtg12 was placed 
in a bicistronic vector upstream of green fluorescent protein (GFP) under the translational 
control of an internal ribosome entry site (IRES).  In this background, expression of GFP 
can be used for independent normalization of the upstream reporter gene (Fig. 6A).   
HA-hAtg12IRESGFP and GST-hAtg5 were co-transfected in HEK293 and 
maintained for 36 hours to allow for expression of the reporter genes.  Cells were placed 
in either complete media, or media from which essential amino acids and serum had been 
removed for 4 hours, after which the cells were harvested.   Aliquots of cell extract, 
normalized for protein, were immunoprecipitated with 12CA5 antibody to the HA 
epitope tag that was fused to HA-hAtg12IRESGFP.  Protein G purified antibody and 
attached protein were processed for western blotting with antibodies against GST or HA.  
Whole cell extracts (WCE) from these samples were processed for western blot and 
probed with an antibody against GFP.  In a separate set of cell extracts, glutathione 
agarose beads were added to affinity purify GST-Atg5.  These pulldowns were prepared 
for western blotting as above, and probed with antibody against GST. 
A band of approximately 100 kDa was observed in the samples that were 
immunoprecipitated for HA-Atg12, and probed with antibody to GST-Atg5 (Fig. 6B, left, 
top panel).  The 100 kDa band was slightly higher than the 85 kDa predicted molecular 
weight of the covalently linked fusion-proteins, but is not inconsistent with what is likely  
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Figure 6.  Conjugation of GST-Atg5 and HA-Atg12.  A. Schematic of epitope tagged 
HA-Atg12IRESGFP and GST-Atg5.  GFP under the translational control of an IRES has 
been placed downstream of HA-Atg12 to allow for normalization of transfection 
efficiency.  B.  Western blot of HEK293 cells co-expressing HA-Atg12 and GST-Atg5.  
Cells represented in left panel were immunoprecipitated with 12CA5 (anti-HA) and 
probed with antibody against GST (top) or HA (middle) showing conjugate and 
unconjugated Atg12.  Expression of GFP is in bottom panel.  Cells in the right panel were 
pulled down with glutathione agarose and probed with antibody against GST showing 
conjugate and unconjugated GST-Atg5. 
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the slightly retarded migration of two covalently linked proteins.  In support of this, a 
similar 100 kDa band was seen by western blot in the matched sets of 12CA5 IP samples 
probed with an antibody against HA for HA-Atg12.  A second band at 22 kDa was 
observed on the blot probed with anti-HA that was likely unconjugated HA-Atg12 (Fig.  
6B, left, middle panel).  In the samples pulled down with glutathione and probed with 
antibody toward GST, two bands, one at 100 kDa and one at 65 kDa were found that 
were consistent with the GST-Atg5/HA-Atg12 conjugate (100 kDa) and with 
unconjugated GST-Ag5 (65 kDa) (Fig. 6B, right panel).  These data show that the 
epitope-tagged proteins HA-Atg12 and GST-Atg5 were expressed as individual proteins 
and were competent for the conjugation reaction to form a covalent linkage.  
Levels of the 100 kDa conjugated hAtg12-hAtg5 complex did not change when 
HEK293 cells were starved of essential amino acids and serum, compared to cells in 
compete media (Fig. 6B, left and right panels).  Expression levels of free GST-Atg5 also 
showed little change in starvation conditions (Fig. 6B, right panel)  However, levels of 
unconjugated HA-hAtg12 dropped significantly with amino acid starvation (Fig.6B, left 
middle panel).  This was not due to differences in transfection efficiency, as expression 
levels of GFP, the second protein in the bicistronic message of HA-hAtg12IRESGFP, were 
unchanged (Fig. 6B, bottom panel).   
Under conditions of amino acid starvation, there is a general arrest of new protein 
synthesis.  In the absence of newly translated protein, there are two possible explanations 
for the short half-life of unconjugated HA-Atg12.  First, it could be conjugated into the 
covalent complex and consumed in the process of making new autophagosomes, or 
second, Atg12 may be degraded by another mechanism.  Discriminating between the two 
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was important, because if unconjugated HA-Atg12 decreased due to consumption by the 
autophagosome-forming process, then HA-Atg12 levels could potentially be used to 
measure changes in autophagy.  Cycloheximide was used to distinguish between the two 
possibilities because it serves two purposes; cycloheximide inhibits translation like amino 
acid starvation, and it inhibits autophagy.  If decreased levels of Atg12 are due to 
autophagic consumption, then cycloheximide should protect levels of HA-Atg12 in 
starved cells.  However, if Atg12 is degraded by another mechanism, cycloheximide 
should not protect levels of Atg12 levels. 
HEK293 cells were co-transfected with HA-hAtg12IRESGFP and GST-hAtg5.  
After allowing sufficient time for expression, control cells were incubated in either 
complete media or starvation media for 4 hours.  Cycloheximide was added to a matched 
set of non-starved and starved cells for the duration of the 4 hour incubation.  After 
harvesting, cell extracts were immunoprecipitated with anti-HA antibody 12CA5, run on 
SDS-PAGE and processed for western blotting as before.  Consistent with previous 
observations, levels of unconjugated Atg12 were significantly decreased in the amino 
acid starved control cells (Fig. 7, lane 2).  In the cycloheximide-treated cells, levels of 
HA-Atg12 were not protected in the starved cells and were also significantly decreased in 
cells maintained in complete media (Fig. 7, lanes 3 and 4).  The cycloheximide results 
suggest that decreased levels of Atg12 in starved cells are not due to autophagic 
consumption and that degradation of Atg12 is not regulated by nutrients or mitogens. 
The cycloheximide result supports the second explanation that Atg12 is likely 
degraded by another mechanism.  Proteasome degradation is a major route for the 
removal and degradation of proteins.  To test if Atg12 is degraded by the proteasome,  
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Figure 7.  Levels of unconjugated HA-Atg12 in amino acid starved HEK293 cells. 
Western blot:  HEK293 cells co-expressing HA-Atg12IRESGFP and GST-Atg5 in 
complete media (lane 1), starvation media (land 2), and complete and starvation media 
with cycloheximide (lanes 3 & 4).  Levels of unconjugated HA-Atg12 are not protected 







Figure 8.  Unconjugated HA-Atg12 is degraded by the proteasome.  Western blot:  
HEK293 cells co-expressing HA-Atg12IRESGFP and GST-Atg5 were treated to 
conditions of complete media (lane 1), starvation media (lane 2), and starvation media 
with the proteosome inhibitor 20µm MG132 (lane 3).  Levels of free Atg12 are protected 








HEK293 cells expressing both HA-Atg12IRESGFP and GST-Atg5 were treated to 
conditions of complete media, amino acid and serum-depleted media, or starvation media 
with the proteasome inhibitor MG132.  Levels of HA-Atg12 were completely protected 
by MG132 in starved cells (Fig. 8), confirming that levels of unconjugated HA-Atg12 are  
due to proteasome degradation and not consumption by the autophagic machinery.  In all 
of these conditions, levels of the hAtg12-hAtg5 conjugate did not change (Figs. 7 & 8). 
These results demonstrate that levels of the hAtg12-hAtg5 conjugate or of 
unconjugated HA-hAtg12 are not suitable readouts for the induction of autophagy.  
However, the stability of the hAtg12-hAtg5 complex in all conditions tested, the short 
half life of unconjugated hAtg12, and the potential role of the proteasome in regulating 
hAtg12 cytoplasmic levels are findings that may have physiological relevance.  
3.1.1.2. LC3 conjugation 
LC3-II has been extensively used as a marker of autophagosomes, both by 
western blotting and by fluorescent microscopy with a GFP-tagged LC3 reporter[20].  
The specificity of the LC3 assay makes it a valuable tool to verify autophagosome 
formation and to validate that the lysosomal degradation pathway is macroautophagy.   
At the beginning of this study, antibodies for endogenous LC3 were not yet 
available, and in a strategy similar to the one used for hAtg12, LC3 was cloned from a 
human B-cell cDNA library and subcloned into a mammalian expression vector with HA 
and myc epitope tags at the amino and carboxy termini respectively.  The myc epitope tag 
at the carboxy-terminus of LC3 was added to slow the electrophoretic mobility of the 
proform of LC3 on SDS-PAGE to allow for better separation from LC3-I.  A similar 
strategy had been successfully used with rat LC3, one of the first mammalian Atg8 
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orthologs identified[20].  It was expected that three forms of human LC3 would be seen 
on SDS-PAGE similar to rat LC3:  the slowest migrating proform, the middle cleaved 
form, LC3-I, and the fastest migrating form with conjugated lipid, LC3-II.  A year after 
LC3 was cloned, a study would report that humans have at least three different isoforms 
of LC3:  LC3A, LC3B and LC3C.  The LC3 in the tagged reporter was determined to be 
LC3B.   
HA-LC3B-myc was transfected into HEK293 cells which were maintained for 
approximately 36 hours to allow for expression.  Cells were washed into either fresh 
complete media or media deficient in essential amino acids and serum and incubated for 
four hours to induce autophagy.  After harvesting, aliquots of cell extracts were 
normalized for equal protein, immunoprecipitated with an antibody to the HA epitope 
tag, and processed for western blotting with an antibody against HA.  Three forms of 
LC3B, pro-LC3B, LC3B-I and the lipidated LC3B-II, were seen by western blot analysis 
(Fig. 9A).  However, in contrast to the three bands seen with epitope tagged-LC3B and 
rat LC3, published immunoblots of human and mouse LC3 usually showed LC3-I and 
LC3-II, but not pro-LC3.  Sequence analysis of the B-cell cloned LC3B reporter revealed 
two abnormalities.  Specifically, an arginine was deleted from the central region of LC3B 
(∆R) and an additional nine amino acids were inserted at the carboxy-terminus (+9aa) 
after the conserved TFG-glycine necessary for lipid conjugation (Fig. 9A).   
The mutant HA-LC3B-myc reporter was tested for its response to known 
inhibitors of macroautophagy, 3MA and chloroquine (see Table 2).  The autophagy and 
PI3K inhibitor 3MA is thought to block macroautophagy early in the formation of  
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Figure 9.  Mutant HA-LC3B-myc reporter.  A.  The mutant HA-LC3B-myc reporter 
has an additional nine amino acids near the carboxy-terminus (in red), and a deletion of 
three nucleotides that code for an arginine (∆R), also in red.  Western blot is shown of 
mutant LC3B reporter in plus and minus amino acid conditions.  B.  The mutant LC3B 
reporter is shown in minus amino acid conditions (lane 1), and with autophagy inhibitors 
10mM 3MA (lane 2) and 100µM chloroquine (lane 3).  C.  Restoration of the deleted 
arginine (R68/R69) of LCB3, with the ‘+9aa’ insertion intact, yields a reporter that 
processes LC3B to LC3B-I and LC3B-II in a manner like endogenous or HA-tagged wild 
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autophagosomes, although the exact mechanism is not known.  Chloroquine blocks  
macroautophagy by preventing acidification of the lysosome and fusion, while allowing 
for the formation of autophagosomes.  Large numbers of autophagosomes have been 
observed to accumulate with the use of chloroquine.  After sufficient time to allow for  
expression, HEK293 cells transiently transfected with mutant HA-LC3B-myc were 
treated for four hours with complete media, starvation media, and starvation media with 
either 10mM 3MA or 100µM chloroquine.  After harvesting, aliquots of cell extracts 
were immunoprecipitated with anti-HA antibody and processed for western blotting as 
before.  The cells starved for amino acids and treated with 100µM chloroquine showed a 
strong accumulation of LC3B-II was seen as expected (Fig. 9B, lane 3).  Interestingly, 
3MA treatment resulted in a significant increase in the proform of LC3B (Fig. 9B, lane 
2), suggesting that 3MA affected early LC3B processing. 
The effect of 3MA on LC3B proform processing led to the investigation of which 
mutation, the ∆R deletion or the nine amino acid insertion, was responsible for the 
delayed cleavage.  The abundance of the pro-form in the mutant LC3B suggests that its 
cleavage by Atg4B is impaired, although not completely inhibited.  It was reasoned that 
the ∆R deletion (of R68 or R69) might affect cleavage by Atg4B because of its proximity 
to phenylalanine 80 (F77 in yeast), an amino acid essential for Atg4 binding and activity 
in yeast[65].  The R68 and R69 residues are highly conserved between Atg8 orthologs 
and species, making the importance of this region likely (Table 3).  Alternatively, the 
proximity of the nine amino acid (+9aa) insertion to the glycine where Atg4B-mediated 
cleavage must occur might partially inhibit the activity of the protease.  In order to 














repaired in a way that reinserted the arginine but left the ‘+9aa’ insertion intact, so that 
the newly created HA-LC3B
+9aa
myc mutant could be tested for expression by western 
blotting.  HA-LC3B
+9aa
myc was transiently transfected in HEK293 cells, and after 
sufficient time to allow for expression, washed into either complete or starvation media 
for four hours.  Cell extracts normalized for equal protein were prepared for western 
blotting as described.  Only the processed forms of the HA-LC3B
+9aa
myc mutant, LC3B-I 
and LC3B-II, were observed by western blot, similar to other published reports of human 
LC3 (Fig. 9C).  Although only a wild type or endogenous LC3 will be used in subsequent 
studies, the mutant LC3B construct is a unique reporter that may prove useful in future 
studies involving the early processing steps of LC3B.   
To facilitate studies which utilize the HA-LC3B-myc reporter, an HA epitope-
tagged wild-type LC3B-myc allele was made and stably integrated into HEK293 cells. 
Expression levels of the stable LC3B reporter are lower than the transiently over-
expressed LC3B reporter, and were later found to be roughly equal to that of endogenous 
LC3 (data not shown).  HA-LC3B
wt
myc4.1H stably expressed in HEK293 cells has the 
benefit of an epitope tag without issues of variable transfection efficiency.  HEK293 cells 
stably expressing HA-LC3B
wt
myc4.1H were tested with either complete or starvation 
media for 4-5 hours.  Cell extracts were collected and processed for western blot as 
before.  The stably expressing HA-LC3B demonstrated increased LC3B-II levels with 
amino acid and serum starvation (Fig. 10A).  However, unlike the transient reporter, 
levels of LC3B-I decreased in cells starved of amino acids.  The decrease in LC3B-I is 
consistent with published reports of endogenous LC3-I and with early interpretations of 
the LC3 assay that rely on ratios of LC3-II/LC3-I to measure autophagy.  
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Figure 10.  MG132 partially protects levels of LC3B-I in starvation conditions.  A.  
HEK293 cells stably expressing HA-tagged wild-type LC3B-myc in complete media 
(lane 1) and starvation media (lane 2).  B.  HA-LC3B
wt
myc4.1H stable cells in complete 
media (lane 1), starvation media (lane 2) and with the proteosome inhibitor MG132 
(20µM) (lanes 3&4).  
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Concerning the use of ratios, to interpret results from the LC3B assay, both a 
decrease in LC3B-I and an increase in LC3B-II are considered.  This makes a starvation 
induced decrease in LC3B-I an important aspect of the LC3B assay.  Although not 
 generally accepted, some researchers have even interpreted decreased LC3-I levels alone  
as evidence of increased autophagy[66].  There are two possible interpretations to explain 
why LC3B-I levels decrease with starvation.  The first, and most obvious, is that in the 
absence of new protein synthesis, LC3B-I levels drop as it is processed to LC3B-II when 
cells need more autophagosomes.  The second is that LC3B-I, like unconjugated HA-
Atg12, may be proteasomally degraded independent of conversion to LC3B-II.  To test 
the latter, HEK293 cells stably expressing HA-LC3B
wt
myc4.1H were incubated in 
complete or starvation media for four hours, either with or without the proteasome 
inhibitor MG132.  Unexpectedly, levels of LC3B-I in starved cells were partially 
protected by MG132.  In contrast, MG132 had no effect on LC3B-I in full media, and did 
not change levels of LC3B-II in either plus or minus amino acid media (Fig. 10B).  This 
indicates that little LC3B-I was degraded proteasomally in conditions of complete media, 
and that LC3B-II was also not degraded proteasomally, as one might predict for a protein 
attached to a membrane degraded in the lysosome.  However, the MG132 data showing 
protection of LC3B-I in minus amino acid media reveal that at a percentage of LC3B-I 
may be degraded proteasomally under autophagy-inducing conditions.  Therefore, 
decreased levels of LC3B-I do not necessarily reflect conversion to LC3B-II and must be 
used cautiously in conjunction with LC3B-II to interpret levels of autophagy. 
The stably expressing HA-LC3B-myc4.1H was tested under conditions known to 
inhibit autophagosome degradation.  Chloroquine and bafilomycin A1 both inhibit 
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autophagy by increasing lysosomal pH to block fusion of lysosomes with 
autophagosomes.  The block of fusion causes an accumulation of autophagosomes and an 
increase in LC3B-II levels.  HEK293 cells stably expressing the HA-LC3B-myc reporter 
were starved of essential amino acids for 5 hours, with or without 100µM chloroquine or 
100nM bafilomycin A1.  After extraction, aliquots of cell extracts were normalized for 
protein concentration, immunoprecipitated with antibody to HA, and processed for 
western blotting.  In the chloroquine and bafilomycin A1 treated cells, the accumulation 
of LC3B-II was much greater than that of control cells (Fig. 11), which was expected 
with strong lysosomal inhibition.  However levels of accumulated LC3B-II in the 
inhibitor-treated cells were essentially the same in complete media as in media depleted 
of essential amino acids and serum (Fig. 11).  The accumulation of LC3B-II in complete 
media was surprising because one would expect that more LC3B-II would accumulate in 
starved cells.  In control cells, the increase of LC3B-II in starvation media was slight.  
The data show that LC3B-II levels reach a limit where no more is produced under plus 
amino acid and minus amino acid conditions.  Without the lysosomal inhibitors, the 
accumulation of LC3B-II is largely determined by its rate of degradation.  And 
surprisingly, LC3B-II is actively produced and degraded in the presence of amino acids 
and serum. 
These finding raise questions about the induction of autophagosome formation.  
Does amino acid and serum starvation cause an actual increase in the rate of LC3B-II 
production?  And is there a way to inhibit the lysosome to give optimal accumulation of 
LC3B-II when under starvation conditions?  Since blocking lysosomal proteolysis and 
autophagosome fusion causes an accumulation of LC3B-II, it should be possible to see  
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Figure 11.  LC3B-II with lysosome inhibitors.  HEK293 cells stably expressing HA-
LC3B
wt
myc4.1H were incubated in complete and starvation media (lanes 1 & 2) with 
100µM chloroquine (lanes 3 & 4) or 100nM bafilomycin A1 (5 & 6).  LC3B-II levels in 
complete media approaches or reaches levels in starvation media, as seen by western 























differences in rates of LC3B-II accumulation at early time points of lysosomal inhibition.  
To test this, HEK293 cells stably expressing the HA-LC3B-myc construct were pre- 
strong lysosomal block, and subsequently extracted at time points ranging from zero to 
starved for sixty minutes without inhibitors, then treated with 100µM chloroquine for a 
four hours.  LC3B-II levels accumulated faster in starved cells compared to cells cultured 
in full media, consistent with amino acid and serum starvation inducing the synthesis of 
LC3B-II (Fig. 12A).  The early time points of 20 and 40 minutes provided the most 
sensitive window to differentiate between LC3B-II levels in plus vs. minus amino acid 
conditions.  Beyond that time, the difference between complete media and starvation 
media rapidly narrowed until LC3B-II levels reached a plateau with no detectable 
difference between the two treatments, consistent with the previous result (Fig. 11).  The 
reason for this plateau effect is not known, but could be explained by a self-limiting 
mechanism that prevents excessive autophagosome formation.  From this data, starvation 
induced increases in LC3B-II can be seen only at early time points under conditions of 
strong lysosomal inhibition.   
Although a chloroquine time course was helpful in visualizing changes in 
autophagic induction, the window of differentiation was small in that the accumulated 
LC3B-II rapidly reached maximum levels with or without amino acids.  In order to see 
changes in autophagy at long time points, it was tested whether partial inhibition of 
lysosomal degradation would allow for the accumulation of LC3B-II while still allowing 
its breakdown.  In this way, a stronger LC3B-II signal could be observed while 
maintaining the ability to see regulation of LC3B-II at short and long time points.  To test 
this, HEK293 cells stably expressing the HA-LC3B reporter were treated with decreasing  
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Figure 12.  Lysosome inhibitors can validate LC3B-II induction and flux.  A.  Time 
course experiment of LC3B-II accumulation with 100µM chloroquine.  At 120 minutes, 
levels of LC3B-II in plus and minus amino acid media are equal.  B. Chloroquine dose 
response experiment.  At lower doses, chloroquine controls autophagosome flux and 




















conditions.  At lower doses of 10µM and 25µM chloroquine, differences in LC3B-II 
levels between the two conditions were apparent (Fig. 12B).  In principle, weak 
lysosomal inhibition enhances the sensitivity of the LC3B assay, without sacrificing the 
ability to see regulation by amino acid availability.   
While chloroquine was useful, its potency occasionally made it difficult to 
correctly dose without reaching maximum LC3B-II accumulation.  Chloroquine raises 
lysosomal pH, affecting many lysosomal hydrolases.  Specific protease inhibitors may be 
less severe but still give the required result.  E64d, combined with either leupeptin or 
pepstatin A, has been used in the literature as an effective inhibitor of lysosomal 
cathepsins.  HEK293 cells stably expressing the HA-LC3B
wt
myc4.1H reporter were treated 
with leupeptin and E64d, or pepstatin A and E64d, in either complete or starvation media 
for 5 hours.  Control cells stably expressing HA-LC3B were incubated in either plus or 
minus amino acid media without inhibitors.  HA-LC3B was immunoprecipitated from 
cell extracts and prepared for western blotting.  Both leupeptin/E64d and pepstatin 
A/E64d were successful in increasing the window of sensitivity of the LC3B assay 
compared to control cells (Fig. 13) without the problem of maximal accumulation.  This 
demonstrates that protease inhibitors can be successfully used for long time periods to 
control autophagosome flux and increase the sensitivity of the LC3B assay. 
The experiments presented here emphasize some of the advantages and 
disadvantages of using a midpoint assay.  In light of the current knowledge of LC3, LC3-
II unquestionably has value for its specificity for autophagosomes.  However, the 
transient nature of autophagosomes and the lack of specific knowledge of regulation of 
events at either formation or degradation, make correct interpretation difficult.  
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Figure 13.  Protease inhibitors can control LC3B-II flux.  HEK293 cells stably 
expressing HA-LC3B-myc were treated with leupeptin (10.0µM) + E64d (5.8µM) or 
pepstatin A (14.6 µM)+ E64d (29.2 µM) for five hours.  This increases sensitivity of 











3.1.2. The BHMT assay 
3.1.2.1. Assay development and pharmacological validation 
Macroautophagy is a multi-step, biological process.  The LC3 assay and electron 
microscopy (EM) are both valuable tools to semi-quantitatively assess levels of 
autophagosomes, but alone, they are inadequate to determine rate or level of autophagy.  
Optimally, one must consider delivery of cargo to the lysosome and its subsequent 
degradation.  The importance of the lysosomal endpoint is widely acknowledged, and 
researchers in mammalian autophagy have developed biochemical methods to measure 
the degradation of long-lived proteins as a group[67].  However, these methods are 
neither sensitive nor specific for macroautophagy.  One goal of this research was to 
develop and validate a functional, biochemical endpoint assay that would be 
reproducible, specific, and sensitive for macroautophagy.  Ideally, this assay would 
measure the vesicular uptake, delivery and lysosomal degradation of cytoplasmic cargo.  
In a literature search to find proteins that might be useful in an autophagy endpoint assay, 
betaine homocysteine methyltransferase (BHMT) emerged as a promising candidate.  
BHMT, a metabolic, cytosolic enzyme in high abundance in liver and kidney, was 
identified by mass spectrometry as a protein that associated with purified autolysosomes 
in rat liver [68].  Although the authors were searching for autophagosome-specific 
membrane proteins, its presence in autolysosomes was likely due to engulfment as 
autophagosome cargo.  In support of this, a specific carboxy-terminal degradation 
fragment of BHMT was found only within the lumen of leupeptin-treated rat 
autolysosomes.  The authors concluded that a leupeptin-resistant cathepsin was able to 
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cleave BHMT to produce a discrete, 32kDa, lumenal fragment that could be visualized on 
SDS-PAGE.   
Based on these observations, a BHMT plasmid-based autophagy reporter assay 
was developed for use in cell culture.  In concept, the assay would measure levels of a 
BHMT lysosomal fragment similar to the one found in rat autolysosomes.  In addition, if 
autophagic flux was high, levels of full-length BHMT might also be expected to decrease 
with increased autolysosomal consumption.  The BHMT reporter was created using a 
subcloning strategy that fused a slightly truncated human BHMT cDNA downstream of a 
glutathione S-transferase (GST) epitope tag and upstream of a small epitope myc tag 
(Fig. 14A).  This allowed for easy enrichment of full-length GST-BHMT and GST-fused 
fragments with glutathione agarose.  Since commercial antibodies to the GST epitope tag 
were readily available, GST-BHMT and GST-fused fragments of BHMT could then be 
easily visualized on a western blot.   
To determine if the chimeric GST-BHMT-myc would be a suitable reporter, it 
was necessary to 1) determine if GST-BHMT-myc, like rat BHMT, had a leupeptin-
insensitive proteolytic cleavage site that could be seen by western blotting, and 2) test if 
degradation could be induced under conditions known to initiate macroautophagy.  The 
GST-BHMT-myc reporter was transiently transfected into HEK293 cells and maintained 
in culture for 24-48 hours to allow for expression.  HEK293 cells expressing GST-
BHMT-myc were incubated for five hours under various media conditions previously 
shown to induce autophagy, such as amino acid deprivation and/or serum starvation.  
Aliquots of cell extracts, normalized for total protein, were incubated at 4ºC with 
glutathione agarose to purify and enrich GST-tagged BHMT and BHMT fragments 
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Figure 14.  Leupeptin-dependent generation of GST-BHMT fragments.  A.  
Schematic of the plasmid-based BHMT reporter, with a glutathione S-transferase (GST) 
epitope tag at the amino-terminus and a myc epitope tag at the carboxy-terminus.  B.  
GST-BHMT fragmentation requires the protease inhibitors leupeptin (10ug/ml) and E64d 
(2ug/ml) (lanes 5-8 vs. 1-4).  Levels of BHMT fragments increase in media depleted of 
12 essential amino acids (lanes 7 and 8).  Serum starvation does not increase levels of 
fragment 1 (lane 6 compared to lane 5, and lane 8 compared to lane 7).  All data shown is 
obtained by glutathione pulldown and western blotting. 
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 which were run on SDS-PAGE and probed with an antibody to GST.  To test for GST-
BHMT fragmentation, half of the cells received the protease inhibitors leupeptin and 
E64d.  Leupeptin and E64d were chosen because they were both used to observe 
accumulation of BHMT fragmentation in the original study by Ueno et al[68].  In 
addition, the leupeptin/E64d cocktail has already been shown to have a modest, 
controlled effect on LC3B processing and thus on macroautophagy in the current study 
(see Fig. 13).  It was expected that the proteases would slow the autophagic process to a 
rate that would allow the accumulation of partial degradation products within the 
autolysosome.  If human GST-BHMT was proteolytically cut in a region similar to rat 
BHMT, generation of a fragment of approximately 35 kDa on SDS-PAGE was expected.   
Consistent with these expectations, a fragment of approximately 35 kDa, labeled 
fragment 1, was observed on western blot in the leupeptin/E64d treated cells that was not 
seen in cells without protease inhibitors (Fig. 14B, lanes 5-8 compared to lanes 1-4).  A 
second fragment, labeled fragment 2, was noted at 25 kDa which was the approximate 
size of either endogenous GST or of the epitope GST tag.  Significantly, accumulation of 
the 35 kDa fragment increased in the absence of essential amino acids (Fig. 14B, lanes 
7&8).  Serum starvation alone, or in combination with essential amino acid starvation, 
did not alter the accumulation of fragment 1 (Fig. 14B, compare lanes 5 and 6, and lanes 
7 and 8).  These data show that BHMT fragmentation occurs in response to the specific 
removal of amino acids rather than serum.  To see changes in the GST-BHMT fragments, 
it is necessary to partially inhibit macroautophagy with protease inhibitors.  In all 
subsequent BHMT experiments, unless otherwise noted, leupeptin and E64d have been 
added to the media to visualize fragmentation.  In addition, although serum deprivation 
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had no effect on induction of macroautophagy, the starvation media used to induce 
autophagy is generally deficient in both amino acids and serum for experimental 
convenience. 
Expression of GST-BHMT requires the transient transfection of the expression 
plasmid.  To compare levels of BHMT fragments between experimental conditions, it is 
necessary to normalize for differences of transfection efficiency.  Normalization to the 
expression of the full length GST-BHMT-myc protein is not preferred because of its 
degradation during active autophagy.  To address the issues of transfection efficiency and 
independent normalization of GST-BHMT, a bicistronic message under the control of a 
single CMV promoter was created by placing GFP downstream of GST-BHMT under the 
translation control of an IRES (Fig. 15A).   
To validate that the generation of GST-BHMT fragments was due to 
macroautophagy, HEK293 cells were transiently transfected with the GST-
BHMTIRESGFP construct, and 48 hours later starved from serum and essential amino 
acids in the presence or absence of a panel of inhibitors known to inhibit 
macroautophagy; 3MA, wortmannin, bafilomycin A1, and puromycin.  Wortmannin and 
3-methyladenine (3MA) are PI3 Kinase inhibitors that are thought to inhibit autophagy 
through their inhibition of the Class III PI3 Kinase, Vps34.  Bafilomycin A1, a potent 
inhibitor of the vacuolar H
+
 ATPase (V-ATPase), prevents acidification of the lysosome 
and lysosome-fused vesicles.  Puromycin, like cycloheximide, is an inhibitor of 
translation and autophagy.  To exclude a role of the proteasome in the fragmentation of 
BHMT, the proteasome inhibitor MG132 was included in the panel of inhibitors.  Each of 
the autophagy inhibitors prevented the accumulation of BHMT fragment 1 and fragment 
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Figure 15.  The original BHMT assay with pharmacological inhibitors.  A.  
Schematic of the GST-BHMT-IRESGFP reporter plasmid.  Placement of an IRES-GFP 
downstream of GST-BHMT in a bicistronic message allows for independent 
normalization of transfection efficiency.  B.  The BHMT assay.  Fragmentation of GST-
BHMT increases with amino acid and serum starvation and is inhibited with the 
macroautophagy inhibitors, 10mM 3MA, 100nM wortmannin, 100nM bafilomycin A1, 
and 50µM puromycin.  The proteosome inhibitor MG132 does not effect fragmentation.  




















2.  As expected, the proteasomal inhibitor MG132 had no effect (Fig. 15B, lanes 3 to 7).  
These data provide pharmacological validation that the GST-BHMT proteolytic 
fragments are generated through macroautophagic delivery of GST-BHMT to the 
lysosome.  
Although levels of BHMT fragment 1 were consistently increased in conditions of 
autophagy induction and inhibited by autophagy inhibitors, fragment 2 was occasionally 
problematic; it was not always induced by amino acid starvation and did not always 
appear to be due to macroautophagy.  If the cleavage sites responsible for the generation 
of fragment 1 and fragment 2 could be identified, then it might be possible to produce a 
more reliable readout for the induction and inhibition of autophagy.  The initial rationale 
to test human BHMT as an autophagy reporter was based on the association of rat BHMT 
with autolysosomes[68].  Human BHMT and rat BHMT are 92% conserved at the amino 
acid level, making it likely that the cleavage site responsible for cleavage of human 
BHMT is at or near the cleavage site predicted by Ueno et al. in rat BHMT[68].  In 
support of this, the calculated molecular weight of the GST protein plus the first amino 
acids of BHMT up to the predicted cleavage site in BHMT is 35 kDa which corresponds 
well with the molecular weight estimated on SDS-PAGE for fragment 1. 
In the crystal structure of rat BHMT, loop L2, which connects β2 and α2 of the (α/β)8 
barrel, is not visible on electron density maps due to a high degree of mobility[69].  The 
cleavage site described by Ueno et al. is within this disordered, flexible loop region, L2, 
of BHMT (Fig. 16A).  Proteolytic cleavage of human BHMT to generate fragment 1 
might also occur somewhere in this flexible, exposed loop, potentially at the same E92 
site described by Ueno et al[68].   
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Figure 16.  BHMT fragment 1 cleavage site maps to loop 2 (L2).  A.  Crystal structure 
of overlapping subunits of rat BHMT, as published by Gonzalez et al[69].  The L2 loop is 
disordered and not visible on the electron density maps.  Sequence of the L2 loop is 
conserved in human BHMT; ^ marks the only residue that is different between rat and 
human.  Site of cleavage to generate peptide in Ueno paper is marked with an arrow.  
Sites considered as contenders for fragment 1 generation are similarly indicated.  
Engineered thrombin recognition site is noted, with mutations marked in red.  B. Western 
blot of control and ‘L2Thr’ mutant.  Starvation of the ‘L2Thr’ mutant generates two closely 
related fragments in lane 4.  In-vitro thrombin cleavage assay has no effect on control but 
efficiently cleaves the ‘L2Thr’ mutant (lanes 7-8) to produce a band consistent with the 



















While examining the L2 and surrounding regions of BHMT for potential protease 
recognition sites, it was noticed that L2 contained a sequence similar to a thrombin 
recognition site.  The BHMT sequence LENRGN was different from a thrombin 
recognition site, LVPRGS, by just three amino acids, and was slightly upstream of the 
predicted E92 site (Fig. 16A).  In an attempt to map the autophagy specific cleavage site 
in human BHMT, a strategy was designed to mutate the three amino acids necessary to 
introduce a thrombin cleavage site in the L2 loop of BHMT.  If fragment 1 was produced 
by cleavage at E92 or somewhere downstream, and if the engineered thrombin site was 
not itself cleaved in vivo, then an in-vitro thrombin-generated fragment could be easily 
analyzed by mass spectrometry to obtain information on the precise cleavage site.  
However, it was possible that lysosomal thrombin-like proteases might cleave the 
introduced thrombin site either preferentially or in addition to the original cleavage site.  
In fact, the latter proved correct, as amino acid starvation of the GST-BHMT L2thr mutant 
resulted in the production of two, very closely associated fragments on SDS-PAGE (Fig. 
16B, lane 4).  The newly generated fragment seen in lane 4 migrated slightly slower on 
SDS-PAGE than control fragment 1, suggesting that the cleavage site for fragment 1 was 
not downstream as supposed, but rather was upstream of the engineered thrombin 
cleavage site.   
To verify that the thrombin cleavage site was functional and that the upper band 
in lane four was generated by cleavage at the introduced thrombin recognition site, 
glutathione Sepharose pull-downs from control and GST-BHMT L2thr mutant cell 
extracts were treated with thrombin protease in-vitro and prepared for western blotting.  
Thrombin cleavage of the BHMT L2Thr mutant generated a band on SDS-PAGE identical 
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in size to the upper band of the doublet (Fig. 16B, lanes 7 and 8).  In-vitro thrombin had 
no effect on GST-BHMT from control cells as expected (Fig. 16B, lanes 5 and 6).  The 
results of the in-vitro thrombin cleavage assay confirm that the upper band was generated 
from the introduced site. 
In an attempt to more closely map the fragment 1 cleavage site, mutations were 
made in the acidic and basic residues upstream of the thrombin cleavage site, E80A, 
D81A, K82Q, but they did not disrupt the production of fragment 1 (data not shown).  To 
date, the exact proteolytic site responsible for fragment 1 is not known, although it is 
thought to be within a few amino acids upstream of the terminal amino acid, R86 
produced by thrombin cleavage. 
The inconsistencies that were observed in the generation of fragment 2 raised 
concerns that its cleavage was not entirely due to lysosomal proteases.  Changes in levels 
of fragment 2 were not easily explained and distracted from the consistent, autophagy-
related changes observed in levels of fragment 1.  The goal of the BHMT assay was to 
create a clean and unambiguous reporter for macroautophagy, so it was necessary to 
make changes in the reporter that would preserve fragment 1, but eliminate fragmentation 
that generated fragment 2.  If the site or region responsible for the generation of fragment 
2 could be identified, then it might be possible to change it by mutation or deletion to 
make it a less favored substrate for its specific protease.  Since the molecular weight of 
fragment 2 was very near the predicted molecular weight of GST alone (predicted to be 
27 kDa), the linker region between GST and BHMT was examined for potential 
proteolytic sites.  Sequence analysis of the GST-BHMT construct revealed a thrombin 
recognition site near the 3’end of the GST epitope tag (Fig. 17A in bold).   
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Figure 17.  Mapping the major cleavage site responsible for fragment 2.  A.  
Sequence analysis of the carboxy-terminal region of GST revealed a thrombin 
recognition sequence (bold and underlined).  The twelve amino acids that were removed 
to make the BHMT∆T reporter are bracketed between the arrows.  B.  An in-vitro 
thrombin cleavage assay was performed with the original BHMT reporter to validate that 
the thrombin cleavage site was functional and capable of producing a fragment near the 
















The GST fused to BHMT was originally subcloned from the PGEX -2T cloning 
vector (accession number U13850).  All PGEX vector GST sequences are identical from 
the amino-terminus through FDHPPKSD (Fig. 17A), but vary in the protease recognition 
sites and sequences that follow.  The thrombin recognition site in the original vector was 
designed to allow cleavage and release of protein fused to GST for purification purposes.  
Thrombin cleavage of the GST-BHMT reporter could be useful in narrowing the region 
of the proteolytic site responsible for the generation of fragment 2, by generating a 
defined fragment that could be compared to the size of fragment 2.  It was also possible 
that the thrombin cleavage site itself might be responsible for generation of fragment 2 as 
was observed with the L2Thr form of BHMT.  Since thrombin-like proteases exist in both 
the cytoplasm and the lysosome, cleavage at this site would explain why fragment 2 
appeared to be of lysosomal origin in some experiments, but not others.   
An in-vitro thrombin cleavage assay was performed to determine the size of a 
thrombin-released GST-BHMT fragment on SDS-PAGE compared to fragment 2.  
HEK293 cells were transiently transfected with the GST-BHMT-myc reporter construct 
and extracted after 48 hours.  GST-BHMT-myc was affinity-purified on glutathione 
Sepharose beads from 300µg of cell extracts.  PBS-washed glutathione beads with bound 
GST-BHMT were incubated at room temperature for 2 hours in 20µl of PBS with 0.5µg 
thrombin.  A negative control was processed in the same manner without thrombin.  
Samples were prepared for western blotting with an antibody against GST.  Independent 
glutathione pull-down was included as a control for the size of fragment 2 (Fig. 17B, lane 
1).  Negative thrombin assay control is shown in Fig. 17B, lane 2.  The fragment released 
by in-vitro thrombin cleavage ran on SDS-PAGE at a molecular weight equal to that of 
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fragment 2 (Fig. 17B, lane 3 compared to lane 1).  It seemed likely that the thrombin 
recognition site was responsible for the generation of fragment 2 in-vivo. 
The amino acids in the carboxy-terminal region of the GST tags vary between the 
different PGEX vectors, and are likely not essential for glutathione interaction or 
antibody recognition. Therefore, a PCR strategy was used to remove the thrombin 
recognition site plus six additional amino acids from the linker region between the GST 
tag and BHMT to create a new reporter called GST∆TBHMT myc (Fig. 17A).   
The new GST∆TBHMTmyc reporter was tested to determine if it retained the 
ability to generate fragment 1 in conditions known to induce and inhibit macroautophagy, 
and to see if deletion of the thrombin cleavage site had removed the cleavage site 
responsible for the generation of fragment 2.  HEK293 cells were transiently transfected 
with GST-BHMT-myc as a control and the GST∆TBHMTmyc construct.  After allowing 
sufficient time to allow for expression, the cells were starved from serum and essential 
amino acids in the presence or absence of a panel of macroautophagy inhibitors:  3MA, 
wortmannin, chloroquine, and bafilomycin A1.  The proteasome inhibitor MG132 was 
included as before.  Glutathione pull-downs were performed from cell extracts and 
prepared for western blotting.  The GST∆TBHMT reporter was as fully responsive to 
induction of autophagy by amino acid starvation and to the effects of macroautophagy 
pharmacological inhibitors in the generation of fragment 1 as the original reporter (Fig. 
18B).  GST∆TBHMT fragment 1 migrated slightly faster on SDS-PAGE as expected due 
to the deletions in the GST linker regions.  Although the ∆T modification seemed to 
reduce the level of fragment 2, it did not completely eliminate generation of a second 
fragment (Fig. 18B, lane 2 compared to lane 1).  On closer examination, the original 
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Figure 18.  The GST-BHMT∆T assay.  A.  Schematic of the GST-BHMT∆T reporter 
construct.  B.  GST-BHMT∆T produces two consistently lysosomal fragments with amino 
acid and serum starvation.  BHMT fragmentation is inhibited by the autophagy inhibitors, 
10mM 3MA, 100nM wortmannin, 100µM chloroquine, or 100nM bafilomycin A1.  GST-
BHMT∆T fragmentation was not inhibited by the proteasome inhibitor MG132.  All data 




      














GST-BHMT-myc reporter fragment 2 is actually a doublet.  The larger, slower migrating  
fragment was eliminated in the BHMT∆T background, but the smaller fragment remained.  
Unlike the original fragment 2, generation of the smaller fragment, called fragment 2′ in 
the ∆T background, correlated well with fragment 1 under conditions of autophagic 
induction and inhibition. 
Although both fragments 1 and 2′ were now consistent in their response to 
autophagic induction and inhibition, it was possible that the overall signal observed in the 
generation of fragment 1 might be diluted by subsequent cleavage to fragment 2′.   If this 
were true, the elimination of the fragment 2′ cleavage site might increase the generation 
of fragment 1 and the overall signal strength.  To do this, two things were considered.  
First, it was assumed that either the same or a similar lysosomal cathepsin was 
responsible for the generation of both fragment 1 and the remaining 2′, since both 
fragments were generated in the presence of the protease inhibitors leupeptin and E64d.  
Second, the size of fragment 2′ again suggested that the cleavage site must be near the 
end of GST.  Ueno et al. indicated the intralysosomal carboxy-terminal fragment of rat 
BHMT was cleaved between glutamate E92and lysine K93 to produce the carboxy-
terminal peptide identified by mass spectrometry[68].  With this information, point 
mutations were made in the carboxy-terminal region of GST that changed two aspartates 
to glycines (D214G, D220G), and a lysine to a glutamine (K218Q) (Fig. 19A).   
While making these modifications, an additional mutation was made in GST to 
address a potential KFERQ-like chaperone-mediated autophagy (CMA) site.  Although it 
seemed unlikely that GST-BHMT was imported via CMA, Majeski and Dice reported 
that glutathione GST was a known CMA substrate[10].  The identified site, NKKFE was 
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found in the GST fused to BHMT, so a N43A mutation was introduced that was known 
to destroy substrate recognition by the CMA complex (Fig. 19A).   
The new GSTmodBHMT construct was subcloned as before to create a bicistronic 
message with a downstream IRES-GFP (Fig. 19A).  HEK293 cells were transiently 
transfected with GSTmodBHMTIRESGFP and maintained in culture for 36 hours to allow 
for expression of the reporter and GFP.  GFP expression on western blot is shown for 
normalization (Fig. 19B, bottom panel).  Cells were treated for five hours with or without 
leupeptin (10ug/ml) and E64d (2ug/ml), which was essential to observe fragment 1 at a 
molecular weight of approximately 35 kDa by western blotting (Fig. 19B, lanes 5-8 
compared to lanes 1-4).  Serum starvation of cells with the full cocktail of essential amino 
acids was not sufficient to induce an increase in fragment 1 (Fig. 19B, lanes 5 vs. lane 6).  
Depletion of essential amino acids was sufficient to increase levels of fragment 1, with 
the presence of dialyzed serum having no effect (Fig. 19B, lanes 7 and 8).  The deletions 
and mutations in the GSTmodBHMT reporter did not prevent the starvation-induced 
generation of fragment 1.  Protease inhibitors were still necessary to see fragment 1, 
which was now the only fragment observed. 
The deletions and mutations in the GSTmodBHMT reporter had successfully 
eliminated the generation of fragment 2 and it seemed prudent to verify that the extensive 
modifications had not affected the generation of fragment 1 with autophagy inhibitors.  
The GSTmodBHMT reporter was transiently transfected into HEK293 cells and treated for 
5 hours with complete media and starvation media with the panel of macroautophagy 
inhibitors as before, including wortmannin, 3MA, bafilomycin A1, chloroquine, and 
puromycin.  Aliquots of cell extracts were pulled down with glutathione Sepharose and 
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Figure 19.  Leupeptin-dependent generation of GSTmodBHMT fragment 1.  A.  
Schematic of the GSTmodBHMTIRESGFPmyc reporter; the thrombin recognition site has 
been removed and N43A, D214G, K218Q, and D220G mutations have been made in 
GST.  B.  GSTmodBHMT fragmentation requires the protease inhibitors leupeptin 
(10ug/ml) and E64d (2ug/ml).  Levels of BHMT fragment 1, but not fragment 2, increase 
in media depleted of 12 essential amino acids (lanes 7 and 8).  All data shown is obtained 














prepared for western blotting.  GSTmodBHMT demonstrated increased fragment 1 
accumulation with amino acid starvation that was effectively blocked with the panel of 
autophagy inhibitors (Fig. 20).  Increased fragmentation of this reporter was also 
observed in cells treated with 40nM rapamycin, an agent reported to induce 
macroautophagy in the presence of full amino acids[54], providing further evidence that 
GSTmodBHMT was a reporter for macroautophagy (Fig. 20 lane 3).  A band near the 
molecular weight of fragment 2 was observed, but is likely endogenous GST, as it was 
also observed in extracts from untransfected cells (data not shown). 
Recently, it was reported that intact microtubules were necessary for 
macroautophagy in hepatocytes and that their disruption with the drug vinblastine 
allowed and potentiated autophagosome formation, but inhibited the vesicular trafficking 
necessary for fusion with lysosomes[70].  Vinblastine was also recently tested for its 
effects on chaperone-mediated autophagy (CMA) by Finn et al., who showed that 
vinblastine did not inhibit CMA in IMR90 cells[71].  For further validation that BHMT 
fragmentation was the result of macroautophagy and not CMA, the BHMT assay was 
tested with the pharmacological agent vinblastine.  HEK293 cells stably expressing 
GSTmodBHMTmyc were starved of essential amino acids and serum for 5 hours.  Cells 
were treated with decreasing doses of vinblastine from 50µM to 5µM, with 100µM 
chloroquine as a positive control for maximum lysosomal inhibition.  Amino acid starved 
cells served as a control for generation of fragment 1.  After the cells were harvested, 
glutathione pull-downs from cell extracts were processed for western blotting.  The 
starvation-induced generation of fragment 1, seen in lane 1, was inhibited by chloroquine, 
seen in lane 2, as expected (Fig. 21).  Generation of BHMT fragment 1 was inhibited by 
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Figure 20.  The BHMT assay with GSTmodBHMTIRESGFPmyc.  Western blot of 
modified BHMT reporter in plus and minus amino acid media and with a panel of 
pharmacological agents:  40nM rapamycin, 100nM wortmannin, 10mM 3MA, 100n 
bafilomycin A1, 100µM chloroquine, 50µM puromycin. The band marked with an * is 
not specific for cells expressing the GST-BHMT constructs and is most likely 






















Figure 21.  Validation of the BHMT assay with vinblastine.  Western blot of HEK293 
cells stably expressing GSTmodBHMT-myc.  Amino acid starved cells represented in 
lanes 3-6 were treated with 50µM, 25µM, 10µM and 5µM vinblastine repectively.  Lane 
1 represents cells in starvation media, and lane 2, starvation media with 100 µM 
chloroquine as a control for a block of lysosomal degradation. Western blot of 
endogenous LC3 is shown in the bottom panel.  BHMT fragmentation and LC3-II are 






















vinblastine in a dose dependent manner, and at 50 µM was as effective as chloroquine at 
inhibiting BHMT fragmentation (Fig. 21, lanes 3-6).  Western blot of endogenous hLC3 
shows an inverse correlation between levels of LC3-II and BHMT fragment 1, 
confirming that vinblastine blocks macroautophagy at a late stage, causing an 
accumulation of autophagosomes.  The vinblastine data provide additional 
pharmacological validation that the BHMT assay does not measure chaperone-mediated 
autophagy, but is specific for macroautophagy. 
The pharmacological inhibitors of BHMT fragmentation strongly argue that the 
BHMT assay specifically measures macroautophagy.  The lysosome inhibitors 
convincingly demonstrate that BHMT fragmentation is lysosomal and the 
macroautophagy inhibitors wortmannin and 3MA, and vinblastine suggest it is not due 
chaperone-mediated autophagy (CMA).  However, the effects of any of these inhibitors 
on microautophagy are not known, and therefore the pharmacological data cannot rule 
out microautophagy as a mechanism of BHMT lysosomal import.   
3.1.2.2. Validation of the BHMT assay by modulating levels of known autophagy genes. 
Silencing of a macroautophagy-specific gene by short-interfering RNA (siRNA) 
would unambiguously validate that BHMT is delivered to the lysosome by 
macroautophagy.  Beclin1, the human ortholog of yeast Atg6, was chosen as one target 
for siRNA.  The expression of Beclin1 is thought to promote autophagy through its 
interaction with the Class III PI3 Kinase, Vps34[72].  Over-expression of Beclin1 
increases macroautophagy in MCF7 cells and monoallelic deletion of Beclin1 promotes 
tumorigenesis in part due to suppressed macroautophagic activity[38].  pSilencer DNA 
plasmid vectors (Ambion), designed with a short hairpin (sh) insert, were used to express 
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target-specific sequences to be processed into siRNA that would silence certain Atg 
genes.  In a manner similar to the HA-LC3B-myc reporter, the GSTmodBHMTmyc 
reporter was stably integrated into HEK293 cells.  This eliminated issues related to the 
co-transfection of shRNA plasmids with a BHMT reporter plasmid, especially when 
multiple transfections were required for efficient gene silencing.  HEK293 cells that 
stably expressed GSTmodBHMT were transfected twice with pSilencer plasmids to 
achieve a transfection efficiency of approximately 90%.  Three different shRNA 
sequences targeting Beclin1 successfully lowered Beclin1 expression by approximately 
60% (Fig. 22). Significantly, in the cells with shRNA targeting Beclin1, generation of 
BHMT fragment 1 in amino acid and serum starved cells was decreased by 
approximately 60% (Fig. 22).  This provides the first direct evidence that an autophagy 
specific gene is necessary for the BHMT assay to generate fragment 1 and that the 
BHMT assay is measuring the process of macroautophagy. 
A second gene of interest in macroautophagy is human unc 51-like kinase 1 
(hULK1).  hULK1 is an ortholog of yeast Atg1, the only protein kinase identified in the 
initial genetic screens in S. cerevisiae[44].  In yeast, one model suggests that Atg1 
activity increases with autophagy induction in response to the decreased phosphorylation 
of Atg13, an associating protein in complex with Atg1[45].  The phosphorylation of 
Atg13 is downstream of the target of rapamycin (TOR).  Inhibition of yeast TOR by 
nitrogen starvation or by its inhibitor rapamycin decreases phosphorylation of Atg13 and 
increases the activity of Atg1.  However, this model is not universally accepted, as 
Abeliovich et al. reports that Atg1 activity is not required for macroautophagy, although 
it is required for the Cvt pathway[46].  Although hULK1 was first described in 1998 as 
 
91 
Figure 22.  Validation of the BHMT assay by silencing Beclin1 with shRNA.  
Plasmid vectors with three different short hairpin inserts designed to target Beclin1 
mRNA with siRNA were transfected twice in HEK293 cells stably expressing 
GSTmodBHMT-myc.  Cells were treated to conditions of plus and minus amino acid 
media.  Levels of BHMT fragment 1 are decreased in cells with decreased levels of 
Beclin1.  Western blot for Beclin1 verifies that levels of endogenous Beclin1 decreased 




















an Atg1 ortholog, data that suggests a role in autophagy has only recently been published.  
It was shown that shuttling of the mammalian autophagy-related protein mAtg9 between 
the trans-Golgi and autophagosomes is inhibited in cells in which hULK1 transcript 
levels are decreased by shRNA, providing the first evidence that human hULK1 plays a 
role in mammalian macroautophagy[52].   
Because hULK1 is a kinase, it seemed likely that conditions known to induce or 
inhibit autophagy might change its specific activity.  This is supported by data in S. 
cerevisiae that Atg1 activity increases in conditions known to induce autophagy[45].  To 
test this, it was necessary to create and express an epitope-tagged hULK1 because 
hULK1 antibodies that were commercially available were not sensitive enough for 
immunoprecipitation or western blotting of the endogenous protein.  hULK1 was cloned 
from a human cDNA library and subcloned into a mammalian expression vector with an 
HA epitope tag at the amino-terminus and a myc tag at the carboxy-terminus.  To make a 
catalytically inactive allele of hULK1, the invariant lysine in subdomain two of the 
catalytic domain, known to disrupt ATP binding in other kinases, was mutated to a 
glutamine (K39Q) by site directed mutagenesis.  The HA-tagged hULK1
KD
 mutant 
migrated faster on SDS-PAGE than HA-ULK1-myc, in a band shift consistent with loss 
of phosphorylation (Fig. 23A).  To test the activity of HA-hULK1-myc and HA- 
hULK1
KD
, the two kinases were tested in an in-vitro kinase assay with myelin basic 
protein (MBP) as a generic substrate.  In the conditions tested, HA-ULK1-myc was 
catalytically active toward MBP and was able to autophosphorylate as expected.  The KD 
mutant was not active toward MBP and did not autophosphorylate (Fig. 23B).  
To test the specific activity of hULK1, HEK293 cells expressing HA-ULK1-myc 
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Figure 23.  Expression and activity of HA-hULK1-myc and HA-hULK1
KD
myc.   A.  
Western blot of  HA-tagged hULK1 and the slower-migrating HA-tagged kinase dead 
hULK1
KD
.  B.  In-vitro kinase assay:  The epitope-tagged wild type hULK1 can 
autophosphorylate and phorphorylate MBP in vitro.  HA-hULK1
KD
myc shows no 
















Figure 24.  Specific activity of HA-hULK1-myc in conditions known to induce or 
inhibit macroautophagy.  HEK293 cells expressing HA-hULK1-myc were treated to 
conditions known to induce autophagy, such as minus essential amino acids and 
rapamycin treatment, or to conditions known to inhibit autophagy, such as 10mM 3MA, 
100nM wortmannin, and 100µM chloroquine.  Top panel shows expression of HA-
hULK1-myc by western blotting.  Middle and bottom panels are autorads showing 
autophosphorylation of HA-hULK1-myc and phosphorylation of the generic substrate, 



















were tested under conditions known to induce autophagy such as amino acid starvation or 
treatment with 40nM rapamycin, as well as conditions that inhibit autophagy such as 
treatment with 100nM wortmannin, 10mM 3MA or 100µm chloroquine.  After four hour 
treatment and extraction, HA-ULK1-myc was immunoprecipitated from cells extracts 
and tested for activity toward MBP in an in-vitro kinase assay.  As a control of 
expression, a western blot of HA-hULK1-myc in crude extracts is shown in the top panel 
(Fig. 24).  Autophosphorylation of hULK1 and phosphorylated MBP are shown in the 
bottom two panels of Figure 24.  Unlike in yeast, the specific activity of HA-hULK1-myc 
did not change in starvation conditions, with rapamycin treatment, or in any of the other 
conditions tested. 
Protein kinase function can be regulated by mechanisms other than changes in 
specific activity.  Expression levels regulate the function of some kinases and could be a 
mechanism of regulation for hULK1.  Although endogenous hULK1 cannot be seen by 
western blotting with the available antibodies, qPCR is a testable method to determine if 
amino acid starvation affects levels of hULK1 mRNA.  Total RNA was extracted from 
HEK293 cells that were maintained in either complete or starvation media for 
approximately 7 hours.  Each condition was repeated in triplicate.  After reverse 
transcription to cDNA with random primers, qPCR was performed on each sample, in 
duplicate, with primers specific to hULK1 and its isoform hULK2.  Quantitation is 
expressed as fold change, normalized to two housekeeping genes, actin and 18S (Fig. 25).  
Amino acid starvation did not significantly change levels of either hULK1 or hULK2 
mRNA, compared to cells in complete media.  Regulation of hULK1 does not seem to 
occur at the transcriptional level. 
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Figure 25.  hULK1 and hULK2 transcript levels are unchanged in amino acid 
starved cells.  T98G cells were maintained in complete media or media depleted of 
essential amino acids and serum for 6 hours.  After extraction of total RNA and RT-PCR, 
qPCR was performed with primers to either hULK1 or hULK2.  Relative levels of 
hULK1 and hULK2 mRNA in amino acid starved cells are compared to cells in complete 
media.   Fold change is normalized to two housekeeping genes:  actin and ribosomal 18S.  
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Figure 26.  HA-hULK1
KD
myc inhibits starvation-induced BHMT fragmentation.  
HEK293 cells were cotransfected with GSTmodBHMTIRESGFP and either HA-
hULK1
KD
myc or empty plasmid.  Generation of fragment 1 is inhibited in cells 
expression HA-hULK1
KD
myc.  Expression levels of GFP and hULK1 by western blotting 





















Although the specific activity of hULK1 did not change observably under 
conditions that modulate autophagy, it was tested how disruption of hULK1 signaling 
might affect autophagy as judged by BHMT fragmentation.  One easy way to test this is 
to use the kinase dead allele of hULK1 as a dominant interfering mutant.  The 
catalytically inactive HA-hULK1
KD
 allele was co-expressed in HEK293 cells with the 
BHMT reporter. After sufficient time to allow for expression, the cells were starved of 
essential amino acids and serum for approximately 5 hours and extracted.  Expression of 
the catalytically inactive hULK1
KD
 mutant consistently inhibited the generation of 
BHMT fragment 1 in starved cells (Fig. 26).  The dominant interfering effect of the 
hULK1
KD
 mutant on the assay suggests that ULK1 activity may be important for 
autophagy.   
There is a caveat to the use of a dominant-interfering allele.  The effects of its 
over-expression can occur through sequestration of either downstream effectors or 
upstream regulatory proteins.  Therefore, the dominant-interfering effect of hULK1
KD
 on 
the BHMT assay might not be specific for ULK1 alone.  To address this caveat, a 
strategy was implemented to decrease the expression of endogenous hULK1 by shRNA.  
hULK1 mRNA levels were measured by qPCR to assess the effectiveness of silencing.  
Two shRNAs were designed to target the three prime untranslated region (3′ UTR) of 
hULK1.  hULK1 sh3′12 and sh3′13 were the most effective in decreasing hULK1 
message by approximately 90% and 80% respectively, as measured by qPCR (Fig. 27A).   
Significantly, when transfected into HEK293 cells stable expressing GSTmodBHMT, each 
of these hULK1 shRNAs inhibited the ability of BHMT to generate fragment 1 in amino  
acid starvation conditions (Fig. 27B).  Therefore, the effectiveness of hULK1 silencing 
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Figure 27.  shRNA-targeted depletion of hULK1 inhibits BHMT fragmentation.  A. 
Plasmid vectors with two different short hairpin inserts designed to target hULK1 mRNA 
with siRNA were transfected twice in HEK293 cells stably expressing GSTmodBHMT-
myc.  Cells were treated to conditions of plus and minus amino acid media.  qPCR 
derived from cells expressing sh3′12 and sh3′13 shows significant knockdown of hULK1 
mRNA to 90% and 80% of normal levels.  Fold change is normalized to the 
housekeeping gene, ribosomal subunit L32.  This is typical of three independent 
experiments.  B.  The BHMT assay is shown in HEK293 cells stabling expressing 
GSTmodBHMT, with a non-specific shNC or the two shRNA hairpins targeting hULK1.  
Generation of fragment 1 is inhibited in cells expressing the shULK1 3′12 and 3′13. 
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on BHMT fragmentation provides further validation of the BHMT assay by targeting a 
second autophagy specific gene, and also demonstrates with an endpoint assay that loss 
of ULK1 alone is sufficient to inhibit autophagy. 
3.1.2.3. Sensitivity of the BHMT assay to amino acids 
In the development and validation of the BHMT assay, essential amino acid 
starvation was the predominant condition used to induce macroautophagy in cell culture.  
For starvation experiments, cells were maintained in culture media that lacked the twelve 
essential amino acids but contained levels of glutamine and non-essential amino acids 
normal for Dulbeccos’s modified essential media (DMEM).  Except for the harsh nutrient 
deprivation seen in ischemia, cells in a physiological setting are rarely forced to respond 
to total starvation.  However, circulating levels of amino acids are known to fluctuate: 
being lower during fasting, in the perinatal period, and in times of poor nutrition; and 
higher after the ingestion of a protein-rich meal.  To test the response of the BHMT assay 
to changes in levels of available essential amino acids, HEK293 cells expressing the 
GSTmodBHMTIRESGFP reporter were incubated in culture with steadily decreasing 
concentrations of the essential amino acids for six hours.  Aliquots of cell extract 
normalized for total protein were pulled down with glutathione agarose and prepared for 
western blotting.  Expression of GFP in WCE is shown on western blot as a 
normalization control for the BHMT reporter (Fig. 28).  It was expected that cells might 
respond to changes in amino acid levels in a linear fashion and that this would be 
reflected in increasing levels of BHMT fragment 1.  However, only minor increases in 
fragment 1 were seen in the range of amino acid concentrations between 100% and 20% 
(Fig. 28A).  The major increase in levels of BHMT fragment 1 was found only after the 
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Figure 28.  The BHMT assay is sensitive to physiologic levels of essential amino 
acids.  A.  HEK293 cells expressing GSTmodBHMTIRESGFP were maintained in media 
containing decreasing concentrations of 12 essential amino acids for 6 hours.  Essential 
amino acids in this experiment are listed in Table 4.  Significant increase of BHMT 
fragmentation is seen at levels less than 20%.  B.  The experiment describe in A was 
repeated with the same conditions, except with titration points in the lower concentration 
range.  Concentration of essential amino acids must be less than 10% of normal DMEM 


























concentration of essential amino acids had decreased by more than 80% of normal culture 
conditions.   
To further define the percentage of essential amino acids required for BHMT 
fragmentation, HEK293 cells expressing the GSTmodBHMTIRESGFP reporter were tested 
in conditions as before, but with a titration of essential amino acids more specific for the 
ranges between 25% and 0%.  Significant accumulation of BHMT fragment 1 was noted 
only when essential amino acids fell below 10% (Fig. 28B).  Expression of endogenous 
LC3 at each of the titration points correlate well with the BHMT assay (Fig. 28B bottom 
panel).  On careful examination of the amino acid composition in DMEM, it was noted 
that for cultured cells, amino acid levels in DMEM are up to 6 times greater than the 
mean reference values for circulating amino acids in human plasma (Table 4).  Therefore, 
the window of response noted with the BHMT assay is likely within the physiological 
range. 
Some of the essential amino acids play a regulatory role in macroautophagy, 
based on inhibition of intracellular proteolysis.  In rat hepatocytes cultured from fetal, 
suckling or weaned animals, Bloomaart et al. showed that intracellular levels of leucine, 
isoleucine, lysine, phenylalanine and tyrosine increased in linear fashion in response to 
extracellular levels of the same[73].  Amino acids within this group effectively decreased 
proteolysis independent of hormonal levels.  These experiments are difficult to perform 
and are not necessarily specific for macroautophagy.  The BHMT assay provides an 
excellent means to test the effects of these and the other essential amino acids on the 
induction of macroautophagy.  To test the response of the BHMT assay to small changes 
in the amino acid content of the media, cultured cells expressing GSTmodBHMTIRESGFP 
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were deprived of select essential amino acids, while all other amino acids were 
maintained at DMEM levels.  Removal of either leucine or arginine alone was able to 
moderately induce autophagy, while loss of isoleucine, valine, lysine, methionine, 
phenylalanine or tryptophan caused only a mild increase in fragmentation (Fig. 29).   The 
removal of the three branched-chain amino acids as a group induced autophagy to levels 
approaching the loss of all essential amino acids.  No change was noted with the removal 
of histidine or threonine (Fig. 29).  Levels of LC3-I and LC3-II in the selectively-starved 
extracts are shown by western blotting with antibody against endogenous LC3, showing 
some response to the loss of individual amino acids, although with less sensitivity (Fig. 
29).  A caveat that must be considered in the interpretation of these results is that 
although amino acid depletion was presumed, intracellular levels of amino acids were not 
measured in this experiment.  However, it has been shown that intracellular levels of free 
branched chain amino acids decrease 90% with a 30 minute starvation period in HEK293 
cells[74].  The data from this experiment suggest that full induction of macroautophagy 
needs the additive effects of a small number of essential amino acids, particularly the 
branched chain amino acids.  The BHMT assay provides a degree of sensitivity to look at 
small changes in macroautophagy not possible with the LC3 assay.  Future experiments 
using the BHMT assay will be able to determine what combination of essential amino 
acids is sufficient to induce a full macroautophagy response. 
3.1.2.4. The BHMT assay is functional in multiple cell lines 
The BHMT assay depends on the activity of a lysosomal cathepsin to cleave 
BHMT in a specific region of the protein to generate fragment 1.  Multiple isoforms of 
cathepsins are expressed to varying degrees in different cell types[75].  To determine if 
 
112 
Figure 29.  Sensitivity of the BHMT assay to single essential amino acids.  HEK293 
cells expressing GSTmodBHMTIRESGFP were incubated in specially prepared DMEM 
media missing one or more essential amino acids for 6 hours.  A.  The BHMT assay was 
tested for sensitivity to the loss of leucine, isoleucine, and valine individually and in 
combination.  B.  The BHMT assay was tested for sensitivity to the loss of each of the 
following essential amino acids:  arginine, histidine, lysine, methionine, phenylalanine, 
threonine, and tryptophan.  A.and B.  Western blot of GFP is shown as a control of 
reporter expression in middle panel.  Bottom panel is a western blot with antibody against 
endogenous LC3 from same samples that were starved for individual amino acids. 
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the BHMT assay was cell type specific or capable of functioning in a broad range of 
cells, the GSTmodBHMTIRESGFP reporter was transiently transfected into an array of cells 
from human, mouse, and rat (Fig. 30 and data not shown).  Cells were starved of essential 
amino acids and serum for 6 hours to induce autophagy, and the autophagy inhibitors 
3MA and chloroquine were added to starved cells to validate that fragmentation was due 
to macroautophagy.  After treatment, cells were harvested and WCE and glutathione pull-
downs were prepared for western blotting as before.  The expression of GFP by western 
blotting is shown as a control for transfection of the BHMT reporter (Fig. 30, second row 
of panels from the top).  Western blot with antibody against endogenous LC3 is included 
for comparison and for validation of chloroquine dosage (Fig. 30, third row of panels 
from top).  Cancer cells were chosen with known mutations or deficiencies that have 
been reported to effect macroautophagy.  Immortal, but not transformed cells of mouse 
origin, NIH3T3 and C2C12, were included to test the efficacy of the BHMT assay in a 
non-tumor cell setting.  Starvation induced BHMT fragmentation was observed in all of 
the cell lines selected (Fig. 30 top panels).  However, the degree of increase over basal 
varied between cell lines.  In each case, BHMT fragmentation was sensitive to 3MA and 
chloroquine, indicating that accumulation of fragment it was due to an induction of 
autophagy. 
In summary, the BHMT assay is effective in transformed and non-transformed 
cells of varying species.  In the present form, its usefulness is limited to cells in culture 
that can be transfected to a level of efficiency that allows sufficient expression of the 
reporter.  Fragmentation of BHMT accurately reflects the state of macroautophagy when 
LC3-II levels alone are ambiguous. 
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Figure 30.  The BHMT assay is functional in multiple cell lines.  
GSTmodBHMTIRESGFP was transiently transfected into T98G cells, MCF7 cells, H1299 
cells, NIH3T3 cells, and C2C12 cells, which were tested under conditions known to 
induce and inhibit macroautophagy for 6 hours.  Levels of BHMT fragment 1 increased 
in all cells with amino acid starvation and were inhibited by the autophagy inhibitors 
10mM 3MA and 100µM chloroquine.  Western blot of GFP is shown as a control for 
transfection efficiency between conditions.  Western blot for endogenous LC3 is shown 
in the bottom panel for comparison. 
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3.1.2.5. Example of the BHMT and LC3 assays with W7 
Ultimately, the value of the BHMT assay lies in its ability to provide an endpoint 
assessment of autophagy.  Its use is not mutually exclusive with the LC3 assay which is 
valued for its specificity in autophagosome formation, but complements the LC3 assay by 
providing a read-out for the autolysosomal completion of autophagy.  By using these two 
assays together, one can gain insight into how a signaling pathway or experimental 
condition affects the autophagic pathway.  To demonstrate the value of using both an 
endpoint assay and a midpoint assay to assess regulation of autophagy, examples in the 
literature were sought for which the BHMT assay would bring clarification. 
The role of Ca
2+
/calmodulin-dependent protein kinases in the regulation of 
autophagy is ambiguous, at least in part due to the difficulties of measuring autophagy.  
Early in the study of autophagy, one method loaded cells with [
3
H]raffinose and 
measured the sedimentable [
3
H]raffinose to assess autophagic sequestration.  With this 
method, a study in 1992 reported that Ca
2+
/CamK-II activity inhibited autophagy, and 
that autophagy was restored by the use of the calmodulin inhibitor W-7[76].  Later, the 
same group published that W-7 had little or no effect on autophagy[77].  Various other 
studies have suggested a role for the Ca
2+
/calmodulin dependent kinase, Death-
Associated Protein kinase (DAPk) and the Ca
2+
/calmodulin-dependent protein kinase, 
elongation factor 2-kinase (EF2-Kinase) in the induction of autophagy[78, 79].  Methods 
used to monitor autophagy in these studies included electron microscopy, 
monodansylcadaverin (a marker of acidic vesicles), and LC3.  The conflicts in the 
conclusions of these studies and the ambiguities of the methods used to measure protein 
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autophagy raise questions about the role of calcium and the Ca
2+
/calmodulin-dependent 
kinases in autophagy.   
Based on what has been reported, the calmodulin inhibitor W-7 could inhibit, 
increase, or have no effect on autophagy.  The BHMT assay in conjunction with the LC3 
assay may be able to resolve whether Ca
2+
/calmodulin-dependent protein kinases are 
necessary for the induction of autophagy.  W-7 was chosen for this experiment because 
its effect on EF2 can be easily assessed by western blotting.  During amino acid 
starvation, EF2 Kinase activity increases in a Ca
2+
/calmodulin dependent manner, and 
increases the phosphorylation of EF2.  The activity of EF2 Kinase and the effectiveness 
of W-7 can be determined by the use of a phospho-specific antibody that recognizes EF2 
(Fig. 31, bottom panel).  To test the effects of W-7 on autophagy, W-7 was added to 
HEK293 cells stably expressing either GST-BHMT or HA-LC3B reporter and 
maintained in either complete media or starvation media for six hours.  Normalized 
aliquots of cell extracts were pulled down with either glutathione agarose of antibody to 
HA and prepared for western blotting.  In the extracts from HA-LC3B cells, LC3B-II 
levels were the same between the control and W-7 treated cells (Fig. 31, second panel 
from the top).  Based on the LC3B assay alone, W-7 appears to have no effect on 
autophagy.  In contrast, W-7 strongly blocked the generation of BHMT fragment 1 in 
starvation conditions (Fig. 31).  The BHMT assay unambiguously demonstrates that W-7 
inhibits autophagy.  Together, the results show that the inhibitory effects of W-7 on 
autophagy do not interfere with the early steps of LC3 processing and autophagosome 




Figure 31.  Example of BHMT and LC3B assays with the calmodulin inhibitor W7.  
HEK293 cells stably expressing either GSTmodBHMTmyc4.1 or HA-LC3B-myc were 
treated for 6 hours in complete or starvation media, with the calmodulin inhibitor W7 
(1µM).  Cell extracts were pulled down with glutathione agarose or antibody to HA and 
prepared for western blotting.  A.  Western blot in top panel shows BHMT fragmentation 
upon amino acid starvation (lane 2) which is inhibited by W7 (lane 4).  Western blot 
showing LC3B is in bottom panel.  LC3B-II levels increase with starvation in control and 
W7-treated cells in a similar manner.  B.  Western blot of cell extracts from 
GSTmodBHMTmyc4.1 and HA-LC3B-myc cell extracts with a phospho-specific antibody 
that recognizes phosphorylated eEF2.  Phosphorylation of EF2 is decreased in cells 
treated with W7. 
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In conclusion, the BHMT assay is a novel endpoint assay for macroautophagy, 
whose specificity has been validated pharmacologically and by shRNA targeting known 
autophagy genes.  Its effectiveness has been demonstrated in multiple cell lines.  The 
BHMT assay alone, or in combination with the LC3 assay, provides a unique method to 
study macroautophagy in cell culture. 
3.2. The BHMT assay and higher order structure 
3.2.1. The carboxy terminus of BHMT is important for generation of fragment 1 
In the process of developing the BHMT assay, it was evident that the generation 
of fragment 1 was lost with severe modification or truncation of the carboxy-terminus.  It 
was originally expected that a carboxy-terminal fragment might be generated from a 
BHMT reporter, similar to the peptide of rat BHMT originally identified by mass 
spectrometry.  To help capture what was expected to be the carboxy-terminal fragment, 
constructs were made that fused a GST epitope tag to the carboxy-terminus of BHMT, 
with a variety of amino-terminus epitope tags.  Two examples are shown (Fig. 32A).  No 
fragmentation of the HA-BHMT-GST reporter was observed in any of three experimental 
conditions:  incubation in complete media, starvation media, or complete media with 
rapamycin (Fig. 32B, lanes 4-6).  When the amino-terminal GST-tagged BHMT reporter 
was fused to a second carboxy-terminal GST tag to create a GST-BHMT-GST reporter, 
the presence of a carboxy-terminal GST was detrimental to generation of the observed 
fragment 1, even though the fusion protein expressed at approximately the same level as 
GST-BHMT-myc (Fig. 32, lanes7-9).  The data led to a hypothesis that a functional 
carboxy-terminus was important for generation of GST-BHMT fragment 1. 
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Figure 32.  Carboxy-terminus of BHMT is important for generation of fragment 1.  
A.  Schematic of three early BHMT reporters:  GST-BHMT-myc, HA-BHMT-GST and 
GST-BHMT-GST.  B.  Each reporter was expressed in HEK293 cells and incubated in 
complete media, media starved of essential amino acids and serum, or media with 40nM 
rapamycin for 5 hours.  Western blot of glutathione agarose pull-downs shows that 
fragment 1 only accumulated in cells transfected with the GST-BHMT-myc reporter 
(lanes 1-3).  Cells transfected with a GST epitope tag at the carboxy-terminus did not 
generate observable fragmentation with either amino acid and serum starvation or with 















The original GST-BHMTwt is in fact a 9 amino acid truncation mutant that could 
correctly be designated ∆C9.  It seemed likely that if the carboxy-terminus was 
important, restoring the carboxy terminus to full length might make BHMT a better 
reporter.  Conversely, it was predicted that a more severe carboxy-terminal truncation of 
BHMT might make a poorer reporter.  To test this, truncated GST-BHMT
∆C142
 was made 
that deleted 142 amino acids from the carboxy-terminus.  This construct did not produce 
fragments with amino acid starvation and expressed poorly, most likely due to instability 
(data not shown).  Separately, a GST-BHMT full length reporter was made that restored 
the nine carboxy-terminal amino acids that had been truncated in the original reporter.  
The full length reporter produced fragments 1 and 2 in a manner identical to the original 
reporter, suggesting that the moderate ∆C9 truncation of the original reporter was 
tolerated without adversely affecting the readout (Fig. 33).  For the remainder of this 
document, the term full length, original, or GST-BHMTwt will refer to the original ∆C9 
construct. 
The above data raised questions about the nature of the carboxy-terminal and its 
role in the generation of GST-BHMT fragment 1.  How much of the carboxy-terminus 
could be truncated without losing the ability to generate fragment 1?  To answer this 
question, a number of progressive carboxy-terminus truncation mutants of BHMT were 
produced.  Each mutant was compared to the original GST-BHMTwt construct in the 
ability to generate fragment 1 when expressed in cells starved of essential amino acids.  
The autophagy inhibitors 3MA and bafilomycin A1 were tested with each mutant to 
validate that any fragment generated from the truncation mutants was due to 
macroautophagy.  GST-BHMT
∆C24
 generated fragment 1 in a manner identical to the 
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Figure 33.  BHMT assay with full length GST-BHMT.  HEK293 cells were 
transfected with either the original BHMT reporter (∆C9) or with a carboxy-terminal 
restored full length GST-BHMT.  After starvation of essential amino acids and serum, 
cell extracts were pulled down with glutathione and prepared for western blotting.  Both 
BHMT reporters generated fragment 1 upon amino acid starvation in a similar manner.  






















Figure 34.  The BHMT assay with truncation mutants:  ∆C24 and ∆C51.  Truncation 
mutants of BHMT were created with a PCR and sub-cloning strategy to remove either 24 
or 51 amino acids from the carboxy-terminus.  BHMT and the truncation mutants were 
transfected into HEK293 cells and treated with starvation media to induce autophagy or 
starvation media with the autophagy inhibitors 10mM 3MA or 100nM bafilomycin A1.  
Compared to control BHMT, truncation of 24 amino acids from the carboxy-terminus of 
BHMT does not prevent generation of fragment 1 with starvation (lanes 3-6), but 






















control (Fig. 34, lanes 3-6).  However, deletion of an additional 27 amino acids in GST-
BHMT
∆C51
 created a truncation mutant that failed to generate fragment 1 under amino 
acid starvation conditions, in spite of the fact that its expression and stability was equal to 
either control or ∆C24 (Fig. 34, lanes 7-9).  Further truncations (∆C92 and ∆C115) 
produced proteins that expressed poorly and were likely unstable and degraded (data not 
shown).  The data confirm that the carboxy terminus of BHMT is important in the 
generation of fragment 1. 
Rat BHMT exists as a homo-tetramer.  Each subunit is an (α/β)8 barrel with an 
extended dimerization arm, a hook region, and a linker region leading to a long alpha-
helix at the carboxy-terminus (Fig. 35).  The carboxy-terminus of BHMT is important for 
the interaction between subunits, and oligomerization is essential for enzymatic activity 
of the endogenous enzyme[80].  The two subunits that form a dimer interact with each 
other through both the dimerization arm, which extends from one subunit and imbeds in 
the structure of its dimer partner, and the hook, a region of intertwining complementary 
strands between the two subunits.  The long carboxy-terminal alpha-helix of each subunit 
interacts with a subunit of the second dimer pair, linking the two dimers to form the 
complete tetramer.  It is likely that truncation of the BHMT carboxy-terminus, or fusion 
of bulky epitope tags to the carboxy end, might disrupt the ability of the subunits to 
interact.    
This raised a question about whether it was catalytic activity or oligomerization of 
BHMT that might be important to be recognized as a substrate for the autophagy.  If 
activity was important, then a catalytically inactive BHMT mutant should not generate 
fragment 1 in starvation conditions.  BHMT is a metabolic enzyme that transfers one 
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Figure 35.  BHMT structure.  BHMT structure is shown with interaction of 3 of the 4 
subunits.  BHMT is a dimer of dimers.  Two subunits interact with each other through the 
dimerization arm (as labeled) and hook regions (shown in enlarged box).  The carboxy-
terminal alpha-helix of each subunit then interacts with a subunit of the other dimer to 
form a tetramer.  Oligomerization of subunits is required for an active enzyme.  The 
truncations that affect the original BHMT reporter (∆C9) and the ∆C24 mutant are in the 
carboxy-terminal alpha helix as labeled on the dark blue subunit.  The ∆C51 truncation 
and the W352A mutation are in the hook region of the dimerization arm as labeled.  The 














methyl group from betaine to homocysteine to generate methionine.  It contains a Zn
2+
 
ion, coordinated by three cysteine residues (C217, C299 and C300) which are necessary 
for its activity[81].  To test whether catalytic activity of BHMT effected its ability to be 
processed by macroautophagy, a mutation reported to kill catalytic activity, C217A[81], 
was introduced by site directed mutagenesis.  HEK293 cells transiently transfected with 
GST-BHMT-myc and the mutant GST-BHMT
C217A
myc were incubated for 4 hours in 
complete media, starvation media, or starvation media with the autophagy inhibitor 3MA.  
After the cells were harvested, glutathione pull downs of cell extracts were processed for 
western blotting.  Both control and GST-BHMT
C217A
 reporters generated similar levels of 
starvation induced fragment 1 that was inhibited by the autophagy inhibitor 3MA (Fig. 
36).  These data suggest that catalytic activity of BHMT does not play a role in its ability 
to generate fragment 1 in starved cells.   
It appeared there was correlation between the ability to generate fraction 1 and the 
ability to form multimers.  The results obtained with the ∆C51 truncation of BHMT 
initiated a search for a single mutation that would affect oligomerization without 
truncating large regions of the protein.  A study by Szegedi and Garrow found that 
mutation of a tryptophan in the dimerization arm of BHMT, W352A, impaired the 
stability of subunit dimerization[80].  The W352A point mutation was made in the 
original GST-BHMT reporter so that oligomerization would be disrupted.  The W352A 
mutant was expressed at levels identical to control GST-BHMT, and cells were cultured 
under the same conditions described in Figure 34.  Like the ∆C51 truncation mutant, the 
W352A point mutant did not generate fragment 1 under starvation conditions (Fig. 37).  
These data show that the predicted ability of BHMT to oligomerize correlates with the 
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Figure 36.  Catalytic activity of BHMT is not required for fragmentation.  The 
C217A mutation in BHMT is known to kill enzymatic activity, and was introduced in 
BHMT by site directed mutagenesis.  HEK293 cells were transfected with either control 
BHMT or BHMT
C217A
 and treated with starvation media to induce autophagy or 
starvation media with 10mM 3MA to inhibit autophagy for 6 hours.  Cells were extracted 
and prepared for western blotting as previously described.   The control and C217A 
mutant BHMTs both generated fragment 1 in starvation conditions that was inhibited by 
3MA.    
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Figure 37.  The BHMT
W352A
 point mutant in the BHMT assay.  A mutation, W352A, 
was introduced into BHMT by site directed mutagenesis that was reported to prevent 
oligomerization and activity.  HEK293 cells were transfected with either control or GST-
BHMT
W352A
 mutant and treated to conditions identical to the previous experiment with 
the truncation mutants (Fig. 34).  Cells were extracted and prepared for western blotting 
as previously described.  Fragment 1 did not accumulate in the BHMT
W352A
 mutant 























ability to generate intralysosomal fragment 1. 
It was necessary to determine if the GST-tagged BHMT mutants could or could 
not oligomerize as predicted. To do so, the original BHMT cDNA was sub-cloned 
downstream of a HA epitope tag and co-expressed in HEK293 cells with each of the 
GST-tagged BHMT constructs.  To demonstrate interaction, glutathione beads were 
added to cell extracts to pull out the GST-BHMT mutants, and the beads were gently 
washed so as not to disrupt interacting proteins.  The purified GST-BHMT complex was 
then run on SDS-PAGE, transferred to PVDF membrane, and probed with an antibody to 
the HA epitope tag.  Expression levels of the GST and HA tagged proteins show that all 
expressed at equivalent levels (Fig. 38, bottom two panels).  As expected, the two 
mutants that were able to generate fragment 1, GST-BHMTwt and GST-BHMT
∆C24
, were 
able to pull down HA-BHMTwt, indicating multimerization (Fig. 38, lanes 1 and 2).  In 
contrast, the two mutants that disrupted the hook region of the dimerization arm by either 
truncation (GST-BHMT
∆C51
) or mutation (GST-BHMT
W352A
) were either unable to pull 
down HA-BHMTwt in the case of the former, or pulled down very small amounts of HA-
BHMTwt in the case of GST-BHMT
W352A
 (Fig. 38, lanes 3 and 4).  The ability of GST-
BHMT
W352A
 to pull down a small amount of HA-BHMTwt is consistent with the 
published report that the W352A mutant is able to form dimers, but in complexes that are 
less stable than wild-type BHMT. 
The data above demonstrate that the ability of the BHMT mutants to assemble 
inversely correlates with the ability to generate fragment 1 with starvation.  How does 
oligomerization affect the ability of BHMT to generate fraction 1 with starvation?  Two 
possibilities are likely:  1) Quaternary structure of BHMT is required for the lysosomal 
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Figure 38.  The carboxy-terminal of BHMT is important for oligomerization.  
HEK293 cells were co-transfected with HA-BHMT and each of the GST-tagged BHMT 
mutants:  wt, ∆C24, ∆C51, and W352A.  After allowing time for expression, cells were 
harvested and cell extracts were processed for glutathione pull-down and western blot.  
Membrane was probed with antibody against HA to demonstrate interaction between 
subunits.  Interacting subunits were demonstrated between HA-BHMT and GST-BHMT 
(lane 1) and HA-BHMT and GST-∆C24 (lane 2).  No interaction was found between HA-
BHMT and GST-∆C51 (lane 3).  A small amount of GST-W352A associated with HA-
BHMT, consistent with the ability of this mutant to form unstable dimers (lane 4).  Each 



















cathepsin to bind, recognize and cut the L2 region to generate fragment 1, or 2) 
Quaternary structure of BHMT is important to be recognized by the autophagic 
machinery and for import into autophagosomes.   
3.2.2. BHMT∆C51 is in autophagosomes 
To distinguish between these two possibilities, an assay was designed that would 





 trafficked inside of autolysosomes, then the first explanation 
would be favored.  However, if BHMT
∆C51
 was not found in autolysosomes, then the data 
would suggest that quaternary structure was important for cargo selection.  The 
accomplishment of this aim would require two steps.  First, a population of intact 





.  Second, autophagosome/autolysosome associating proteins 
such as BHMT would be digested with a protease, with or without a membrane-
disrupting detergent.  This protection assay would determine if ∆C51 was enclosed 
within a membrane compartment (Fig. 40A).  Resistance to proteolytic digestion in the 
absence of a detergent would indicate the target protein is enclosed and protected in a 
membrane structure. 
The isolation and enrichment of intact autolysosomes was challenging due to their 
transient nature, low abundance, and high rate of turnover within the cell.  To increase the 
abundance of autophagosomes and autolysosomes, cells were starved of essential amino 
acids for 12 hours with protease inhibitors leupeptin and E64d to slow lysosomal  
proteolysis and turnover of the autolysosomal population.  GST-BHMT and HA-LC3B-
expressing HEK293 cells treated in this manner were collected, disrupted by dounce 
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Figure 39.  BHMT on a Sucrose gradient.  A.  Schematic of the sucrose gradient 
protocol.  Transfected HEK293 cells are extracted and processed by differential 
centrifugation to isolate the light membrane fraction (LMF).  The LMF is then loaded on 
a discontinuous sucrose gradient for ultra-centrifugation.  Fractions are collected by 
upward displacement, numbered 1 at the top to 11 at the bottom of the gradient.  
Fractions are then analyzed by either glutathione pull-down, immunoprecipitation, or 
TCA precipitation.   B.  BHMT fragment 1 co-fractionates with the lysosomal marker 













Figure 40.  Protection assay.  A.  Schematic of the protection assay protocol.  Briefly, 
sucrose gradient fractions are prepared and incubated for 5 minutes with trypsin to digest 
outer membrane proteins, and with trypsin and Triton X-100 to digest protein both inside 
and outside of the enclosed membrane space.  B.  Validation of conditions for protection 
assay.  Left panel shows total trypsin digest of BHMT in cytosolic fraction.  Pooled 
fractions 5 and 6 are digested with trypsin, with and without the detergent Triton X-100.  
Full length BHMT, fragment 1 and LC3B-II that remain in the presence of trypsin are 












homogenization and gently centrifuged to remove intact nuclei and large membrane 
remnants.  The post-nuclear supernatant (PNS) was collected and centrifuged at high 
speed to pellet the light membrane fraction (LMF), consisting of autophagosomes, 
autolysosomes, lysosomes, mitochondria and other small organelles or microsomes.  The 
LMF pellet was washed to remove excess cytoplasmic protein, gently resuspended in the 
homogenization buffer, and loaded on a prepared discontinuous sucrose gradient.  After 2 
hours of ultra-centrifugation at 2º C to separate the subcellular organelles by density, 1 ml 
fractions were collected by upward displacement.  The first fraction collected from the 
top of the gradient was labeled fraction 1 and the densest fraction from the bottom was 
labeled fraction 11 (Fig. 39A).  
Aliquots of fractions from the sucrose gradient were then analyzed for the 
presence of autolysosomes.  Figure 39B is representative of fractions 5 through 8 from 
cells starved of essential amino acids.  LC3B-II, a marker of both autophagosomes and 
newly fused autolysosomes, accumulated only in cells starved for essential amino acids, 
with the highest levels in fraction 5.  GST-BHMT fragment 1 also accumulated as 
expected in fractions collected from amino acid starved cells (Fig. 39B).  BHMT 
fragmentation was first observed in fraction 5, and peaked in fractions 6 and 8.  A 
western blot for an endogenous lysosomal membrane protein, lysosome-associated 
membrane protein 1 (LAMP1), demonstrates that BHMT fragment 1 and LAMP1 co-
fractionate and peak in identical fractions, validating that BHMT fragmentation is 
lysosomal.   
Although fragment 1 of GSTmodBHMT
wt
 co-fractionated with autolysosomes, full 
length BHMT could be found in every fraction of the gradient.  This could be due to the 
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abundance of an over-expressed protein that is known to oligomerize and associate with 
the cytoskeleton.  GSTmodBHMT
wt
 elutes from a gel filtration column over a broad range 
of molecular weight fractions, suggesting the propensity of this protein to form higher 
order complexes (data not shown).  Having established that autophagosomes and 
autolysosomes could be tracked on a sucrose gradient, LC3B-II marked fractions 
enriched in these vesicles were pooled to test if GSTmodBHMT
wt
 was sequestered within 
vesicles.  The post-LMF supernatant, which contained GSTmodBHMT
wt
 but was expected 
to be devoid of vesicular structures, was used as a negative control.  In the post-LMF 
supernatant, trypsin alone was able to fully degrade full-length GSTmodBHMT
wt
 (Fig. 
40B, left panel).  At the end of the 5 minute trypsin digest, all that remained was a 
fragment approximately the size of GST.  Aliquots of pooled fractions 5 and 6 were 
digested with trypsin alone, or with trypsin plus 0.2% Triton X-100.  After the reaction 
was stopped with soybean trypsin inhibitor (STI), GSTmodBHMT
wt
 and HA-LC3B were 
pulled down with glutathione or HA-antibody attached to Sepharose beads, and run on 
SDS-PAGE.  Approximately half of LC3B-II and full length BHMT, and most of BHMT 
fragment 1 remained after the trypsin digest (Fig. 40B, right panel).  However, LC3B-II, 
full length BHMT, and BHMT fragment 1 were completely degraded when identical 
aliquots were digested with trypsin 0.2% TritonX-100 under the same conditions (Fig. 
40B, right panel).  This assay demonstrates that in fractions 5 and 6, but not in the post-
LMF supernatant, some of BHMT and fragment 1 and approximately half of LC3B-II  
were within intact vesicles, likely autolysosomes and autophagosomes.  It is likely that 
not all vesicles were intact, as a portion of fragment 1 was digested with trypsin alone. 
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With evidence that the protection assay was functional, sucrose gradients were 




.  To 
enrich the LMF with autophagosomes, the HEK293 cells were starved of essential amino 
acids and serum for 12 hours with the autophagy inhibitor chloroquine (100µM).  
Prolonged treatment with chloroquine was used to inhibit fusion of autophagosomes and 
lysosomes, causing an accumulation of autophagosomes loaded with undegraded cargo.  
After differential centrifugation, the LMF was loaded on discontinuous sucrose gradients 
and fractions were collected as before.  Levels of LC3-II peaked in fractions 5 and 6 and 
were more broadly distributed throughout the gradient, indicating that the chloroquine-
induced block of fusion had created a more heterogeneous population of autophagosomes 
(Fig. 41A).  Aliquots of fractions from each gradient, one from cells expressing 
GSTmodBHMT
wt 
and one from cells expressing GST-BHMT
∆C51
, were digested with 




 were protected from the 
action of trypsin (Fig. 41B) and levels of sequestered protein correlated well with LC3-II.  




, is sequestered into 
autophagosomes and 2) the carboxy terminus and/or quaternary structure of BHMT is 
important for lysosomal cathepsin cleavage to generate fragment 1, but may not play a 
role in autophagosomal delivery. 
3.2.3. BHMT∆C51 and 3MA 
The above data show that BHMT
∆C51
 is within autophagosomes and by inference, 
likely within autolysosomes.  A second experiment was designed to validate  
the actual degradation of ∆C51 in autolysosomes.  The above data showed that the 





Figure 41.  Protection assay with GST-BHMT and GST-BHMT
∆C51
.  A.  HEK293 
cells expressing GST-BHMT or GST-BHMT
∆C51
 were incubated for 6 hours in media 
from which essential amino acids and serum had been removed and with 100µM 
chloroquine to enrich fractions in autophagosomes.  Sucrose gradient fractions were 
prepared as described.  A.  Equal aliquots of each gradient fraction were precipitated with 
TCA and prepared for western blotting with antibody against endogenous LC3.  With 
chloroquine, LC3-II is found in multiple lower fractions.  LAMP1 is found only in 
fractions 5 and 6.  B.  Protection assay was performed in conditions described on each 
fraction from GST-BHMT and GST-BHMT
∆C51
 expressing cells.  BHMT and BHMT
∆C51
 
are both protected from the protease action of trypsin in fractions corresponding well 
with LC3, suggesting that both BHMT and BHMT
∆C51




















the L2 loop, but the “no thrombin” GST∆TBHMT has a lysosomal cleavage site outside 
BHMT that may not be dependent on the carboxy-terminus.  The GST∆TBHMT reporter 
generated two fragments, fragment 1 and fragment 2′ (Fig. 18).  Unlike the original 
reporter, both fragments of GST∆TBHMT were invariantly lysosomal.  Quaternary 
structure might not be important for cleavage of GST in this linker region to generate 
fragment 2′.  If this prediction was correct, then fusion of GST∆T to BHMT
∆C51
 should 
make a ∆C51 reporter capable of generating fragment 2′ in a manner similar to 
GST∆TBHMT. 
To test this, ∆C51 was sub-cloned into the GST∆T background to match 
GST∆TBHMT.  The GST∆T versions of BHMT and ∆C51 were expressed in HEK293 
cells and tested under conditions of amino acid starvation to induce autophagy, and 
treated with 3MA and wortmannin to inhibit autophagy as before.  Both fragments 1 and 
2′ in the control GST∆TBHMT were generated be amino acid starvation and were 
completely sensitive to 3MA and wortmannin (Fig. 42, left panel).  The accumulation of 
fragment 2′ also increased in the ∆C51 mutant with amino acid starvation, consistent with 
an autophagic response.  However, while completely sensitive to wortmannin, ∆C51 
fragment 2′ was partially resistant to the effects of 3MA (Fig. 42, right panel).  This was 
surprising because it suggested that there was a difference between the processing of 
∆C51 and full length BHMT. 
The sucrose gradient provides a level of resolution between light and dense 
autolysosomes that might be useful in determining how ∆C51 differs from BHMT.  
HEK293 cells expressing GST∆TBHMT or GST∆TBHMT
∆C51
 were starved of essential 
amino acids and serum to induce macroautophagy.  The LMF fractions from cells
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Figure 42.  GST∆TBHMT
∆C51
 generates fragment 2′ under starvation conditions.  
The ∆C51 mutant was sub-cloned into the BHMT∆T background to see if it would 
generate fragment 2′.  HEK293 cells expressing either GST∆TBHMT or GST∆TBHMT
∆C51
 
were starved of essential amino acids and serum to induce autophagy and treated with 
starvation media with 10mM 3MA or 100nM wortmannin to inhibit autophagy.  Cell 
extracts were prepared for western blot as previously described.  In control BHMT cells, 
fragments 1 and 2′ accumulate under starvation conditions and are inhibited by 3MA and 
wortmannin (left panel).  In starvation conditions, GST∆TBHMT
∆C51
 generated increased 
levels of fragment 2′.  GST∆TBHMT
∆C51
 fragment 2′ levels were inhibited by 






















Figure 43.  GST∆TBHMT
∆C51
 fragment 2′ co-fractionates with LAMP1 in sucrose 
gradient fractions.  HEK293 cells expressing cells expressing GST∆TBHMT or 
GST∆TBHMT
∆C51
 were starved of essential amino acids and serum to induce autophagy 
or GST∆TBHMT
∆C51
 were starved of essential amino acids and serum to induce 
autophagy.  After 6 hours, the LMF of cell extracts were prepared and separated by 
density on a sucrose gradient as described.  Glutathione extracts and WCE were prepared 
for western blotting as described.  BHMT fragments 1 and 2′, ∆C51 fragment 2′, and 
LAMP1 cofractionate and peak in fractions 6 and 8.  Lower right panel shows 
distribution of LAMP1-marked vesicles in gradients prepared from 3MA-treated 
HEK293 cells.  Note that in fractions from 3MA-treated cells, distribution of LAMP1 















expressing each BHMT mutant were isolated by differential centrifugation and loaded on 
sucrose gradients as before.  Glutathione pulldowns from gradient fractions were 
analyzed for GST-tagged proteins and peptides by western blotting.  Under amino acid 
starvation conditions, GST∆T BHMT generated fragment 1 and 2′ as expected.  GST∆T 
BHMT
∆C51
 generated fragment 2′ that co-fractionated perfectly with BHMT fragments 1 
and 2′ and with LAMP1 (Fig. 43).  This was consistent with the presence of 
autolysosomes in fractions 6 and 8. 
To determine the effect that 3MA might have on the two autolysosome fractions, 
sucrose gradient fractions were prepared from the LMF of HEK293 cells which were 
starved of essential amino acids and serum as before, but in the presence of 10mM 3MA.  
TCA precipitation and western blot analysis of the 3MA-treated fraction, prepared as 
before, showed decreased LAMP1 staining in the denser fraction 8 (Fig. 43, lower right 
panel).  This is consistent with previous reports that 3MA changes the distribution of 
lysosome-type vesicles on density gradients[82].  It suggests that 3MA may prevent the 
formation of denser autolysosomes or other amphisomes. 
The resolution provided by the sucrose gradients was used to examine the 
fractionation pattern of GST∆TBHMT or GST∆TBHMT
∆C51
 in the presence or absence of 
3MA.  HEK293 cells expressing either GST∆TBHMT or GST∆TBHMT
∆C51
 were starved 
of essential amino acids and serum as before, with or without 10mM 3MA.  After 
extraction, the LMFs from each treatment and BHMT reporter were isolated by 
differential centrifugation and loaded on discontinuous sucrose gradients to resolve 
autolysosomes by density as before.  GST∆TBHMT fragments 1 and 2′ were observed in 
fractions 5-10, peaking in fraction 9.  Both fragments were completely sensitive to the 
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effects of 3MA (Fig. 44).  As before, GST∆TBHMT
∆C51
 generated fragment 2′ which co-
fractionated with the two fragments of   GST∆TBHMT.  However, although fragment 2′ 
was as sensitive to 3MA in fractions 7 to 10 as control, it was completely resistant in 
fractions 5 and 6 (Fig. 44).   Western blot analysis with antibody against endogenous LC3 
showed that LC3-II co-fractionated with BHMT fragments, and like GST∆TBHMT
∆C51
 
was resistant to 3MA only in the middle fractions (Fig. 44).  In this experiment, 3MA 
effectively prevented fragmentation of GST∆TBHMT in all fractions, but prevented 
fragmentation of GST∆TBHMT
∆C51
 only in the denser fractions.  What types of vesicles 
are in these fractions of different densities? 
The LAMP1 data show that 3MA affects the distribution of LAMP1 in the dense 
fraction of the sucrose gradient.  LAMP1 is a membrane-spanning protein found 
predominantly on lysosomes, but can also be found on some autolysosomes, 
amphisomes, and late endosomes.  To further characterize the nature of the vesicles in the 
light and dense fractions of the sucrose gradient, a lysosomal disrupting agent, glycyl-L-
phenylalanine 2-naphthylamide (GPN) was used.  GPN is hydrolyzed by the lysosomal 
cathepsin C, producing an intralysosomal accumulation of product that osmotically 
ruptures the lysosomal membrane.  GPN is most effective in small mature lysosomes, and 
is less effective in larger digestive bodies such as autolysosomes and amphisomes where 
it must compete with other substrates.  It does not disrupt intact autophagosomes[83].  
Two sets of HEK293 cells, starved of essential amino acids and serum, were collected 
and gently disrupted by dounce homogenization.  One set was incubated for 6 minutes at 
37º with the lysosome disrupter GPN, after which both sets were processed as described 
to separate the LMFs by density on matched sucrose gradients.  Fractions 6 -9 were 
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Figure 44.  GST∆TBHMT
∆C51
 fragment 2′ is resistant to 10mM 3MA in the lighter 
sucrose gradient fractions.  HEK293 cells expressing GST∆TBHMT or 
GST∆TBHMT
∆C51
 were starved of essential amino acids and serum to induce autophagy 
or were treated under starvation media with 10mM 3MA.  The LMF of each sample was 
prepared and fractionated by density on a sucrose gradient.  Western blots of glutathione 
pull-downs and TCA precipitation samples were prepared as before.  Top panel shows 
fractions from cells expressing GST∆TBHMT.  Fragments 1 and 2′ show good sensitivity 
to 3MA.  Middle panel shows fractions from cells expressing GST∆TBHMT
∆C51
.  
Fragment 2′ is sensitive to 3MA in the denser fractions, 7-10, but is completely resistant 
to 3MA in fractions 5 and 6.  Bottom panel:  Like ∆C51, endogenous LC3 is also 
resistant to 3MA in fractions 5 and6, and sensitive to 3MA in fractions 7-9 (no LC3 is 





















Figure 45.  Characterization of sucrose gradient fractions with GPN.  HEK293 cells 
were extracted in PBS and gently dounced to rupture the plasma membrane.  One set was 
exposed to the lysosome disrupter GPN.  Cells were then processed as before to obtain 
the LMF, which was processed on prepared sucrose gradients. Gradient fractions were 
precipitated with TCA and prepared for western blotting with an antibody against 
LAMP1.  In the GPN-treated samples, LAMP1 was decreased in fraction 6 compared to 
control.  In fraction 8, LAMP1 levels were equivalent between the GPN-treated and 
control samples.  GPN is a more effective inhibitor of cathepsin C in mature lysosomes, 
which predicts that fraction 6 contains mature lysosomes and that fraction 8 is 





                   




























probed for LAMP1.  LAMP1 in the denser fraction was not affected by GPN, while 
levels of LAMP1 in fraction 6 were reduced, suggesting that in HEK293 cells, mature 
lysosomes are in the lighter fractions (Fig. 45).  The combined data of the previous 
experiments suggest answers to the following questions: 
What type of vesicles are in the light and dense sucrose gradient fractions (See 
Table 5)?  1)  Mature lysosomes are in fractions 5/6 and are not in fractions 8/9.  This is 
supported by the GPN data and LAMP1 antibody staining by western blotting.  It is also 
supported by previous data with chloroquine, which prevents lysosomal fusion.  With 
chloroquine, LAMP1 is only seen in the lighter fractions.  2)  Autophagosomes are likely 
in fractions 5/6.  This is supported by the LC3 data and by previous gradient data of 
amino acid starved cells with the HA-LC3B reporter.  3)  Autolysosomes are in fractions 
5/6.  These fractions are marked by both LAMP1 and LC3-II.  BHMT fragment 1 and 2′ 
demonstrates the presence of functional autolysosomes.  4)  Autolysosomes are in 
fractions 8/9.  This is supported by the western blot data of LAMP1 and LC3-II.   BHMT 
fragment 1 and 2′ in the dense fractions supports the presence of functional 
autolysosomes.  5)  Autophagosomes may be in fraction 8/9.  The denser fractions are 
more likely to be digestive organelles, however the data cannot rule out denser 
autophagosomes.  The chloroquine data suggest that dense autophagosomes can form if 
lysosomal fusion is inhibited.   
What is 3MA doing?  1)  3MA quantitatively decreases LAMP1, LC3-II and 
BHMT fragmentation of either mutant in dense fractions.  Therefore, 3MA likely inhibits 
the formation of dense autolysosomes and perhaps dense autophagosomes.  2)  3MA 
inhibits the generation of GST∆TBHMT fragment 1 and 2′ in fractions 5/6.  3)  3MA does 
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not inhibit fragmentation of GST∆TBHMT
∆C51
 in fractions 5/6.  4)  LC3-II levels are not 
affected by 3MA in fractions 5/6.  This raises the following question: 
Does the 3MA-resistant generation of GST∆TBHMT
∆C51
 fragment 2′ occur in 
autolysosomes or lysosomes?  1)  The protection assay data validate that 
GST∆TBHMT
∆C51
 is normally sequestered in autophagosomes, however it does not rule 
out a compensatory mechanism of lysosomal import of the ∆C51 mutant by 3MA or 
microautophagy.  2)  The co-fractionation of LAMP1 and LC3-II in the presence of 3MA 
supports a hypothesis of autolysosomal degradation, but it too does not rule out a 
lysosomal-only mechanism. 
The persistence of LC3-II in fractions 5/6 is surprising, because 3MA is thought 
to block autophagosome formation by inhibiting the Class III PI 3-kinase, Vps34.  
However, the sucrose data suggest that LC3-II vesicles are formed in the presence of 
3MA   To determine what affect 3MA might have on the production and turnover of 
LC3, HEK293 cells stably expressing HA-LC3B-myc were used to test the effects of 
3MA on LC3B-II flux in either complete or starvation media.  3MA treatment caused a 
slight increase in levels of LC3B-II compared to control cells, which suggested that 3MA 
was not inhibiting LC3B-II formation, but was likely inhibiting LC3B-II flux, similar to 
the effects of leupeptin and pepstatin A.   
If 3MA treatment was in fact revealing LC3B-II flux, than inhibition of the 
lysosome in 3MA-treated cells should cause an accumulation of LC3B-II.  To test this, 
the HEK293 cells stably expressing HA-LC3B-myc were treated with or without 3MA as 
before, but with the additional treatment of 25µM chloroquine.  The accumulation of 
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Figure 46.  Lysosomal flux of LC3B-II in cells treated with 3MA.  HEK293 cells 
stably expressing HA-LC3B-myc were treated to complete or starvation media for 4 
hours, with and without 10mM 3MA, extracted and prepared for western blotting as 
before.  LC3B-II levels in 3MA treated cells were slightly increased compared to control 
cells (lanes 3 and 4, compared to lanes 1 and 2).  A second set of HA-LC3B-myc stable 
cells were treated under the same condition, except with added 25µM chloroquine for a 
stronger inhibition of lysosomal turnover.  Surprisingly, LC3B-II levels in the 3MA and 
chloroquine-treated cells were increased almost to the level of the control cells (lanes 7 
and 8, compared to 5 and 6).  This suggests that LC3B-II continues to be made and 
























LC3B-II levels in cells treated with 3MA plus chloroquine was significant, reaching 
levels approximately half of that found in control cells (Fig. 46, lanes 7 and 8, compared 
to lanes 5 an 6).  This demonstrates that in the presence of 3MA, LC3B-II continues to be 
made and that it is degraded in the lysosome.  The surprising conclusion is that LC3B-II, 
and presumably LC3B-II decorated vesicles, are made and degraded by the lysosome in 
the presence of 3MA.  Quantitatively, LC3B-II turnover in the presence of 3MA is 
decreased, but is still significant compared to control.  
These data support the hypothesis that the fragmentation of GST∆TBHMT
∆C51
 
occurs in autolysosomes in the presence of 3MA, even though GST∆TBHMT degradation 
has been inhibited.  This result is surprising.  The autophagy field defines 
macroautophagy almost exclusively in terms of sensitivity to 3MA.  The data suggest that 
there is a 3MA sensitive and a 3MA insensitive macroautophagy.  GST-BHMT is 
processed by the former and ∆C51 by the latter.  This is important because 3MA inhibits 
a signaling molecule, VPS34. It suggests that production of new PI3P is important for the 
autophagic machinery to recognize BHMT, but is either not necessary or lower levels are 
necessary for macroautophagy-related degradation of ∆C51.  The ability of the BHMT 
mutants to form higher order structure suggests how these two types of macroautophagy 
are different.  (See discussion). 
3.3. Regulation of autophagy:  S6 Kinase and mTOR 
mTOR is well known for its role in responding to changes in nutrients, mitogens, 
and ATP to regulate cell growth.  In times of stress such as amino acid starvation, mTOR 
signaling is down-regulated and its downstream effectors p70S6K and 4E-BP1 are 
hypophosphorylated.  This results in reduced translation and increased autophagy.  Other 
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stressors such as hypoxia are well known inhibitors of the mTOR pathway and not 
surprisingly, there are suggestions in the literature that hypoxia and ischemia induce 
autophagy.  Hypoxia-ischemia creates a severe energy crisis in cells that are deprived of 
nutrients and the oxygen necessary for energy production, and generally results in cell 
death.  In a physiological context, normal cells exposed to conditions of ischemia after 
arterial occlusion normally die by apoptosis, although in some models, the mechanism of 
cell death is proposed to be through excessive autophagy.  Evidence in support of the 
latter includes TEM showing extensive vacuolization and decreased LC3-I levels in 
damaged tissue compared to control[66].  The question that arises from this data is 
whether these cells would have sufficient ATP to activate and sustain autophagy under 
ischemic conditions.  Multiple steps of the autophagic process require ATP and even 
small changes of ATP levels have been shown to slow autophagic proteolysis[84].  It is 
likely that decreased ATP negatively affects the ATP-dependent steps of LC3 
conjugation, lysosome acidification, and vesicle fusion.   
Experimental conditions of hypoxia-ischemia can be tested in cell culture and the 
BHMT and LC3B assays can both be used to measure the effects at two different stages 
of the autophagic process.  HEK293 cells stably expressing either GSTmodBHMTmyc or 
HA-LC3B-myc were used for these experiments to eliminate potential effects of 
transfection reagents.  The two cells lines were maintained in either complete or 
starvation media, with or without glucose.  One set was maintained at normoxia (37ºC, 
5% CO2 and 21% O2), and a matched set was incubated at hypoxia (37ºC, 5% CO2, and 
1% O2).  The duration of the experiment was approximately five hours.  In normoxia, 
BHMT fragment 1 accumulated normally in conditions of amino acid and serum 
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starvation.  Glucose starvation slightly decreased the level of fragmentation (Fig. 47, 
lanes 3&4 compared to lanes 1&2).  LC3B-II levels were in agreement with BHMT 
fragmentation, showing induction with amino acid and serum starvation and slightly less 
LC3B-II with glucose deprivation (Fig. 47, lanes 1-4, second panel from the top).  At 1% 
O2 with full glucose, autophagy by both BHMT and LC3B assays was not impaired, 
compared to control (Fig. 47, lanes 6 & 7 compared to lanes 1 & 2).   However, in the 
experimental condition of ischemia, defined as loss of amino aids, serum, and glucose at 
1% O2, LC3B-II levels were severely decreased and accumulation of amino acid 
starvation-induced BHMT fragment 1 was significantly less than control (Fig. 47, lanes 7 
and 8).  In this experiment, BHMT fragmentation and LC3B-II levels both suggest that 
autophagy is inhibited in these conditions of ischemia.   
However, even with impaired LC3B processing, there was a small amino acid 
starvation-induced increase of BHMT fragmentation in ischemia.  Some turnover of 
autophagic cargo did occur in ischemia.  It suggests that in ischemia, as amino acid, 
glucose, O2 and ATP levels fall, mTOR is down-regulated, and an attempt is made to 
activate an autophagic response.  However, as the ischemic-induced energy crisis 
continues, the cell utilizes and exhausts the limited resources of LC3-II and ATP in 
response to the loss of amino acids and autophagy is inhibited.  Understanding how cells 
respond to ischemic conditions has physiological relevance in tumor biology as well as in 
pathological infarct.  
The BHMT assay for autophagy is a good tool to look at the signaling pathways 
involving mTOR and p70S6K, and phosphorylated S6.  Amino acid starvation inactivates 
the mTOR pathway, which inactivates p70S6K and results in the dephosphorylation of 
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Figure 47.  The BHMT and LC3B assays in a cell culture model of ischemia.  
HEK293 cells stably expressing either GSTmodBHMTmyc4.1 or HA-LC3B-myc were 
incubated for 5 hours in complete media with and without glucose, or in media deficient 
in essential amino acids and serum, with and without glucose.  One set was maintained in 
conditions of normoxia (37ºC, 5% CO2 and 21% O2) and another set was maintained in 
hypoxia (37ºC, 5% CO2, and 1% O2).  The cellular condition of ischemia is mimicked in 
the cells deprived of amino acids, serum, glucose and oxygen (lane 8).  Amino acid 
starvation induced the accumulation of BHMT fragment 1 in both normoxia and hypoxia.  
No significant increase in fragment 1 was noted with glucose starvation in either 
normoxia or hypoxia.  The combined effects of experimental ischemia inhibited BHMT 
fragmentation, although a slight increase in fragment 1 is noted in lane 8 compared to 
lane 7.  LC3B-II production was significantly decreased in the absence of glucose and 





















S6[85].  This has led to the suggestion that inactivation of S6K and dephosphorylation of 
S6 are important events in the induction of autophagy[54].  In order to test if starvation 
induced S6 dephosphorylation is necessary for the induction of autophagy, a 
constitutively active allele of S6K was used that is known to be active in the absence of 
amino acids.  HEK293 cells were co-transfected with GSTmodBHMTIRESGFP and the 
constitutively activate allele of p70S6K, p70S6K
T389E,D3E
, or vector control.  After 
allowing sufficient time for expression, the cells were treated in complete media or media 
deficient in essential amino acids and serum with protease inhibitors, to induce 
autophagy.  After 6 hours, cells were harvested and cells extracts were prepared for 
glutathione pulldown and western blotting.  Expression of GFP is shown as a control of 
GSTmodBHMTIRESGFP transfection efficiency.  Western blotting with anti-myc antibody 
is shown to verify expression of the p70S6K allele.  As expected, amino acid starvation 
significantly increased BHMT fragmentation in the control (Fig. 48, lane 2).  
Surprisingly, expression of the constitutively active allele of p70S6K
T389E,D3E
 did not 
inhibit BHMT fragmentation, but rather appeared to slightly increase the accumulation of 
BHMT fragment 1 in both basal and starvation conditions (Fig. 48, lanes 3 and 4)).  The 
expression p70S6K
T389E,D3E
 is expected to send a positive signal to S6, the downstream 
substrate of p70S6K.  WCE aliquots were prepared for western blotting with an antibody 
against phospho-S6.  In control cells, S6 was dephosphorylated during the 6 hour 
starvation period, but remained phosphorylated in the presence of the p70S6K
T389E,D3E
  
allele as expected (Fig. 49, lanes 2 and 4).  Expression levels of total S6 protein are 




Figure 48.  Active p70S6K
T389E,D3E
 does not inhibit autophagy; over-expression of 
RHEB inhibits autophagy.  HEK293 cells expressing GSTmodBHMTIRESGFP were 
transfected with an activated allele of p70S6K
T389E,D3E
 or with mycRHEB.  After 
allowing time for expression, the transfected cells were treated with complete media or 
were treated under amino acid starvation conditions for 6 hours to induce autophagy.  
Cell extracts were prepared as previously described for western blotting.  In control cells 
and cells expression the active S6K, levels of BHMT fragment 1 increased in starvation 
conditions (lanes 1-4).  Active S6K was not sufficient to inhibit autophagy, and levels of 
fragment 1 were actually a little greater than control.  In the cells expressing the upstream 
activator or mTOR, BHMT fragmentation and autophagy were inhibited in starved cells.  
Controls of expression of the BHMT reporter, RHEB and S6K are shown in panels 2-4.  
The bottom panel is a western blot of endogenous LC3 from each sample.  Neither S6K 


















Figure 49.  S6 phosphorylation in cells with activated p70S6K
T389E,D3E
 and 
mycRHEB.  Western blot of cell extracts from BHMT experiment in Figure 48 with a 
phospho-specific antibody against S6.  Total S6 is shown in bottom panel as a control of 
expression.  As expected, phosphorylation of S6 is decreased in cells starved of essential 
amino acids, compared to cells in complete media (lane 2 compared to lane 1).  
Phosphorylation of S6 is protected in cells starved from amino acids that over-express 
activated p70S6K
T389E,D3E

























Figure 50.  4E-BP1 phosphorylation in cells with activated p70S6K
T389E,D3E
 and 
mycRHEB.  Western blot of cell extracts from BHMT experiment as in Figure 48 with a 
rapamycin control for each condition.  Top panel is western blot with a phospho-specific 
antibody against 4E-BP1.  Total 4E-BP1 is shown in bottom panel as a control of 
expression.  In control cells, amino acid starvation causes a band-shift collapse.  
Rapamycin also causes a slight band shift down of 4E-BP1.  Phosphorylation and total 
levels of 4E-BP1 are equivalent between cells expressing active S6K and control cells in 
each condition tested.  In last four lanes, over-expression of RHEB protects phospho-4E-
BP1 in starved cells, but not in rapamycin-treated cells.  Note that expression levels of 
total 4E-BP1 are decreased in cells with over-expressed RHEB.  This is most evident in 























If the amino acid signal for autophagy is through mTOR, then activation of 
mTOR should inhibit autophagy.  Although there are no activated alleles of mTOR, over-
expression of its upstream activator RHEB has been shown to activate mTOR in the 
absence of amino acids.  To test the role of mTOR on autophagy, HEK293 cells were co-
transfected with GSTmodBHMTIRESGFP and mycRHEB or vector control and treated 
under plus and minus amino acid media conditions as before.  Over-expression of 
mycRHEB completely inhibited the induction of autophagy as judged by the 
accumulation of BHMT fragment 1 in amino acid starved cells (Fig. 48, lanes 5 and 6).  
The RHEB data support a hypothesis that the signal to autophagy goes through mTOR 
and that activation of mTOR is sufficient to inhibit autophagy.  Ectopic expression of 
either p70S6K
T389E,D3E
 or RHEB did not effect levels of LC3-II, shown in the bottom 
panel of Figure 48. 
Like activated S6K, mycRHEB should also send a positive signal to S6.  WCE 
aliquots of samples were prepared for western blotting with an antibody against phopho-
S6.  In control cells, amino acid and serum starvation inhibited the phosphorylation of S6.  
In cells expressing the mycRHEB allele, phosphorylation of S6 was retained in minus as 
well as plus amino acid conditions.  Western blot with antibody against total S6 is shown 
as a control of expression.  This suggests that phosphorylation of S6 does not inhibit 
autophagy and supports the hypothesis that the signal to autophagy does not go through 
p70S6K or S6.   
The RHEB and p70S6K data suggest that the signal to autophagy goes through 
mTOR but is not through p70S6K.  The small increase that was observed in BHMT 
fragment 1 in cells transfected with activated p70S6K
T389E,D3E
 could suggest that the 
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over-expressed allele was interfering with a mTOR-dependent pathway parallel to 
p70S6K.  Another well-known effector of mTOR signaling is 4E-BP1, a negative 
regulator of the translation initiation factor, eIF-4E.  To test the effects of RHEB and 
p70S6K
T389E,D3E
 on 4E-BP1 phosphorylation, an experiment identical to the one in Figure 
48 was performed with the addition of a rapamycin control for each condition tested.  A 
western blot was prepared from whole cell extracts with antibody against phosphorylated 
4E-BP1.  Levels of total 4E-BP1 are shown in the bottom panel as a control (Fig.50).  In 
control and p70S6K
T389E,D3E
 cells, 4E-BP1 was phosphorylated in plus amino acid media, 
but phosphorylation was inhibited in cells that were starved of amino acids (Fig. 50, lanes 
1 and 5, compared to 3 and 7).  4E-BP1 in rapamycin-treated cells shows a slight band-
shift down, which can be seen with both phospho and total 4E-BP1 antibodies (lanes 2 
and 6).  In starved cells expressing the p70S6K
T389E,D3E
 mutant, little change in 4E-BP1 
phosphorylation was noted compared to control cells.  S6K does not appear to have 
dominant interfering effect.  Expression of ectopic RHEB increased the phosphorylation 
of 4E-BP1 in either plus or minus amino acid conditions, and rapamycin was effective in 
blocking the phosphorylation (Fig. 50, lanes 9-12).  Surprisingly, the expression of total 
4E-BP1 was slightly decreased in the RHEB samples compared to control or 
p70S6K
T389E,D3E
 (Fig. 50, lane 12).  The band-shift pattern of 4E-BP1 makes 
interpretation of expression difficult in some instances, but rapamycin is effective in 
collapsing the band-shift, making the decrease in expression more obvious in the 
rapamycin-treated sample.  Sustained mTOR signaling, through the over-expression of 
RHEB, increased phosphorylation of 4E-BP1 and decreased the expression of the protein.   
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While the mechanism through which mTOR signals to autophagy is still not 
known, the 4E-BP1 data suggest that a possible mechanism may involve signaling 
through 4E-BP1 and the initiation of translation.  The potential link between 4E-BP1, 
translation, and autophagy is consistent with other studies that link autophagy and 






4.1 Development of Autophagy Assays 
The study of mammalian autophagy has been hindered by the complexity of the 
process.  It requires the coordinate assembly of autophagy-specific proteins to build an 
autophagosome, an intact cytoskeletal network for trafficking, and a functional lysosome 
to degrade both the autophagosome and its cargo.  Much of the study of autophagy has 
centered on the autophagosome itself and on the Atg proteins that assemble it.  Two of 
the most commonly used methods to study autophagy involve electron microscopy and 
LC3.  Both are based on the identification and quantification of autophagosomes.  
Although autophagosome formation is of fundamental importance, its degradation must 
be considered to understand and study the complete process of autophagy.  An ideal 
assay would measure both sequestration and delivery to the lysosome.  One goal of this 
study was to identify a substrate for macroautophagy that could be used to study the 
entire process, from engulfment through to lysosomal degradation. 
4.1.1. Atg12 and Atg5 Conjugation 
Much of what is known about the molecular mechanism of autophagosome 
formation originated from genetic studies in S. cerevisiae mutants that were defective in 
autophagy.  Among the autophagy-specific genes identified by this approach were Atg12, 
Atg5, Atg7, and Atg10.  Together, the proteins coded by these genes function in one of 




autophagosome membrane[26].  Atg12 is a ubiquitin-like modifier that is activated in an 
ATP dependent step by the E1-like enzyme Atg7, transferred to the E2-like enzyme 
Atg10, and finally conjugated to Atg5 through the formation of an isopeptide 
bond, linking the carboxy-terminal glycine of Atg12 to the ε-amino group of lysine 149 
of Atg5.  The linked Atg12-Atg5 proteins then form a larger complex with Atg16[26].  
This large complex can be found on the convex side of a forming autophagosome and 
may function as a coating complex to help in the curvature of the forming membrane.  
The Atg12-Atg5 conjugation system is fully conserved in higher organisms, underscoring 
the importance not only of this mechanism, but of autophagy itself.  In Atg5
-/- 
mouse 
embryonic fibroblasts (MEFs), autophagosomes do not form, and surprisingly, LC3-I is 
not conjugated to LC3-II, suggesting functional interaction between the two conjugation 
systems[27].  If Atg5
K130R





 and Atg16 associate with small vesicles in the absence of Atg12, 
however the small vesicles do not grow[27].  Recent studies have shown that calpain-
mediated cleavage of Atg5 produces an Atg5 fragment that induces apoptosis[86], 
however there is no known function for unconjugated Atg12.  
At the beginning of this study, it seemed likely that the formation of new 
autophagosomes might require the assembly of more Atg12-Atg5 based complexes to 
coat the newly generated membrane.  Changes in levels of either the complex or the 
individual conjugate partners would then be a novel way to assess the cells demand for 
new autophagosomes  The data demonstrate that levels of the Atg12-Atg5 conjugate are 
exceedingly stable and do not appear to be regulated by amino acid starvation, inhibition 
of autophagy, or by levels of new protein synthesis.  The conjugation occurs without 
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autophagy stimulus and appears to be irreversible.  It is now known that there is a large 
cytoplasmic pool of the Atg12-Atg5-Atg16 complex and only a small percentage is 
associated with autophagosomal membranes[87].  Apparently, the Atg12-Atg5 complex 
exists in excess to meet cellular demand.  The Atg12-Ag5-Atg16 complex does not stay 
associated with autophagosomes after formation is complete, and it is likely that the cell 
recycles and reuses the complex, keeping a stable pool available at all times.  This makes 
the Atg5-Atg12 conjugate unsuitable as a measure of autophagy. 
Unlike the conjugate, levels of Atg12 dropped significantly with amino acid 
starvation.  This suggested two possible explanations.  Either more Atg12 was recruited 
to the covalent complex during starvation, or it was degraded by another mechanism.  
Since conjugate levels were unchanged, the latter explanation was more likely.  
Cycloheximide provided an elegant way to discriminate between the two possibilities.  
As an autophagy inhibitor, it should protect levels of Atg12 if Atg12 levels are turned 
over by autophagy.  As a translation inhibitor, it should cause levels of Atg12 to drop if 
Atg12 is degraded through another mechanism.  The data support the latter.  
Cycloheximide also did not protect Atg12 levels during nutrient rich conditions, 
suggesting that Atg12 stability is not significantly regulated by the nutrient conditions of 
the cell.  A major non-lysosomal mechanism for protein degradation in the cytoplasm is 
the protesome and data with the proteasome inhibitor MG132 confirm that unconjugated 
Atg12 was likely degraded by this mechanism. 
Unlike ubiquitin, which has many targets, Atg12 is only known to have one, 
Atg5.  Levels of unconjugated Atg12 and Atg5 are thought to be very low.  It could be 
that the only cellular function of Atg12 is to post-translationally modify Atg5.  Although 
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there is one report that suggests that unconjugated murine Atg12 facilitates LC3 
processing, the data is based on overexpression and the authors clearly state that there is 
no evidence of unconjugated, endogeonous Atg12[88].  It is possible that unconjugated 
Atg12 may be either unnecessary or deleterious to the cell, making quick elimination in 
the best interest of the cell.   Atg8 (LC3), the second ubiquitin-like modifier in 
autophagy, shares the same E1 enzyme, Atg7, with Atg12 in the conjugation process.  In 
murine cells, Atg12 is the preferred substrate for Atg7, over LC3 and the other murine 
Atg8 orthologs[89].  This suggests that the Atg12-Atg5 conjugation takes preference over 
LC3 modification, and supports the idea that free unconjugated Atg12 is undesirable.  It 
is also possible that the preference of Atg7 for Atg12 is to keep an excess supply of 
Atg12-Ag5 complex.   
In conclusion, neither the Atg12-Atg5 conjugation system nor changing Atg12 
levels proved suitable for the measurement of autophagy.  The stability of the Atg12-
Atg5 complex is an interesting observation that may be useful to validate knock-down of 
conjugation-specific ATG genes.  HA-Atg12 and GST-Atg5 not only conjugate to each 
other, but they form conjugates with their endogenous partners as well (data not shown).  
The stability of the conjugate in normal cells allows for reliable interpretation of 
decreases induced by siRNA to Atg7 or Atg10 in future studies.  The limited stability of 
unconjugated Atg12 is an interesting observation which may have physiological 
relevance.   
4.1.2. LC3 conjugation and autophagy 
LC3, the mammalian ortholog of Atg8, is a ubiquitin-like modifier in the second 
UBL conjugation system in autophagy.  Pro-LC3 is translated in a form that requires 
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proteolytic cleavage by Atg4B to expose the carboxy-terminal glycine required for 
conjugation.  It shares the E1-like enzyme Atg7 with the Atg12, but has its own E2-like 
enzyme, Atg3. Unlike any of the other known UBLs, LC3 does not modify another 
protein, but is conjugated to a lipid, most likely phosphatidylethanolamine, which 
anchors LC3-II to the autophagosome membrane[90].  LC3 is one of at least seven Atg8 
orthologs in mammals, including GATE-16, GABARAP-I, GABARAP-II, and hAtg8L, 
LC3A, LC3B, and LC3C[23, 90].  All have been reported to associate with 
autophagosomes, though other functions are likely.  LC3-II is the first, reported protein to 
specifically associate with autophagosomes, making it a valuable tool to identify these 
structures. 
LC3 processing has been embraced by much of the research community as an 
assay to measure autophagosomes by both biochemical and fluorescent assays[20, 91].  
The later relies on the localization of a chimeric LC3 fused to a fluorescent protein, 
normally green fluorescent protein (GFP).  Cytoplasmic, punctate structures containing 
GFP-LC3 are thought to represent autophagosomes and autolysosomes.  GFP- and RFP-
LC3 reporters have been developed in the context of this study and punctate structures 
can be observed and compared between individual cells (data not shown).  However, 
populations of each are found in both well-fed and starved cells making reproducible and 
sensitive counting of punctate structures problematic.   
The biochemical LC3 assay has been heavily used in the study autophagy, 
sometimes in conjunction with the fluorescent assay.  The lipid attached to LC3-II 
changes its electrophoretic mobility to create a faster migrating band that can be easily 
separated from LC3-I by SDS-PAGE.  Changes in either levels of LC3-II or in ratios of 
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LC3-II/LC3-I are often used to assess autophagy[20].  In rare cases when LC3-II cannot 
be seen, decreased levels of LC3-I have been interpreted as increased autophagy[66].  
Recently in the literature, issues concerning interpretations of the LC3 assay were raised 
by one the original investigators who introduced it[92].  Autophagosomes are not a 
product of autophagy and therefore, levels of autophagosomes do not always directly or 
linearly correlate with autophagy.  They are intermediate structures in flux, and levels of 
LC3-II only measure how much is present at a given moment.  High rates of autophagy 
can result in decreased LC3-II and low turnover at the lysosome can increase LC3-II.  
Both the fluorescent and biochemical LC3 assays have a high potential for false positive 
and false negative interpretations.  However, if carefully used and interpreted, the LC3 
assay maintains its value of specificity.  For this reason, the biochemical LC3 assay was 
developed and carefully assessed in this study to provide a tool to independently confirm 
published findings and to compare autophagosome and autolysosome accumulation with 
an endpoint assay 
During the subcloning of LC3, a mutant with the deletion of a conserved arginine 
(R68 or R69) in LC3 was discovered that retarded cleavage of pro-LC3 so that all three 
forms of LC3 were seen on SDS-PAGE.  An additional insertion of nine amino acids 
between the conserved glycine and the translational stop also occurred during subcloning 
but was found not to affect cleavage.  The region of LC3 affected by the deleted arginine 
is in a stretch of residues that is highly conserved in all the isoforms and orthologs of 
Atg8 from human to yeast.  R68 in particular is 100% conserved in all species examined, 
with the exception of the plant Arabidopsis (Table 3).  These residues are very near to a 
region containing two residues (F77 and F79 in yeast Atg8, F80 and L82 in human LC3) 
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that in yeast are important for the binding of Atg8 to the protease Atg4[65].  In the 
structure analysis of human Atg4B, the active site of Atg4B is occupied and inhibited by 
an autoinhibitory loop[93].  The core region of LC3, potentially involving F80 and L82, 
binds Atg4B, causing a conformational change to release the autoinhibitory loop and 
open the active site so that the carboxy-terminal tail of LC3 can bind the open cleft of the 
protease and be cleaved.  Large bulky proteins fused to the carboxy-terminus of LC3 do 
not affect the ability of Atg4B to cleave LC3 efficiently in an in-vitro cleavage assay, 
supporting the conclusion that the additional 9 amino acids at the carboxy-terminal of the 
mutant LC3 reporter did not contribute to the delayed processing[94].  In one study of 
yeast Atg8, an alanine mutation was made in K66 (comparable to R69 in LC3) and tested 
for the ability to rescue autophagy in ∆atg8 cells.  No defect was found in the K66A 
mutant within the limitations of their assay[65].  With the data from the mutant LC3 of 
this study, it is likely that the K66A mutation would be functional, though delayed in 
processing.   
The mutant LC3 reporter was tested for its response to two classic autophagy 
inhibitors:  chloroquine and 3MA.  Chloroquine enters the lysosome and acts as a proton 
sink, increasing the lysosomal pH and inhibiting lysosomal function and fusion with 
other vesicles.  As expected, levels of LC3-II accumulate in the presence of 100µM 
chloroquine.  3MA inhibits the Class III PI3K, Vps34.  The product of Vps34 activity is 
phosphatidylinositol 3-phosphate (PI3P) which is found on cytoplasmic vesicles and is 
thought to be required for autophagy.  Although the mechanism is not clear, it is thought 
that PI3P is necessary for the assembly of Atg proteins at the newly forming 
autophagosome.  One Atg protein that interacts with and possibly regulates Vsp34 is 
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Beclin1.  Some studies have shown that decreased Beclin1 effects LC3-processing, so 
3MA effects on LC3 are likely due to inhibition of Vps34[72].  Inhibition by 3MA causes 
an increase in the proform of LC3 in the mutant reporter, but does not affect 
accumulation of LC3-II.  It is likely that the 3MA-mediated increase in the proform of 
LC3 is the result of a defect in the recruitment and colocalization of the substrate proLC3 
with the Atg4B enzyme.  Proteins that bind PI3P do so through FYVE or PX domains, 
neither of which is found in LC3 or Atg4B.  Although interaction of proLC3 and Atg4B 
may be limited, the data show that LC3-II is still processed in the presence of 3MA.  If 
PI3P is specifically responsible for Atg4B localization to the autophagosome, then in the 
presence of 3MA, less Atg4B would be available for both the cleavage of proLC3 and the 
de-lipidating activity or LC3-II necessary for vesicle fusion, thereby affecting autophagy 
in at least two distinct steps of the process.  In the latter scenario, LC3-II levels would be 
frozen with no new production and no degradation.  The mutant LC3 reporter may be 
useful for future studies on the early processing steps of LC3 processing.   
The stable expression of HA-LC3-myc in HEK293 cells was a useful way to 
study the behavior of LC3 under various conditions.  Four conclusions can be drawn 
from data generated by this reporter.  First because some LC3-I may be degraded 
proteasomally under starvation conditions, LC3-I levels do not necessarily represent 
changes in autophagy.  This is important because decreased levels of LC3-I have been 
used to invoke increased autophagy in the use of LC3-II to LC3-I ratios and occasionally 
as a stand-alone marker.  It is possible that not all LC3-I observed by western blotting is 
newly synthesized and modified.  Some LC3-II at the autophagosome membrane must be 
cleaved and removed by Atg4B before vesicle fusion can occur.  The electrophoretic 
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mobility of the released LC3-I would likely be the same as newly modified LC3-I.  It has 
been suggested that released yeast Atg8-I is reused, however the data does not describe 
the exact site of the second cleavage[95].  Although some deubiquitinating (DUB) 
enzymes cleave the functionally-related ubiquitin from small adducts, the structure of 
human Atg4 is most similar to the UBP family of DUB enzymes which cleave the 
ubiquitin molecule from proteins[93].  Cleavage of LC3 at a peptide bond to remove PE 
would also remove the carboxy-terminal glycine, making it incompetent for a new round 
conjugation.  If correct, it is conceivable that a pool of incompetent LC3 would be 
proteasomally degraded during starvation.  It also explains why LC3-I levels are not 
proteasomally degraded in nutrient rich conditions, as this pool of LC3-I is likely newly 
processed from proLC3. 
The second conclusion that was apparent from the LC3 data is that levels of LC3-
II do not directly correlate with autophagy and can easily be misinterpreted.  
Autophagosomes are intermediate, transient vesicles in a constant state of flux and LC3-
II levels are ‘snapshots’ that reflect the balance between synthesis and degradation at a 
specific moment in the process.  Degradation is an important part of the regulatory 
process and LC3-II levels can increase, decrease, or not change under starvation 
conditions.  The data show that inhibition of lysosome degradation can be used as a tool 
to demonstrate LC3-II flux at short and long time points, dependent on the strength of the 
inhibition.  The data in this study are consistent with recently published data that 
lysosomal protease inhibitors are necessary to properly interpret LC3-II levels[92]. 
Strong lysosomal inhibition shows that a significant amount of LC3-II turns over 
in nutrient rich conditions.  This observation is supported by data published by Kochl et 
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al. that examined the effect of microtubule disrupting agents on macroautophagy in both 
full and minimal media[70].  It suggests a significant degree of autophagosome 
membrane flux during nutrient rich conditions and raises a question about whether amino 
acid starvation increases LC3-II processing.  The chloroquine time course data from this 
study show that levels of LC3-II accumulate faster under starvation conditions, consistent 
with an interpretation that LC3-II is processed at a faster rate under starvation conditions.  
Conceptually however, the unexpected level of LC3-II flux in complete media is not 
inconsistent with a form of a mammalian Cvt-like pathway or of a cytoplasmic version of 
pinocytosis, with constant internal LC3-II-marked membrane flux through the lysosome.  
Interestingly, LC3-II levels appear to be self-limiting. The limiting factor does not appear 
to be LC3-I, because in nutrient rich media, levels of LC3-I are maintained and still 
available.  It has been suggested that the E1-like conjugating enzyme Atg7 may be 
limiting[88].  However, overexpression of Atg3, Atg7, or Atg4B does not appear to 
promote LC3-II processing or autophagy (data not shown).  The exact nature of this 
feedback is not yet known. 
The ultimate conclusion of the data generated from the study of LC3 is that LC3-I 
and LC3-II data must be interpreted cautiously.  There is a growing acknowledgement in 
the field that LC3-II levels alone are not sufficient to measure autophagy.  To address 
this, some studies interpret LC3-II levels only in conjunction with measurement of the 
degradation of long-lived proteins.  Unfortunately, these methods are neither sensitive 
nor specific for macroautophagy.  An ideal assay would measure a product of autophagy 




4.1.3. The BHMT assay  
There is a need in the field of mammalian autophagy for an assay that would 
specifically and sensitively measure the lysosomal degradation of an autophagy cargo 
protein.  This need led to the development of the BHMT assay.  Highlights of the 
discussion will focus on three topics.  Why choose BHMT?  Is the BHMT measuring 
macroautophagy?  What is the sensitivity and linearity of the BHMT assay? 
The decision to turn a metabolic enzyme, betaine homocysteine methyltransferase 
(BHMT) into a reporter for autophagy began with a published report that rat BHMT 
associates with purified autolysosomes[96].  One specific proteolytic fragment of rat 
BHMT was found only on the inside of autolysosomes of rats that were administered the 
protease inhibitor leupeptin, suggesting that there was a leupeptin-resistant cathepsin 
specific for a particular site in BHMT[96].  Despite the fact that the authors of a follow-
up paper suggested their attempts to create an exogenous BHMT reporter for autophagy 
had been unsuccessful[68], BHMT was chosen as one of several promising candidates for 
a plasmid-based reporter assay for autophagy in cell culture. 
It was assumed that if proteolytic fragments of BHMT were generated 
lysosomally, they would not be abundant.  However, creation of an epitope-tagged 
BHMT fusion protein would allow for purification and enrichment of rarified fragments.  
After several unsuccessful attempts to fuse BHMT to GST, HA or myc epitope tags in an 
assortment of different combinations, a successful combination was found that fused GST 
to the amino terminus of BHMT and myc to the carboxy terminus.  In conditions known 
to induce macroautophagy, a leupeptin-resistant GST-fused fragment, termed fragment 1, 
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of the expected size accumulates quantitatively.  Attempts to isolate a carboxy fragment 
with antibody to myc were not successful (data not shown). 
Multiple forms of the BHMT reporter were generated in the course of this study.  
Each reporter consistently generated fragment(s) in conditions known to induce 
autophagy, such as starvation from essential amino acids, and to a lesser degree, 
rapamycin treatment.  The starvation-induced generation BHMT fragment(s) was 
inhibited by every macroautophagy inhibitor tested:  3MA, wortmannin, chloroquine, 
bafiolomycin A1, puromycin, cycloheximide, and vinblastine.  Further validation of the 
lysosomal nature of the fragments generated from BHMT is found in the co-fractionation 
of BHMT fragments with the lysosomal marker, LAMP1, in fractions collected from the 
LMF compartment of cells separated by density on sucrose gradients. 
Although the pharmacological data with the BHMT assay suggest that lysosomal 
import occurs through macroautophagy, other mechanisms of autophagy must be 
eliminated as either primary or alternative routes to the lysosome for GST-BHMT.  One 
mechanism of autophagy considered is chaperone-mediated autophagy (CMA) which is 
induced by long term amino acid and serum starvation[10].  There are no known 
pharmacological inhibitors of CMA, making elimination of a CMA-dependent 
mechanism difficult.  The hsc73 protein recognizes substrates of CMA through exposure 
of a sequence of amino acids typified by the ribonuclease A sequence, KFERQ[97].  The 
KFERQ sequence is often degenerate to the point of being unrecognizable, but 
examination of the human BHMT sequence failed to find any KFERQ-like sequences.  
The inability to identify a KFERQ sequence in human BHMT is consistent with a 
published report that KFERQ-like sequences could also not be found in rat BHMT[68].  
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Unexpectedly, in a published review of chaperone-mediated autophagy, GST was 
included in a list of known CMA substrates with KFERQ-like sequences[10].  Mutation 
of the obligate Q or N in KFERQ to an alanine is sufficient to mask recognition by the 
chaperone complex.  The GST
N43A
BHMT mutation did not change BHMT fragmentation 
in response to starvation of serum and essential amino acids, or to any of the 
macroautophagy inhibitors, suggesting that CMA was not a mechanism responsible for 
BHMT lysosomal import. A recent study found that vinblastine, 3MA, and wortmannin 
did not inhibit CMA[71] and all were effective in blocking the accumulation of BHMT 
fragment 1.  The pharmacological data of vinblastine, 3MA, and wortmannin support the 
idea that CMA is not a mechanism of lysosomal import for BHMT.   
A third argument against import by CMA can be made from the data on higher 
order structure.  Multimerization of BHMT is necessary for cleavage of the L2 loop to 
produce fragment 1.  The need for oligomerization suggests that BHMT must be 
imported into the lysosome with quaternary structure intact.  During CMA, proteins in 
the chaperone complex bind LAMP2a at the lysosome membrane and then unfold so that 
the protein can be threaded through the lysosomal membrane and enter the luminal space.  
It seems extraordinarily unlikely that BHMT could regain its quaternary structure in the 
lysosome after entering by the CMA mechanism and be cleaved to generate fragment 1. 
In addition, in the course of this study, siRNA targeting LAMP2 successfully 
reduced expression of LAMP2 protein by approximately 90%.  Of the two shRNAs 
tested, one did not effect BHMT processing and one slightly enhanced BHMT 
fragmentation (data not shown).  The latter result is consistent with a report with selective 
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knock-down of LAMP2a causes a compensatory increase in macroautophagy[12].  
Together, these data support the hypothesis that BHMT is not a substrate for CMA. 
Microautophagy is a third mechanism that could import GST-BHMT directly into 
the lysosome.  There is very little published information available about lysosomal 
invagination and import, although it is generally considered to be a constitutive process, 
with one exception.  In yeast there is a report that TOR positively regulates 
microautophagy as a mechanism to reduce vacuole size after rapamycin treatment and 
macroautophagy-induced swelling of the vacuole[9].  The protein complex at the vacuole 
membrane that mediates this process is conserved in mammals, although the existence of 
a similar mechanism in mammals is not known.  However, in this scenario, rapamycin 
would be expected to inhibit, not induce degradation.  To eliminate microautophagy as a 
mechanism of BHMT lysosomal import, it was necessary to knock out a 
macroautophagy-specific gene. 
Beclin1, the human Atg6 ortholog, is a good candidate for specific targeting by 
shRNA because its role in macroautophagy is widely accepted in the autophagy field, its 
silencing is often cited as validation of macroautophagy, and available antibodies are 
sensitive enough to demonstrate changes in levels of endogenous protein.  Low levels of 
Beclin1 have been linked to decreased autophagy in MCF7 cells, while over-expression 
of Beclin1 in MCF7 cells Beclin1 has been shown to induce autophagy and reduce 
tumorigenicity[38].  It should be noted that in this study, ectopic expression of HA-
Beclin1-myc in the cells tested is not sufficient to increase autophagy, as determined by 
either the LC3 or BHMT assays (data not shown).  There could be cell-specific 
differences between the MCF7 cells in the cited work and the cells used in this study.  
 
195 
Another possibility is that overexpressed Beclin1 in HEK293 cells forms sub-
stoichiometric complexes that are not autophagy competent.  One study found that 
overexpessed Beclin1 required the coexpression of a mutant associating protein, PIST, to 
induce autophagy[98]. Alternatively, the epitope tags fused to Beclin1 may interfere with 
any autophagy-promoting function.  Ectopic expression of Beclin1 without epitope tags 
should help resolve the latter issue.  The data show that shRNA targeting three distinct 
regions of the Beclin1 mRNA decreased expression of Beclin1 protein.  Significantly, 
depletion of Beclin1 is sufficient to decrease accumulated levels of BHMT fragment 1 in 
starved cells, establishing unambiguously that the BHMT assay is reading 
macroautophagy.   
The second autophagy-specific target chosen to validate the BHMT assay is the 
serine-threonine kinase orthologous to yeast Atg1, hULK1.  In humans, hULK1 
expression has been linked to the trafficking of Atg9 between the trans-Golgi network 
(TGN) and late endosomes[52].  The link between hULK1 and mAtg9 is consistent with 
impaired trafficking of Atg9 in yeast ∆atg1 mutants between the pre-autophagosomal 
structure (PAS) and non-PAS structures[47].  Two separate shRNAs targeting hULK1 
effectively decreased levels of accumulated BHMT fragment 1 in amino acid starved 
cells, validating that the BHMT assay is measuring macroautophagy by depletion of a 
second autophagy gene.   
Regarding autophagy, the ability of shRNA targeting ULK1 to inhibit BHMT 
fragmentation indicates that hULK1 and its isoform hULK2 do not seem to have 
overlapping functions.  hULK1 and hULK2 share the same basic domain structure with 
an amino terminal kinase domain, a central proline-serine rich domain, and a carboxy-
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terminal domain.  The catalytic and carboxy-terminal domains are well conserved 
between the two isoforms, with little conservation noted in the central proline-serine (PS) 
rich domain[50].  It has been suggested that the human Atg8 orthologs GATE-16, 
GABARAP, and to limited degree LC3, bind the middle PS domain of hULK1[99].   
Future experiments that exchange domains between these two kinases will help 
determine what regions of the kinase are essential for autophagy. 
The above data indicate that hULK1 is important for autophagy and should be 
studied regarding its role in regulating autophagy.  This study attempted to answer three 
questions regarding hULK1 and autophagy:  1) Is hULK1 specific activity effected when 
autophagy is induced by amino acid starvation or rapamycin or when cells are treated 
with autophagy inhibitors? 2) Do levels of hULK1 change in response to the induction of 
autophagy and is this a mechanism of regulation? 3) Is hULK1 activity required for 
autophagy? 
In yeast, there are two theories regarding Atg1 activity and macroautophagy.  
Kamada et al. reported that activity was necessary for autophagy while Abeliovich et al. 
found that Atg1 protein was necessary for macroautophagy and the related Cvt pathway, 
but its activity was only required for the Cvt pathway[45, 46].  Both studies suggest that 
Atg1 functions in a complex of proteins and that phosphorylation of Atg13 and Atg1 
regulate Atg1 activity.  The data in this study show that the catalytically inactive 
hULK1
KD
 inhibits the generation of fragment 1, suggesting that hULK1 activity may be 
necessary for mammalian autophagy.  However, levels of over-expressed hULK1
KD
 are 
likely greater than endogenous hULK1, making the formation of sub-stoichiometric 
complexes possible which could interfere with parallel pathways. 
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This led to the study of hULK1 specific activity in conditions known to induce or 
inhibit autophagy.  Kamada et al showed that two well known inhibitors of TOR, 
starvation or rapamycin, increase yeast Atg1 specific activity[45].  In contrast to the yeast 
data, the results here show that the specific activity of HA-ULK1-myc does not change in 
response to starvation or rapamycin, and is not affected by inhibitors of autophagy such 
as 3MA, wortmannin or chloroquine.  What might explain this?  An obvious explanation 
would be that yeast Atg1 and human hULK1 are not regulated in the same manner.  
Some kinases are regulated by levels of expression and there is one report that levels of 
ULK1 mRNA increase with viral infection in neurons[100].  Since hULK1 mRNA 
increased in the case of viral infection, and because viral invasion is one way to induce 
autophagy, it seemed possible that hULK1 levels might increase with amino acid 
starvation.  The data with qPCR show that levels of hULK1 mRNA remain essentially 
unchanged after 6 hours of amino acid starvation.  It does not appear that amino acid 
starvation regulates hULK1 at the transcriptional level. 
How else might hULK1 be regulated?  Yeast Atg1 is regulated by the post-
translation modification of associating proteins.  Atg13 must be de-phosphorylated for 
Atg1 to be active which suggests that an active phosphatase is required to regulate Atg1 
activity.  It may be that hULK1 requires the association and/or modification of other 
proteins for regulated activity that is not reflected in an in-vitro assay.  It is also possible 
that the amino or carboxy termini of hULK1 may be important for regulation of its 
activity.  The epitope tags fused to hULK1 may interfere with the regulation of its 
activity.  Little is known about the importance of domains, post-translational 
modifications, or regulatory proteins for either of the hULKs.  Potential issues of 
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interference caused by the fusion of epitope tags to the hULK1 protein are currently 
being addressed by making a non-tagged construct for ectopic expression. 
It may be that hULK1 is constitutively active and regulated by localization, 
expression or other mechanism.  Autophagy is a membrane trafficking process, and it is 
possible that hULK1 re-localizes to or from membrane structures in autophagy-
stimulating conditions.  This is consistent with its role in mAtg9 trafficking.  Preliminary 
studies with the epitope tagged hULK1 have failed to demonstrate differences in 
distribution between cytosolic, nuclear, or membrane fractions of cell extracts (data not 
shown).  This issue will be revisited with a non-epitope-tagged version of the kinase. 
In-vitro kinase assays demonstrate that hULK1 can autophosphorylate, and 
metabolic labeling with 
32
PO4 shows that hULK1 is phosphorylated in-vivo.  This 
suggests that phosphorylation is a mechanism of regulation of hULK1.  The activation 
loop (T-loop) in subdomain VIII of hULK1 contains a cysteine-glycine pair of amino 
acids that is highly conserved in members of the AGC and CaM kinase families.  Kinases 
that belong to these family groups are phosphorylated on a conserved threonine in the T-
loop by an upstream kinase.  Mutation of this conserved threonine to an alanine in 
hULK1 renders hULK1 catalytically inactive (data not shown) suggesting importance of 
T-loop phosphorylation in the activation of hULK1.  In the structurally related hULK2, a 
priming phosphorylation event is apparently necessary for autophosphorylation and 
activity, as prolonged treatment with calf intestinal treatment renders hULK2 inactive 
(data not shown).  This phosphorylation event is likely T-loop phosphorylation.  The 
inability of hULK2 to reactivate after prolonged CIP treatment makes it unlikely that 
hULK2 phosphorylates its own T-loop, although it cannot be ruled out if another priming 
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phosphorylation is required.  hULK2 also shows a high preference for serine over 
threonine, providing additional evidence that T-loop auto-phosphorylation is unlikely.  
Interestingly, in the yeast genetic screens, no potential up-stream kinase was identified 
for Atg1.  The failure to identify an up-stream kinase in the autophagy screens supports 
the yeast model which suggests Atg1 activity is not required for autophagy.  
Phosphorylation by other kinases may also be important for activity of hULK1 as it has 
been suggested that PKA may phosphorylate yeast Atg1[101].  Future studies are planned 
to purify and identify the hULK1 upstream T-loop kinase. 
There are no known endogenous substrates of either Atg1 or hULK1.  Pull-down 
experiments and proteomic analysis can be used to identify potential substrates of 
hULK1.  Many of the Atg proteins are phospho-proteins, and hULK1 can phosphorylate 
some of them in-vitro (data not shown).  With the tools developed in this study, changes 
in metabolic labeling of Atg proteins in cells depleted of hULK1 will be used to study 
effects of hULK1 on Atg post-translational modifications.  Regarding activity of hULK1 
and autophagy, future experiments are planned that will attempt to rescue the autophagy 
defect caused by the shRNA-mediated decrease of hULK1 with expression of either the 
catalytically active or kinase dead alleles of hULK1.  If successful, these types of 
experiments will validate the importance of hULK1 in autophagy and will help determine 
if catalytic activity is important for autophagy.   
In physiology, there are times when circulating amino levels are low, such as after 
prolonged fasting or in postnatal infancy.  Amino acid levels are an important part of the 
regulation of macroautophagy based on what is reported in the literature[73] and on the 
response of the BHMT assay.  The data show that the BHMT assay is not sensitive to 
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high levels of essential amino acids.  Most of the studies with the BHMT reporter have 
been done in transformed HEK293 cells that are cultured in DMEM with high amino acid 
levels.  Do transformed cells adapt to high levels of amino acids, or is the cellular sensing 
mechanism for amino acids unaffected.  A linear response of BHMT fragment 1 
accumulation to extra-cellular levels of amino acids is only seen when levels of DMEM 
essential amino acids fall below 10%.  This was surprising until levels of the amino acids 
in DMEM were compared to the normal adult reference ranges.  The response of cells in 
culture is within the physiological range.  It appears that cells do not adapt to high levels 
of amino acids, but maintain sensitivity at more physiological levels.  The BHMT assay 
responds appropriately to physiological levels of essential amino acids, especially when 
one considers that it is measuring the endpoint of a biological process. 
Interestingly, the BHMT assay does not respond equally to the individual 
essential amino acids.  It is possible that the intracellular levels of the essential amino 
acids may not reflect the extracellular environment within the time frame of the 
experiment.  Bloomaart et al. demonstrated that not all amino acids are in equilibrium 
with the extracellular environment[73].  However, he also showed that the intracellular 
levels of a select group of amino acids reflect extracellular concentrations in a linear 
fashion.  His findings included leucine, isoleucine, lysine, phenylalanine and tyrosine, 
some or all of which were suggested to be amino acids that regulate autophagy[73].  In 
support of this, the BHMT assay shows sensitivity to leucine, phenylalanine, lysine, and 




It is possible that the mechanisms that sense amino acids levels may have 
selective sensitivity for individual amino acids.  How does the cell sense and respond to 
these particular amino acids?  There are two kinases that sense amino acids and both have 
been implicated in autophagy:  mTOR and the eIF2alpha kinase, GCN2[54, 102].  Amino 
acids, particularly leucine, strongly activate p70S6 kinase through mTOR[103].  How 
does mTOR sense amino acids?  Recent studies suggest that amino acids increase Vps34 
activity which in turn activates mTOR[36, 37].  This is counter to reports that amino acid 
starvation activates Vps34[33], however it is likely that Vps34 functions in distinct 
complexes that may affect mTOR in opposing ways.  How does Vps34 sense amino 
acids?  This mechanism is not yet known and may involve internal and external signals.  
One report suggests that amino acids may act as a first messenger and signal through 
plasma membrane receptors[104].  
GCN2 responds to levels of intracellular amino acids.  GCN2 is an eIF2α kinase 
that is activated by the deacylation of tRNA.  Once activated, it phosphorylates the 
eukaryote initiation factor 2 alpha (eIF2α) at S51 causing a general translation arrest, but 
facilitating the translation of GCN4, a transcription factor that has been shown to regulate 
several autophagy genes[105].  In yeast, amino acid starvation induces autophagy 
through GCN2; however rapamycin can induce autophagy in the ∆gcn2 mutant[102].  
One explanation for this could be that GCN2 and TOR activate autophagy through 
parallel pathways.  The BHMT assay indicates that full autophagy activation requires the 
additive effects of multiple amino acids, supporting the idea that mTOR and GCN2 might 
respond independently to the same nutrient stress.  If true, there could be distinct levels of 
autophagy activation.  Intracellular levels of leucine and the other branched chain amino 
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acids decrease by as much as 90% within 30 minutes of amino acid withdrawal without 
affecting the acylation of their respective tRNAs[74].  Thirty minute starvation is 
sufficient to inactivate mTOR which may activate autophagy initially, followed by a 
second tier of activation by GCN2.  Interestingly, both GCN2 and mTOR regulate 
translation at the level of initiation, suggesting that translation initiation is an important 
part of the regulation of autophagy. 
Lysosomes are dynamic organelles that differ between cell types in their 
complement of hydrolytic enzymes.  It was tested to see if the BHMT would generate an 
identifiable fragment in starved cells of other types and species.  Cell tested include 
T98G cells, MCF7 cells, H1299 cells, NIH3T3 cells and C2C12 cells.  T98G cells are 
human glioblastoma cells that are negative for expression of PTEN.  Loss of PTEN 
results in sustained signaling through the PI3 Kinase/Akt pathway, a growth signaling 
pathway that activates mTOR and is generally thought to suppress macroautophagy[57].  
Despite the loss of PTEN, T98G cells were capable of a robust, macroautophagic 
response to amino acid deprivation.  MCF7 cells are human, breast carcinoma cells that 
are reported to have depleted levels of the autophagy-specific protein, Beclin 1.  It has 
been shown that MCF7 cells have decreased levels of macroautophagy, which could be 
increased by overexpression of exogenous Beclin 1[38].  The MCF7 cells tested with the 
BHMT assay were capable responding to amino acid starvation, although the percent 
increase of accumulated fragment in starved cells compared to control was less than in 
T98Gs.   
H1299 cells are human lung cancer cells that are devoid of the tumor suppressor 
p53.  The induction of p53 has been linked to increased autophagy through several 
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mechanisms, including negative effects on mTOR and through the lysosomal protein, 
damage-regulated autophagy modulator DRAM[106, 107].  The dramatic accumulation 
of BHMT fragment in starved H1299 cells demonstrates that macroautophagy can 
respond to amino acid starvation in a p53-independent manner.  It may be the p53 is 
required for an autophagic response to genotoxic stress, but is not necessary for a 
response to amino acid starvation.  NIH3T3 cells are immortalized mouse fibroblast and 
C2C12 cells are immortalized mouse myoblasts.  Both mouse cell lines generated a 
fragment of the same size as fragment 1 in human cells, implicating a similar lysosomal 
cathepsin.  The C2C12 cells did not transfect to a very high efficiency and consequently 
the level of fragment 1 was low, but fragmentation with starvation still occurred that was 
sensitive to both 3MA and chloroquine.  In conclusion, the lysosomal protease that 
cleaves BHMT to generate fragment 1 is generally distributed between various cell types 
and species, broadening the possible applications of the BHMT assay.   
4.2. BHMT and higher order structure 
The BHMT data suggest that quaternary structure is maintained within the 
autophagosome.  This conclusion is supported by the data that fragment 1 is only 
generated from BHMT subunits that can form multimers.  While it is possible that the 
cathepsin that cleaves L2 requires an intact carboxy-terminus to bind and cleave, the 
resistance of the GST-BHMT
W352A
 mutant to generate fragment 1 argues against this 
possibility. 
Second, monomeric and multimeric BHMT molecules are both substrates for 
macroautophagy.  This conclusion is supported by the protection assay and by the 
generation of fragment 2′ in the GST∆TBHMT and GST∆TBHMT
∆C51
 reporters.  
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Quaternary structure of BHMT is not important for the proteolytic cleavage in the region 
of GST to produce fragment 2′.  Although this was not the expected result, it raises an 
interesting question.  Why is BHMT degraded through macroautophagy and not by 
another mechanism?  The BHMT truncation mutants and W352A point mutant all appear 
to make stable proteins.  More severe truncations, however, result in unstable protein that 
is likely proteasomally degraded soon after translation.  An attractive hypothesis is that 
macroautophagy is a preferred mechanism to remove enzymes or organelles 







that could be harmful to the cytoplasmic environment.  In support of this, a rare 
autosomal recessive disease, mitochondrial myopathy and sideroblastic anemia (MSA), is 
caused by an unknown gene mutation that maps to the chromosomal region of 
hULK1[108].  As the name suggests, the disease is marked by excessive accumulation of 
iron stores, which could be caused by a defect in macroautophagy. The crystal structure 
of BHMT predicts that although ∆C51 and W352A BHMT mutants cannot oligomerize, 
they likely assemble into normal (α/β)8 barrel subunits, with the Zn
2+ 
 intact, making 
them both macroautophagy substrates.
 
Third, the data of GST∆TBHMT and GST∆TBHMT
∆C51
 on sucrose gradients 
provide evidence of a 3MA-sensitive and 3MA-resistant macroautophagy.  GST∆TBHMT 
is a substrate of the first and GST∆TBHMT
∆C51
 is a substrate of both.  This result is 
surprising because the autophagy field defines macroautophagy almost exclusively in 
terms of sensitivity to 3MA. 
Does macroautophagy proceed in cells treated with 3MA?  3MA’s inhibition of 
Vps34 is likely partial inhibition.  Strong inhibition of PI3K activity with wortmannin is 
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sufficient to inhibit fragmentation of both forms of BHMT and macroautophagy, which 
suggests that in cell treated with 3MA, some PI3P is still made.  Is it enough to support 
autophagy?  The data of the HA-LC3B reporter show that in the presence of 3MA, LC3-
II is produced and lysosomally degraded.  Is this LC3-II part of a cargo vesicle?   
The data of GST∆TBHMT
∆C51
 fragment 2′ on the sucrose gradient argue that the 
LC3-II produced in the presence of 3MA is actively sequestering and delivering 
GST∆TBHMT
∆C51
 to the lysosome.  What is the difference between the light (5/ 6) 
fractions and the dense fraction (8) on the sucrose gradient?  The dense fractions are 
sensitive to 3MA and the lighter are resistant.  From the sum of the date, the following 
characterization of fractions 6 and 8 could be made (Table 5).  The more buoyant fraction 
6 contains autophagosomes, newly formed autolysosomes, and pure lysosomes.  Fraction 
8 contains denser autolysosomes/amphisomes.   
In 3MA treated cells, LAMP1 in fraction 8 is decreased.  The decrease of LAMP1 
in fraction 8 in 3MA-treated cells suggests that PI3P is required for the fusion events 
necessary to generate dense autolysosomes/amphisomes.  The density shift of LAMP1 
from fraction 8 to fraction 6 is consistent with sucrose gradient data from wortmannin 
treated cells (data not shown).  Does the LAMP1 in fraction 5/6 represent lysosomes or 
more boyant autolysosomes?  The co-fractionation of GST∆TBHMT
∆C51
 fragment 2′ and 
LC3-II with LAMP1 in 5/6 suggests that autolysosomes form in fractions 5/6 when levels 
of PI3P are limiting.   
Why is GST∆TBHMT
∆C51
, but not BHMT degraded in 3MA-treated cells?  What 
is the relationship between PI3P and the different abilities of these two mutants to 
oligomerize?  It could be through a mechanism that involves proteins that are regulated 
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by binding to PI3P.  Downstream effectors of hVps34 signaling bind to PI3P through a 
FYVE domain (first described in proteins Fab1, YOTB/ZK632.12, Vac1, and EEA1) or 
in some instances through a Phox homology (PX) domain.  Despite the importance of 
PI3P in autophagy, there are very few Atg proteins that actually bind PI3P.  The few Atg 
proteins that have FYVE or PX domains are involved in cargo recognition of the Cvt 
pathway.  Could this type of cargo recognition be involved in mammalian autophagy and 
in the selection of BHMT?  A model of this type of recognition proposes the existence of 
a FYVE-domain adapter protein that would recognize oligomeric but not monomeric 
BHMT to bring it to the autophagosome (Fig. 51).  Or perhaps BHMT normally forms 
complexes FYVE-like proteins, as BHMT reportedly associates with both autolysosomes 
and mitochondria, even though it does not itself have a FYVE domain, PX domain, or 
other membrane tethering modifications.  Thus, when PI3P is available and autophagy is 
induced, its association with autophagosomes is through a PI3P-dependent mechanism.   
If a FYVE adapter-like protein recognizes only BHMT, how does 
GST∆TBHMT
∆C51
 become sequestered in autophagosomes?  GST∆TBHMT
∆C51
 is a 
BHMT monomer in a non-functional conformation.  Is there a mechanism that cells use 
to target misfolded, non-essential, or aggregated proteins for macroautophagy?   Reports 
show that p62/SQSTM1 can function as an adapter-like protein that physically links 
aggregates of mutant huntingtin protein with LC3 and autophagosomes for 
degradation[109].  The association between p62 and the mutant huntingtin protein 
requires p62’s ubiquitin-association (UBA) domain.  Is this a cellular mechanism that 
cells use to recognize and remove misfolded proteins by macroautophagy?  It is proposed  
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Figure 51.  Proposed model for 3MA-sensitive and 3MA-insensitive 
macroautophagy.  In the proposed model, production of PI3P enriches autophagosomes 
with its normal cargo through FYVE or PX-containing adapter molecules.  When PI3P 
levels are limiting, this cargo is no longer favored.  Abnormal protein structure is 
recognized by adapter proteins that directly interact with Atg8-orthologs at the 
autophagosome membrane.  These complexes are modeled after p62s proposed role in 




     
 
209 
that this type of mechanism explains the degradation of the GST∆TBHMT
∆C51
 monomer, 
and that when PI3P is limiting, degradation of these aggregates continues. 
The p62-like adapter mechanism involves direct targeting of aggregates to LC3.  
Could other Atg8 orthologs have similar roles?  And does this explain one of the 
unanswered questions in autophagy of why there are so many mammalian Atg8 
orthologs?  When LC3-II was first described as being specific for autophagosomes, the 
data did not suggest that LC3-II was on all autophagosomes.  This suggests that the other 
Atg8 isoforms may have functions similar to LC3, and indeed, all have been found 
onautophagosomes.  The data that links p62 and LC3 is significant.  The plethora of the 
other Atg8 orthologs suggests that there may be multiple adapters and autophagosome 
receptors for the clearance of cellular ‘garbage’ like GST∆TBHMT
∆C51
.  
It is proposed that there are two types of macroautophagy, a signaling autophagy 
and a structural autophagy (Fig. 51).  Both require some PI3P.  The signaling autophagy 
requires sufficient levels of PI3P for recognition of normal cargo such as BHMT.  The 
structural autophagy requires less PI3P and the coordinate activity of the Atg proteins 
that participate in autophagosome formation.  Under starvation conditions with readily 
available PI3P, both BHMT and GST∆TBHMT
∆C51
 are degraded.  When PI3P is limiting, 
cargo recognition is limited, but the structural, basal autophagy continues to degrade 
abnormal cargo, such as GST∆TBHMT
∆C51
.   
In mammalian cells, Vps34 plays a role in trafficking decisions that control the 
destination of internal vesicles.  The proposed model suggests that substrates of the 
signal-dependent autophagy are more regulated than random.  It makes energetic sense to 
be selective in the process of degradation of proteins that require new synthesis when the 
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crisis has past.  There are other stressors that induce autophagy such as viral or pathogen 
invasion, where non-specific wholesale degradation of cellular protein might not be 
desired.  However, there are no conditions where accumulated, misfolded, or aggregated 
protein is desirable.  It is this second, structural autophagy that is valuable for the health 
of the cell and organism. 
4.3. Regulation of autophagy and p70S6 Kinase 
 
The protein kinase mTOR plays a central role in the ability of cells to sense 
growth signals, amino acid levels, and energy in order to make decisions that effect the 
translation of new proteins, cell growth and proliferation.  The signals through mTOR to 
its downstream effectors p70S6K and 4E-BP1 regulate events involved in the initiation of 
translation and regulate events in macroautophagy (Fig. 5).  If nutrients are readily 
available from the extracellular milleau, mTOR signals for the cell to grow.  When 
extracellular nutrients are scarce, down-regulation of mTOR signaling increases 
autophagy to degrade internal proteins for the energy and raw materials necessary for 
survival. 
What is the relationship between p70S6 kinase and autophagy?  There is strong 
correlative evidence of an inverse relationship between phosphorylation of the ribosomal 
subunit S6 and autophagy in a mammalian setting.  The negative correlation between 
phosphorylated S6 and autophagy has led to a proposed model that places phosphorylated 
S6 at the endoplasmic reticulum.  In the proposed model, the inhibition of mTOR causes 
de-phosphorylation of S6 and its release from the rough ER.  The smooth ER created by 
the loss of ribosomes is proposed to be one source of the autophagosome membrane[54].  
This mechanism directly links mTOR, p70S6 kinase and S6 with autophagy. 
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In Drosophila, it has been proposed that p70S6 kinase must be active for efficient 
autophagy[58].  How is p70S6 kinase active if TOR is inactive?  It has been suggested 
that residual activity of p70S6 kinase remains when TOR is first inactivated.  This 
activity is both sufficient and required for autophagy.  Without TOR activity, it is also 
self-limiting, preventing uninhibited autophagy from progressing to the point of cell 
death.   
In the current study, using the BHMT assay as a measure of macroautophagy, 
there is no correlation between the phosphorylation of S6 and autophagy.  Both the 
constitutively active allele of S6K and RHEB increase the signal to S6 in the absence of 
amino acids.  However RHEB inhibits autophagy and active S6K does not inhibit 
autophagy, suggesting that the inhibitory signal to autophagy is through mTOR, but does 
not go through the p70S6K arm of the pathway. 
The constitutively active S6K does cause a slight increase in levels of BHMT 
fragment 1.  If the model from Scott et al. in Drosophila is correct, then S6K activity may 
be pushing a maximum signal to autophagy.  An alternate explanation is that the over-
expressed allele may have a dominant interfering effect by sequestering mTOR.  Others 
have shown that this can have a negative effect on mTOR’s other substrate, 4E-BP1.  
However, the phosphorylation data with 4E-BP1 suggest that in this instance that 
activated S6K did not inhibit mTOR signaling to 4E-BP1. 
Interestingly, the RHEB-mediated sustained positive signal through the mTOR 
pathway caused hyperphosphorylation of 4E-BP1 and decreased total 4E-BP1 protein.  
Decreased levels of a negative regulator of eIF-4E cause unregulated translation, which 
may lead to tumorigenesis.  The RHEB-induced decrease of 4E-BP1 could be a 
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mechanism that explains how a strong positive signal through the mTOR pathway might 
lead to cancer.  Does the mTOR signal to autophagy go through 4E-BP1?  The hypothesis 
is attractive because it links the signal to autophagy with a signal for the initiation of 
translation.  It is also consistent with the role of the eIF2α kinases, which also inhibit 
translation initiation and promote autophagy[102].  Future studies will explore the 
potential relationship between eIF4E and autophagy.  In conclusion, the above data 
confirm that the signal to autophagy is through mTOR, but that it does not go through 
p70S6 kinase.   
The re-addition of amino acids to cells increases Vps34 activity and activates 
mTOR signaling, thereby inhibiting autophagy.  However autophagy also requires Vps34 
activity.  Autophagy’s need for Vps34 activity is supported by the data that fragmentation 
of both BHMT mutants is completely inhibited by wortmannin.  How is it that both 
mTOR and autophagy require Vps34 activity and both are inhibited by wortmannin, but 
active mTOR inhibits autophagy?  It could be explained in terms of levels of PI3P.  
Vps34 activity increases levels of PI3P, a well known way to modulate signaling 
pathways through the recruitment of proteins with FYVE and PX domains.  It is likely 
that the Vps34 activation of mTOR may involve these types of PI3P-dependent 
molecules with a low affinity for PI3P.  Thus high levels of PI3P would activate mTOR.  
Amino acid starvation would drop PI3P to levels that are high enough to support 
autophagy, but too low to activate mTOR.  A decrease in mTOR signaling would then 
increase autophagy. 
The 3MA treatment of cells expressing the two types of BHMT cargo suggests 
that modulating levels of PI3P during starvation that might effect the selection of cargo.   
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Figure 52.  Proposed model for Vps34, PI3P, and mTOR regulation of autophagy.  
In nutrient rich conditions, PI3P levels are high, mTOR is active and autophagy is at 
basal levels.  With amino acid starvation, PI3P levels decrease, mTOR signaling is 
decreased and the inhibition on autophagy is relieved.  In ischemia, Vps34 activity 
decreases and PI3P levels fall.  In these conditions, autophagy of normal cargo ceases, 















A model has been proposed in which adapter proteins facilitate the selection and 
degradation of cytoplasmic proteins.  Regulated cargo requires the recognition of PI3P by 
FYVE or PX proteins.  However, structurally abnormal protein continues to be degraded 
when PI3P levels are low.  However, if Vps34 activity is completely inhibited, as 
happens with wortmannin treatment, autophagy cannot proceed.   
This suggests that there are levels of PI3P in the cell that effect the progression of 
autophagy (Fig. 52).  At high levels, mTOR is active and autophagy is inhibited.  At low 
levels, mTOR is inactive and autophagy is active.  If PI3P levels continue to decrease, 
autophagy also becomes inhibited.  Under what physiological condition might this occur?   
The data show that ischemia is one situation where both mTOR and autophagy are 
inhibited.mTOR signaling is down-regulated in response to decreased levels of amino 
acids and ATP.  The ischemia experiment was designed to determine how these cellular 
stressors affect autophagy.  It has been suggested in the literature that cells subjected to 
conditions of ischemia induce autophagy as a means of survival[110].  This mechanism is 




) solid tumors survive in a 
nutrient-poor environment, until an adequate blood supply can be established to supply 
nutrients[110].  Is autophagy induced in ischemia?  In an in-vitro model of ischemia, 
Degenhardt et al, concluded ischemia induced autophagy, based on GFP-LC3 
localization[110].  The data here, using a similar model of ischemia, show that autophagy 
as measured by BHMT was inhibited in ischemic conditions, and was slightly inhibited 
by loss amino acids and glucose.  It is likely that the limited response was due to 
decreased levels of ATP.  Autophagy is very energy dependent.  Multiple steps of the 
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autophagic process require ATP and even small changes of ATP levels have been shown 
to slow autophagic proteolysis[84].   
In ischemic conditions, defined as loss of nutrients, serum, glucose and low 
oxygen, both LC3-II processing and BHMT fragmentation were strongly inhibited.  
Down-regulation of mTOR does not necessarily mean that the cell has increased 
autophagy.  It is likely that inactive mTOR relieves an inhibitor signal that allows 
autophagy to proceed as long as sufficient ATP is available for the events required for 
autophagy.  However, even in full ischemia, a small increase of BHMT fragment is 
observed under amino acid starvation conditions, suggesting that some autophagy was 
induced.  But the severe decrease in LC3-II suggests that as ATP levels drop, the ATP-
dependent step of LC3 processing is likely negatively affected. 
Together, the data suggest that Vps34 activity and levels of PI3P determine if 
mTOR is active or inactive (Fig. 52).  If mTOR signaling is down-regulated and 
autophagy is active, modulation of PI3P levels can determine the type of cargo that will 
be degraded.  A severe decrease in PI3P will inhibit autophagy.  Ischemia is a situation 
where mTOR is off and there is only a small autophagy response.  Could this be an 
example of PI3P levels dropping below a threshold necessary to support autophagy?  It is 
likely that the glucose starvation and ischemia conditions also decrease PI3P.  This is 
consistent with the published report that glucose starvation or AICAR, an activator of 
AMPK decreases Vps34 activity[37].  In addition, conditions of glucose deprivation and 
hypoxia are two potential stressors that cells face in a physiological situation.  Decreased 
ATP and oxygen can ultimately lead to the production of misfolded proteins.  Under 
these conditions, clearance of unfolded proteins would be a priority, and the proposed 
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mechanism might explain how cells are able to mount a response to selectively remove 
this population of aggregate-prone protein.  This model predicts that BHMT
∆C51
 under the 
same stress conditions would continue to generate fragment 2´.  Future experiments are 
planned to test ∆C51 in this cell culture model of ischemia. 
Diseases of aging such as Alzheimer’s, Parkinson’s, Huntington’s, and Inclusion 
Body Myositis are all major neurological and muscular diseases associated with the 
accumulation of aggregated proteins.  Therapeutic strategies that increase autophagy can 
help alleviate the cellular stress of abnormal protein accumulation.  Rapamycin, a 
negative inhibitor of mTOR, has already shown promise as a drug of choice by increasing 
the degradation of mutant huntingtin protein.  The studies here predict that in times of 
nutrient stress, the cell has adapted macroautophagy such that misfolded proteins are 
preferentially degraded for the benefit of the cell.  
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